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 Stereochemistry and its significance to drugs 
1.1.1. Basic definitions 
Stereoisomers are compounds that have the same constitution (same molecular formula, same atomic 
bonding) but differ in the spatial orientation of the atoms or groups of atoms within the molecule. This is 
due to the presence of one or more stereogenic centers in the compound, i.e. an atom where the 
interchange of two ligands or substituents creates a new stereoisomer. When a pair of stereoisomers 
are non-superimposable mirror images of each other they are called enantiomer. Enantiomers possess 
identical physico-chemical properties, outside chiral environments, except that they rotate the plane of 
polarized light in opposite directions and by equal amounts. An equimolar mixture of enantiomers is 
called a racemate or a racemic mixture [1; 2]. Dextromethorphan (DXM) is an example of a drug 






When the stereoisomers are not enantiomers of each other are termed diastereoisomers [1; 2]. An 
example of compounds having diastereoisomers is the antiviral drug dolutegravir which has two 




















Figure 2 Dolutegravir (left) and its (4R, 12aR) Diastereomer (right) 
 
1.1.2. Stereoselectivity and physiological activity  
The significance of drug stereochemistry in pharmacology was recognized since 1926 [3]. Due to the 
different spatial arrangement of the chiral drugs, they may not interact in the same way with receptors 
and/or enzymes. In other words, they interact in a stereoselective way with the targets, which is shown 










simplified in Fig. 3. This may lead to different pharmacological responses that range from inactivity to 
different undesirable effects, which may include toxicity or teratogenicity. Many publications addressed 
the significance of stereochemistry in drug research and development [4–9].  
 
 
Medetomidine (MDT), studied in manuscripts 3 and 4, is a good example of enantiomers with different 
potency. Dexmedetomidine (D‐MDT) is used as a sedative in anesthesia management in surgery and 
in intensive care medicine [10; 11]. D-MDT displayed much higher activity in animal experiments, 
compared to its enantiomer levomedetomidine [12; 13].  
DXM (Fig. 1), which is studied in manuscript 2, is an example of the undesirable effects of the enantiomer 
since it is widely used as an antitussive in over-the-counter cough and cold medicines [14]. DXM has 
an ent-morphinan structure, while its enantiomer levomethorphan (LVM, Fig. 1) has a morphinan 
structure and is an opioid analgesic drug with strong respiratory depression. The compound was never 
clinically developed and is classified as a controlled substance worldwide [15].  
 
1.1.3. Chiral drugs in market and chiral switches 
As of 2008, a review of the new chiral drug development in Japan reported an increasing trend in the 
pharmaceutical development of single isomers rather than racemates [16]. Parallel to this, the annual 
distribution of FDA-approved drugs from 1992 to 2008 indicated a clear trend that the racemate drugs 
are decreasing from 1992 (about 21%) to 2008 (5%), without any new racemic drug introduction in 2001 
and 2003. The chiral drugs increased from 30–40% in the 1990s to around 60% or above since 2000 
[5].  
Binding Site                      Binding Site                                 Binding Site 
Active Enantiomer            Inactive Enantiomer           Inactive Enantiomer 
Rotatio
 
Figure 3 The active enantiomer has a 3-dimensional structure that allows drug domain A to interact with binding 
site domain a, B to interact with b, and C to interact with c. In contrast, the inactive enantiomer cannot be aligned 
to bind the same 3 sites simultaneously. The difference in 3-dimensional structure allows the active enantiomer 
to bind and have a biological effect, whereas the inactive enantiomer cannot (reproduced with permission from 
[9]). 




The concept of “chiral switches” was introduced in the late nineties [17; 18], which means replacement 
of an already approved racemate by a single enantiomer [19], but the term was redefined to include 
drugs that were essentially developed as racemates but not necessarily approved and marketed as 
racemates prior to the switch [20]. Chiral switch is not to be mixed up with the sequence of operations 
that alternate between equilibrium and non-equilibrium conditions to switch the absolute configuration 
of a chiral center [21]. Dexmedetomidine (D-MDT), which is studied in manuscripts 3 and 4, represents 
an example of a chiral switch where the racemate MDT was available for veterinary use in the United 
States in 1996, while D-MDT was approved in 2006 for use in dogs and cats [22], but D-MDT was 
already approved by the US-FDA in 1999 for human use [23]. 
Chiral switching has potential advantages that include improving therapeutic index through increased 
potency and selectivity and decreased side-effects; improving the onset and duration of effect; and a 
decreasing propensity for drug-drug interactions, mediated largely by exploitation of stereoselectivity 
in pharmacokinetic properties [19].  
The chiral switches are thoroughly reviewed in the literature [24–26]. However, patenting of single 
enantiomers of already approved racemate is controversial. The main contra arguments are that it is 
mainly meant to extend patent franchise and protect against generic competition with the racemate, in 
addition to the enormous expenditure with no evidence of superiority of the single enantiomer over the 
racemate at comparable doses in some cases [27; 26]. 
 
1.1.4. Regulatory guidelines for the enantiomeric purity of drugs 
The United States food and drug administration (FDA) issued a guideline on the Development of New 
Stereoisomeric Drugs in 1992 [28] and the European medicines agency (EMA) issued a similar one in 
1993 [1]. However, both guidelines did not specify a limit for the enantiomeric purity of single isomeric 
substances [29; 30]. Although the guideline of International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (ICH) regarding specifications for test procedures 
and acceptance criteria for new drug substances and products (Q6A) excluded the chiral impurities from 
the thresholds defined in the guidelines Q3A and Q3B, but there is general consent that enantiomeric 
impurities should be considered in the same manner as other impurities [31–33]. DXM (Fig. 1) 
represents a good example for the development of regulations regarding enantiomeric purity since it 
was only covered by test of specific rotation in the pharmacopoeias. In 2013, severe adverse effects 
including cyanosis, respiratory distress, and seizures in addition to 60 fatalities were reported by the 
World Health organization due to consumption of dextromethorphan cough syrups contaminated with 
the respiratory suppressant enantiomeric impurity LVM [34; 35]. This led to introducing chromatographic 
tests for the enantiomeric purity of DXM in the United States Pharmacopeia [36] and the International 
Pharmacopoeia [37]. 
 




 Capillary Electrophoresis  
1.2.1. Basic principles and instrumentation  
Capillary electrophoresis (CE) is a physical analytical technique based on the migration of charged 
analytes in an electrolyte solution inside a capillary under the influence of a direct-current electric field 
[38; 36]. The separation takes place usually in a narrow bore fused silica capillary with an inner diameter 
(ID) of 25-100 micrometers, but it was later extended to include microfluidic or nanofluidic channels 
(primarily on plastic or glass chips) [39].  
A basic CE system (Fig. 4) is composed of silica capillary whose both open ends are immersed in two 
containers filled with an ionic solution known as the Background electrolyte (BGE). The same solution 
is also filled into the capillary. An electrode is immersed in each container (a cathode and an anode), 
and both are attached to a high voltage power supply that supplies a direct current having an adjustable 




The most common CE separations involve aqueous buffers as BGEs, although other solvents are also 
(less frequently) applied in non-aqueous Capillary electrophoresis (NACE), where polar organic solvents 
(e.g. Methanol, acetonitrile, formamide, N-methylformamide) are used to prepare the BGEs [40]. 
CE silica capillaries are coated with a polymer (e.g. polyimide) to ensure flexibility, therefore a 
contactless detector is installed on the so-called detection window which is UV-Vis transparent part of 
the capillary usually situated near the outlet end in the capillary. The prevalent contactless (on capillary) 
detection principle is UV Absorption which is a default part of the commercial CE systems either as an 
adjustable single wavelength detector or a photo diode array detector (DAD). Contactless conductivity 

















Figure 4 Schematic configuration of a basic CE system with on capillary detection 




the latter being very sensitive but only capable of measuring fluorescent samples which may require 
prior sample labeling. A sensitive and selective direct mass spectrometric (CE-MS) detection is also 
possible by coupling the open end of the capillary through an interface to the detector [41].  
Different approaches are deployed for introduction of sample solution into the capillary. These include 
hydrodynamic injection (HDI) by applying pressure or vacuum, electrokinetic injection (EKI), and gravity 
(siphoning) [42]. HDI and EKI are predominantly applied for sample injection.  
Joule heating is inherent to CE because of the electric current established across the capillary filled with 
an electrolyte solution. It is necessary to maintain the temperature of the capillary stable in order to 
ensure a good peak shape and a reproducible separation. Thermostatic mechanisms for CE capillaries 
depend on air or liquid cooling by using perfluorinated compounds [43]. 
CE systems are usually connected to a computer that controls the device and acquires the detector 
signals. In early systems the signals were recorded with an integrator. Most instruments for routine use 
have an integrated autosampler. 
 
1.2.1.1. Driving forces in capillary electromigration 
The mobility of an analyte under an electric field is determined by two phenomena, electrophoresis and 
electroosmosis [44; 38].  
Electrophoresis is the force that drives charged particles in solution under the action of an electric field. 
The electrophoretic mobility of a solute (µep) depends on its own characteristics (charge, molecular size 
and shape) and those of the buffer where the migration takes place (type and ionic strength of the 
electrolyte, pH, viscosity and additives) [42]. The electrophoretic velocity (νep) of a solute, assuming a 
spherical shape, is given by the equation: 
 





�  (1) 
 
Where: q = the effective charge of the solute, η = viscosity of the electrolyte solution, r = Stoke’s radius 
of the solute, V = applied voltage, L = total length of the capillary, E = V/L electric field strength. 
 
If two analytes have different mobilities, in a CE system, they will be separated as they migrate in 
different velocities.  
 
Electroosmosis has a fundamental role in CE operation. When an electric field is applied to a 
conductive solution in a capillary that has fixed charges on its interior wall, a plug-like flow of solvent is 
generated inside the capillary, called electro-osmotic flow (EOF). In a bare (uncoated) fused silica 
capillary, the inner surface contains ionizable silanol groups (SiOH) that have pka values from 4 to 6. At 
pH values higher than 4, silanol groups ionize, and thus the inner capillary surface has a negative charge 
[45]. As hydrated cations accumulate near the surface, a so-called double layer (Fig. 5) is built. The 
EOF results from the effect of the applied electric field on the solution double layer at the wall and drives 




the solutes towards the cathode in this case. The EOF velocity depends on the electro-osmotic mobility 
(µeo) which in turn depends on the charge density on the capillary internal wall and the buffer 
characteristics (conductivity and viscosity) [46]. The electro-osmotic velocity (νeo) is given by the 
equation: 





�  (2) 
 
Where: ε = buffer solution’s dielectric constant, ζ = zeta potential of the capillary surface. 
 
The predominant factor that controls the zeta potential in a bare silica capillary is the pH of the BGE, 
therefore the EOF becomes faster with the higher pH values and reaches the maximum when the 




Figure 5 Electro osmotic flow (EOF) in a bare fused silica capillary 
 
The overall velocity of the solute (ν) is the sum of both driving forces: 
𝜈𝜈 = 𝜈𝜈𝑒𝑒𝑒𝑒 +  𝜈𝜈𝑒𝑒𝑒𝑒 = 𝐸𝐸 × (𝜇𝜇𝑒𝑒𝑒𝑒 +  𝜇𝜇𝑒𝑒𝑒𝑒)   (3) 
 
Dividing equation (3) by the strength of the electric field E results in the effective mobility (µeff): 
𝜇𝜇𝑒𝑒𝑒𝑒𝑒𝑒 = 𝜇𝜇𝑒𝑒𝑒𝑒 +  𝜇𝜇𝑒𝑒𝑒𝑒 (4) 
 
The electrophoretic mobility and the EOF may act synergistically driving the analyte in the same direction 
or against each other in different directions. Cations migrate to the cathode in an uncoated silica capillary 
since their own mobility is in the EOF direction, while Anions that tend to migrate oppositely due to their 
charge are ruled by the EOF value that can drive them to the cathode when it is faster than their own 
electrophoretic velocities. Hence, both cations and anions can be separated in one run with a suitable 
EOF. The EOF can be suppressed, modified, or even reversed by derivatizing the capillary wall or 
coating it using different strategies [47]. 





1.2.2. Examples of capillary electrophoresis modes 
1.2.2.1. Capillary zone electrophoresis (CZE)  
Very often, capillary electrophoresis refers to CZE, which is the simplest form of CE. In this mode, the 
analytes are separated in a capillary containing only buffer without any anticonvective medium [38; 36], 
and separation occurs because solutes migrate at different velocities and in discrete zones. CZE can 
be performed in the presence or absence of EOF and its high flexibility allows analyzing compounds 
with low and high molecular weights [48].  
 
1.2.2.2. Micellar electrokinetic chromatography (MEKC)  
MEKC is a hybrid of electrophoresis and chromatography where samples are separated by differential 
partitioning between two phases. The main advantage is that it can simultaneously separate neutral 
solutes as well as charged ones [42]. Surfactants are added to the BGE to enable the separation of 
neutral species at a concentration above its critical micelle concentration (CMC), which leads to the  
formation of micelles (aggregates of surfactant molecules) that are often spherical with the hydrophobic 
tails oriented towards the center, and the charged heads forming the surface adjacent to the buffer. 
Sodium dodecyl sulfate (SDS) is predominantly used as the surfactant in MEKC. The micelles act as a 
pseudo stationary phase, where the analytes will distribute between them and the bulk aqueous phase 
depending on their partition coefficient. The hydrophilic neutral analytes having no affinity for the micelle 
remain in the aqueous phase and migrate with the EOF, while hydrophobic neutral species will migrate 
in the micellar phase depending on their hydrophobicity, which in turn affects the mobility of their “carrier” 
micelles. The migration behavior of charged analytes is more complex since it combines the hydrophobic 
partitioning, electrophoretic mobility and electrostatic interaction with the micelles [50; 48].  
 
1.2.2.3. Capillary gel electrophoresis (CGE) 
The separation takes place inside a capillary filled with a gel that acts as a molecular sieve in this mode. 
The sieving effect occurs as solutes of various sizes migrate through the gel filled capillary toward the 
detector, as smaller molecules migrate faster through the network of the gel and thus can be separated 
from larger ones. This technique is applied in biochemistry for the separation of analytes having no 
differences in mass-to-charge ratio (e.g. nucleic acids and proteins or their complexes) [48; 42; 49].  
 
 
1.2.3. Capillary electrophoresis for chiral analysis 
1.2.3.1. Theory of chiral separation in CE 
Chiral separation in CE can be achieved indirectly, i.e. via derivatizing the samples with a single 
enantiomer reagent which binds covalently to the enantiomers in the sample and forms diastereomers 




that can be separated in an achiral environment. Nevertheless, the prevalent method is the direct 
separation by adding a suitable chiral selector to the BGE which enables the enantioresolution, via the 
formation of transient diastereomeric complexes with the enantiomers in a thermodynamic equilibrium 
[51; 52]. 
When using a single selector, and assuming the 1:1 stoichiometry of the analyte–selector complexes, 
the equilibria between the S and R enantiomers of the analyte and the chiral selector, C, are given by: 
𝑆𝑆 + 𝐶𝐶 → 𝑆𝑆𝐶𝐶            𝐾𝐾𝑆𝑆 =
[𝑆𝑆𝑆𝑆]
[𝑆𝑆][𝑆𝑆]
    
𝑅𝑅 + 𝐶𝐶 → 𝑅𝑅𝐶𝐶            𝐾𝐾𝑅𝑅 =
[𝑅𝑅𝑆𝑆]
[𝑅𝑅][𝑆𝑆]
   (5) 
The solute enantiomers may exist in a complexed and a noncomplexed form in the presence of a chiral 





where µC is the mobility of the analyte–selector complex, µf the mobility of the free analyte, K the 
complexation constant of the corresponding enantiomer, and [C] the molar concentration of the chiral 
selector [53; 54].  
In order that an enantioseparation takes place, a difference in the effective mobilities of the enantiomers, 
𝜇𝜇𝑒𝑒𝑒𝑒𝑒𝑒𝑆𝑆  and 𝜇𝜇𝑒𝑒𝑒𝑒𝑒𝑒𝑅𝑅  is required: 











As seen in equation (7), the enantioseparations in CE are governed by the difference of complex 
mobilities and/or the difference of complexation constants. These two enantioselective principles are 
called the chromatographic and the electrophoretic mechanisms.  
The chromatographic (or thermodynamic) mechanism, which also governs enantioresolution in HPLC, 
is based on the different affinities of the selector toward the solute enantiomers, which can be expressed 
as complexation constants (KS ≠ KR) [52]. 
The electrophoretic enantioselective mechanism results from differences in the mobilities of the 
enantiomer-selector complexes, for example as a result of differences in their hydrodynamic radii or the 
so-called complexation-induced pKa shift [55; 56].  
The separation in chiral CE can be due to both mechanisms, but the chromatographic mechanism is 
typically the dominant one since the enantiomer–selector complexes have similar charge densities and 
their hydrodynamic radii do not differ significantly [52]. Nevertheless, it is also possible to obtain an 
enantioseparation when both enantiomers have similar affinities to the selector (KR = KS) [56]. 
 




1.2.3.2. Cyclodextrins as chiral CE additives 
Many additives can be used as chiral selectors in CE separations. These include cyclodextrins, 
macrocyclic antibiotics, crown ethers, polysaccharides and proteins among others [57; 58]. 
Nevertheless, cyclodextrins are the most used chiral selectors in CE due to their stability, UV-
transparency, availability, the large number of derivatives, and the affordability of most of them [59–61]. 
Cyclodextrins (CDs) are cyclic oligosaccharides, which consist of α1,4-linked d-glucopyranose units. 
The three native CDs are α-CD which consists of six glucose units, β-CD seven and γ-CD eight. The 
three-dimensional structure of CDs is like hollow toroids with a lipophilic cavity and a hydrophilic outside 
[59]. The narrow rim contains the primary 6-hydroxyl groups, while the wider rim features the secondary 
2- and 3-hydroxyl groups (Fig. 6). A large number of CD derivatives can be prepared by chemical 
derivatization of the hydroxyl groups and many of them are commercially available [62; 58]. CDs are 




Figure 6 The general formula of CDs where: α-CD (n=6), β-CD (n=7) and γ-CD (n=8) (left), the three-dimensional 
toroidal shape of the CDs with the spatial positions of OH groups (2,3,6) and hydrogens (2,3,4,5) (middle), and 
the structure of γ-CD showing the substitution sites on the hydroxyl groups (right) 
 
The native α-, β-, and γ-cyclodextrins have many neutral derivatives (methyl, ethyl, hydroxyalkyl, etc.) 
or ionizable ones (aminomethyl, carboxymethyl, sulfobutyl ether, etc.) groups. The structures of the most 
frequently use CDs in this work are summarized in Table 1. 
  









CD n R2 R3 R6 
α-CD 6 H H H 
M-α-CD 6 CH3 CH3 CH3 
HP-α-CD 6 CH2-CHOH-CH3 CH2-CHOH-CH3 CH2-CHOH-CH3 
CM-α-CD 6 CH2-COOH CH2-COOH CH2-COOH 
S-α-CD 6 SO3H SO3H SO3H 
β-CD 7 H H H 
M-β-CD 7 CH3 CH3 CH3 
DM-β-CD 7 CH3 CH3 CH3 
TM-β-CD 7 CH3 CH3 CH3 
HE-β-CD 7 CH2-CH2-OH CH2-CH2-OH CH2-CH2-OH 
HP-β-CD 7 CH2-CHOH-CH3 CH2-CHOH-CH3 CH2-CHOH-CH3 
CM-β-CD 7 CH2-COOH CH2-COOH CH2-COOH 
SBE-β-CD 7 (CH2)4-SO3H (CH2)4-SO3H (CH2)4-SO3H 
S-β-CD 7 SO3H SO3H SO3H 
HS-β-CD 7 H H SO3H 
γ-CD 8 H H H 
M-γ-CD 8 CH3 CH3 CH3 
HP-γ-CD 8 CH2-CHOH-CH3 CH2-CHOH-CH3 CH2-CHOH-CH3 
CM-γ-CD 8 CH2-COOH CH2-COOH CH2-COOH 
S-γ-CD 8 SO3H SO3H SO3H 
M-α-CD, methyl-α-CD; HP-α-CD, hydroxypropyl-α-CD; CM-α-CD, carboxymethyl-α-CD; S-α-CD, 
sulfated α-CD; CM-β-CD, carboxymethyl-β-CD; M-β-CD, methyl-β-CD; DM-β-CD, heptakis(2,6-di-O-
methyl)-β-CD; S-β-CD, sulfated β-CD; HP-γ-CD, hydroxypropyl-γ-CD; CM-γ-CD, carboxymethyl-γ-CD; 
M-γ-CD, methyl-γ-CD; S-γ-CD, sulfated γ-CD; HS-β-CD, heptakis(6-di-O-sulfo)-β-CD; HP-β-CD, 
hydroxypropyl-β-CD; SBE-β-CD, sulfobutylether-β-CD, TM-β-CD, heptakis(2,3,6-tri-O-methyl)-β-CD 
 
 
1.2.3.3. Chiral CE in pharmaceutical analysis  
A key feature of CE is the overall simplicity of the instrumentation. Moreover, CE has many established 
benefits such as the small sample volume (usually a few nanoliters), high separation efficiency, low cost, 
eco-friendliness due to the reduced use of organic solvents, and high flexibility in method development 




[65; 66]. Consequently, it has been increasingly used for the analysis of pharmaceuticals [67–70; 49; 
71] including of peptides/proteins, chiral pharmaceuticals, and other small-molecule drugs.  
As an effective method for stereoisomer separations, chiral CE is widely applied for analytical 
enantioseparations of drug compounds in pharmaceuticals and biological media [62; 72–77]. 
Although CE and other electromigration techniques are well‐established in the analysis of biomolecules, 
such as DNA and proteins, they are still not widely used as routine methods for the enantiomeric purity 
of drugs in the official compendia compared to HPLC [78].  
 
 Experimental design in development of analytical separation methods 
The classic development and optimization of analytical separation methods depended in the past on 
screening the effect of each factor affecting the separation alone (one-factor-at-a-time or OFAT). This 
approach is time consuming due to the large number of experiments and it doesn’t take the factors 
interaction into account. Quality by design (QbD) approach has largely replaced OFAT as a strategy for 
the development of analytical separation methods in the recent years. QbD is described as the definition 
of a systematic approach for the setting up of analytical methods [79]. It employs multivariate design of 
experiments (DoE) and risk assessment tools for the identification of the critical process parameters 
(CPPs), which are the experimental factors that influence the critical quality attributes (CQAs) of the 
method [79–83]. This leads to understanding of the quantitative effects of the CPPs on the analytical 
process [84]. Risk analysis is also an essential part of the analytical pharmaceutical development which 
incurs the product and the process [85; 86]. The steps of an analytical separation method development 
using QbD are described concisely here, with specific concentration on CE and chiral CE methods. 
 
1.3.1. Determination of the analytical target profile and scouting experiments 
The first step in QbD-assisted method development is defining the analytical target profile (ATP), which 
is a set of criteria that define what will be measured and the performance criteria of the method, but 
without necessarily specifying the method itself [87]. The aim of an analytical separation technique is to 
obtain an assay that allows the successful separation and quantification of the analytes in a short 
analysis time, with accepted reproducibility and ruggedness [81]. The CQAs are quality criteria for the 
results generated by analytical method and can be defined considering the ATP. The analytical run time 
and the resolution (enantioresolution in chiral CE) are mainly identified as CQAs in CE methods, but 
they may also include the theoretical plate count, signal to noise ratio, and/or signal intensity [80; 83].  
Initial scouting experiments are performed afterwards in order to provide an idea of the method that can 
be further optimized. This includes in case of chiral CE screening different chiral selectors to identify a 
suitable one (or a combination).  
 




1.3.2. Identification of the CPPs 
Many factors affect the CQAs of separation methods such as the column (length, type, dimensions, 
particle size), and the mobile phase composition in HPLC. Initial risk assessment of the factors leads to 
fixing some of them and identifying others as CPPs for further optimization by DoE.  The CPPs include 
may include quantitative as well as qualitative factors.  
The CPPs in CE methods are selected from many factors that affect the method which can be 
categorized as instrumental parameters and factors related to the electrolyte solution.  
Instrumental parameters include the applied voltage which can be increased to shorten the run time, 
but this would increase the capillary temperature through Joule heating and may cause peak broadening 
due to viscosity gradients in the buffer inside the capillary. The capillary temperature is another 
instrumental factor which affects the migration velocity mainly through decreasing the BGE viscosity, 
but care should be taken for the stability of the samples. The dimensions of the capillary (length and 
internal diameter) are also important factors, where a longer capillary increases the separation times 
but enhances the resolutions and yields lower field intensity with lower current thereby. A larger internal 
diameter enhances the sensitivity of the detection but increases the current for a given field intensity 
and BGE composition. 
Electrolyte solution factors include the buffer type, which should be appropriately chosen for in the 
pH range of interest, and the buffer concentration to ensure proper capacity and minimize current 
generation. Buffer pH is an important factor since it affects the charge of the analyte or additives and 
can also change the EOF. Organic solvents (methanol, acetonitrile, etc.) may be added to aqueous 
BGEs to increase the solubility of the solute or other additives and/or to affect the degree of ionization 
of the sample components. In addition, the type and concentration of the chiral selector(s) in chiral CE, 
affects the enantioresolution, the BGE viscosity, and the generated current in case of charged selectors. 
 
1.3.3. Knowledge space and initial screening of factors 
After identifying the CPPs and the CQAs in light of the ATP and the initial scouting experiments, the 
knowledge space is determined by DoE. In order to perform a reasonable number of analytical runs, the 
effect of the CPPs as factors (within predefined ranges) on the CQAs as responses is usually determined 
by screening designs (e.g. fractional factorial designs) [79; 81]. The resulting statistical model leads to 
an initial estimation of the relative effects of the factors on each CQA, which can be estimated by 
graphical tools. Subsequently, some factors are fixed considering the results and the others are 
considered CQAs and further optimized.  
 
1.3.4. Design space definition by response surface methodology 
The design space for analytical methods can be defined as a zone of theoretical robustness where no 
drastic changes in the levels of the CQAs of the method should be observed [79]. The design space is 




determined by response surface methodology (RSM) which comprises the prediction and optimization 
of the responses by using response-surface designs (e.g. central composite designs or full factorial 
designs) [88; 89].  
 
1.3.5. Working point and robustness testing 
The definition of the design space allows selecting a working point that meets the required CQAs within 
an accepted risk of failure. Subsequently, the robustness [90] of the working point is verified in order to 
ensure its suitability for use before further validation [84]. 
 
 Cyclodextrin-selectand complexation 
Complexation of guest molecules often occurs via their inclusion into the CD cavity either from the 
narrower or the wider side of the torus, displacing solvent molecules from the cavity. The driving forces 
are Van der Waals and hydrophobic interactions, hydrogen bonding with the hydroxyl groups on the 
rims, and steric factors. In the case of charged CD derivatives, ionic interactions also play a role [91–
93]. While most selector-selectand complexes were shown to be of the inclusion type, several studies 
demonstrated the formation of external complexes which led to effective CE enantioseparations [94–
96]. 
Structural information on the complexes can be obtained by NMR and X-ray analyses. Nuclear 
Overhauser effect-based NMR methods, in particular rotating frame nuclear Overhauser effect 
spectroscopy (ROESY), allow the determination of correlation of spatially close nuclei and proved to be 
a valuable tool to elucidate the structure of selector-selectand complexes [97–100]. Furthermore, as 
NMR is a solution technique, experiments can be carried out under conditions comparable to those used 
in CE with regard to BGE composition, pH and temperature. 
CE can be applied to study the complexation between high- and low-molecular weight compounds [101–
104].  
 
1.4.1. Stoichiometry of CD complexes 
The stoichiometry of CD complexes has been determined by many techniques [105–107], including 
NMR spectroscopy [97; 98; 100]. The most commonly reported stoichiometry for CD complexes is 1:1 
(solute:CD) [105; 107; 106] although higher order aggregates have also been published. The 
composition 1:2 is the second most abundant [107]. In contrast, stoichiometries of 1:3, 2:1 and 2:2 have 
been rarely reported. Furthermore, ternary CD complexes including additional background electrolyte 
components such as SDS in addition to the analytical solute with a ratio of 1:1:1 were described [108; 
109].  
 




2. Scopes and objectives 
 
The regulatory requirements for the chiral purity of pharmaceuticals have become more important over 
time. Although chiral HPLC is widely used for this purpose as it is mainly the method of choice in 
compendial monographs for the enantiomeric purity determination, but chiral capillary electrophoresis 
is also a strong and flexible tool thereof, with an increasing number of examples published over the 
years. 
In the recent years QbD methodology largely replaced the trial and error approach which involves 
optimizing one experimental factor each time. QbD has become a standard approach followed foe 
method development in analytical separation techniques including CE. 
Regarding chiral CE, cyclodextrins are the most widely applied selectors due to their versatility, stability, 
UV-transparency, and the commercial availability of many derivatives. The underlying mechanisms of 
chiral recognition using CDs can be studied with CE itself by calculating the thermodynamic parameters 
that govern the separation. NMR spectroscopy is also an important tool for elucidating the structures of 
the CD complexes with the analytes. Additionally, molecular dynamics (MD) simulations help to 
understand the complexation mechanisms. 
 
Considering all this, the aim of the work was: 
- Development and validation of CE assays for the enantiomeric purity of the drugs Amb, DXM 
and D-MDT at the 0.1% level, with acceptable accuracy and precision. 
- Following a QbD methodology for method development, optimization and validation. 
- Elucidation of the chiral separation mechanisms for DXM and D-MDT. 
- Explaining the role of a dual selector system in peak shape improvement in the case of DXM. 
- Using CE, NMR, and molecular dynamics to understand the role of CD cavity size and CD 
substitution pattern in the reversal of enantiomeric migration order. 
- Clarifying an unusual complexation behavior of γ-CD and daclatasvir which is observed in CE, 
by using NMR and mass spectroscopy in addition to CE methods. 
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Introduction
Pulmonary arterial hypertension (PAH) is a rare disease 
that can be idiopathic or heritable in nature, or associated 
with other pathophysiological conditions such as sclero-
derma or congenital heart disease [1]. It is characterized by 
narrowing of the small pulmonary arteries and increased 
vascular resistance eventually leading to right ventricular 
failure [2]. The exact pathophysiological processes lead-
ing to PAH are still unknown although it is recognized that 
PAH has a multifactorial pathobiology involving various 
biochemical pathways and cell types [3]. Endothelin-1, a 
21-amino acid peptide, that plays a key role in the pathobi-
ology of PAH exerts vasoconstrictor and mitogenic effects 
via binding to the endothelin A and B receptors in the pul-
monary vascular smooth muscle cells [4].
(S)-Ambrisentan [(S)-2-[(4,6-dimethylpyrimidin-2-yl)
oxy]-3-methoxy-3,3-diphenylpropanoic acid, Fig. 1] is a 
diphenylpropanoic acid derivative which acts as a selec-
tive endothelin receptor antagonist with a bioavailability 
and half-life which allow once-daily dosing [5]. It was 
approved by US Food and Drug Administration (FDA) in 
2007 [6] and by the European Medicines Agency (EMA) 
in 2008 [7]. Several HPLC methods for the determination 
of (S)-ambrisentan and its related substances in bulk drug 
or dosage forms [8–12] as well as LC–MS methods for the 
analysis of the drug in plasma [12–15] have been reported. 
Because (S)-ambrisentan is an enantiomerically pure drug 
possessing (S)-configuration, LC methods have been devel-
oped for the analysis of the chiral purity of the drug [16, 
17].
Abstract A quality by design approach utilizing experi-
mental design methodologies was applied to develop a 
CE method to evaluate the enantiomeric purity of (S)-
ambrisentan, a selective endothelin receptor antagonist 
used for the treatment of pulmonary arterial hypertension. 
Initial method scouting was performed by screening native 
cyclodextrins (CDs) as well as neutral CD derivatives and a 
positively charged derivative at pH 5 and pH 9, identifying 
γ-CD as suitable selector at pH 5. Upon defining the criti-
cal quality attributes and the critical process parameters, 
i.e., chiral resolution and run time, method development
was performed by application of a screening design for the 
identification of the significant variables and, subsequently, 
by a response surface methodology for obtaining the design 
space. A Plackett–Burman design was employed for robust-
ness testing. The final working point conditions used a 
background electrolyte composed of a 50-mM sodium ace-
tate buffer, pH 4.0, containing 30 mM γ-CD in a 75-μm 
ID fused-silica capillary with an effective length of 40 cm 
at an applied voltage of 25 kV and a capillary temperature 
of 25 °C. The method was validated according to the ICH 
Q2(R1) guideline and allowed the determination of a rela-
tive concentration of the (R)-enantiomer of 0.1 %.
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CE has long been recognized as a suitable technique for 
enantioseparations including the analysis of the chiral purity of 
drugs due to the high separation efficiency and low consump-
tion of sample and chemicals [18–21]. Therefore, the aim of 
the present study was the development of a CE method for the 
determination of the chiral purity of (S)-ambrisentan. Qual-
ity by design (QbD) was employed as a risk-based approach 
in analytical method development [22–24]. Using prede-
fined critical quality attributes, a screening phase followed 
by response surface methodology allowed the definition of a 
design space in combination with Monte Carlo simulations.
Materials and Methods
Chemicals
(S)-Ambrisentan (purity 99.7 %) and (R)-ambrisentan (purity 
99.6 %) were a gift from Zentiva (Praha, Czech Repub-
lic). A commercial sample was from TCI Europe (Zwijn-
drecht, Belgium). β-cyclodextrin (β-CD) was from Wacker 
Chemie AG (Burghausen, Germany). Hydroxyethyl-β-
cyclodextrin (HE-β-CD, degree of substitution (DS) ~4.9), 
γ-cyclodextrin (γ-CD), and metformin hydrochloride were 
from Sigma-Aldrich (Steinheim, Germany). α-Cylodextrin 
(α-CD), hydroxypropyl-α-cyclodextrin (HP-α-CD, DS ~4.5), 
methyl-β-cyclodextrin (M-β-CD, DS ~12), hydroxypropyl-
β-cyclodextrin (HP-β-CD, DS ~4.5), hydroxypropyl-γ-
cyclodextrin (HP-γ-CD, DS ~4.5) and (2-hydroxy-3-N,N,N-
trimethylamino)propyl-β-cyclodextrin chloride (TMA-β-CD, 
DS 2.5–4.5) were from Cyclolab Ltd. (Budapest, Hungary). 
Boric acid, sodium tetraborate decahydrate, glacial acetic 
acid and sodium hydroxide were from Merck (Darmstadt, 
Germany). Water was purified by a GenPure system (Thermo 
Fischer, Waltham, USA).
Sample Solutions
A stock solution of (S)-ambrisentan at a concentration of 
1.4 mg L−1 was prepared in water/methanol/0.1 M sodium 
hydroxide (6:2:2, v/v/v), while a stock solution of (R)-
ambrisentan at a concentration of 0.5 mg mL−1 was pre-
pared in water/methanol/0.1 M sodium hydroxide (8:1:1, 
v/v/v). Dilution of the stock solutions to the appropriate 
concentrations was performed in such a way that the sam-
ple solutions were obtained in the solvent system water/
methanol/0.1 M sodium hydroxide (8:1:1, v/v/v). Sample 
solutions were stored at –20 °C for a maximum of 14 days. 
Prior to use, the solutions were filtered (0.22 μm) and soni-
cated for 5 min.
Instrumentation
CE experiments were performed using a Beckman P/ACE 
MDQ capillary electrophoresis system (Beckman Coul-
ter, Krefeld, Germany) equipped with a UV–Vis diode 
array detector. The 32 Karat software (version 8.0) was 
used for system control, data acquisition and processing. 
40/50.2-cm fused-silica capillaries with an ID of either 50 
or 75 μm and an OD of 363 μm were from BGB Analy-
tik (Schloßböckelheim, Germany). A new capillary was 
successively rinsed at a pressure of 20 psi (138 kPa) with 
0.1 M sodium hydroxide for 10 min, water for 15 min, and 
acetic acid 1 % (v/v) for 20 min. At the beginning and end 
of each day, the capillary was rinsed with 0.1 M sodium 
hydroxide for 5 min, water for 10 min and acetic acid 
1 % (v/v) for 20 min. Between analyses, the capillary was 
flushed with water for 1 min, acetic acid 1 % (v/v) for 1 min 
and the background electrolyte (BGE) for 3 min. The BGE 
consisted of 30 mM γ-CD in 50 mM acetic acid, adjusted 
to pH 4.0 by the addition of 0.1 M sodium hydroxide. The 
BGE was filtered (0.22 μm) and sonicated for 10 min prior 
to its use. The applied voltage was 25 kV, and the capil-
lary temperature was set at 25 °C. Hydrodynamic sample 
injection was performed at a pressure of 0.7 psi (4.8 kPa) 
for 5 s. UV detection was carried out at the cathodic end at 
200 nm.
Software
MODDE 10.1 (Umetrics, Umea, Sweden) was used for the 
experimental design and statistical analysis of the screen-
ing, response surface methodology and robustness testing. 
The data obtained from the respective designs were fitted to 
a model using the quadratic polynomial equation [25]:
where y is the predicted response (resolution or migra-
tion time), β0 is the intercept, βi are the coefficients to be 
optimized (voltage, temperature, buffer pH and concen-
tration, and/or CD concentration), βij are the interaction 



























Fig. 1  Structures of (S)-ambrisentan and (R)-ambrisentan
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coefficients, and βii are the quadratic coefficients, with the 
interaction effect terms restricted to two-factor interactions. 
Microsoft Excel 2007 was used for the statistical analysis 
of the validation data.
Results and Discussion
Quality by design for analytical methods requires to define 
the analytical target profile and, subsequently, to develop 
and validate the method considering the critical quality 
attributes and critical process parameters [22–24]. Thus, 
the analytical target profile was defined as a method allow-
ing the precise determination of the (R)-enantiomer at a 
relative concentration of 0.1 % within an analysis time of 
less than 10 min.
Method Scouting
(S)-Ambrisentan is a weak acid with a pKa of about 4.0 
[26]. Therefore, a 100-mM sodium acetate buffer, pH 5.0, 
and a 25-mM sodium tetraborate buffer, pH 9.0, were ini-
tially evaluated. At these pH values, (S)-ambrisentan will 
be negatively charged. Native CDs as well as the neutral 
CD derivatives M-β-CD, HE-β-CD, HP-α-CD, HP-β-CD 
and HP-γ-CD and the positively charged CD derivative 
TMA-β-CD were studied as chiral selectors at concen-
trations of about 25 mM in a 50-μm ID capillary with 
an effective length of 40 cm at a capillary temperature of 
20 °C and an applied voltage of 20 kV. A sample solution 
containing 40 μg mL−1 (S)-ambrisentan and 20 μg mL−1 
(R)-ambrisentan was used. Neutral CDs were evaluated 
under normal polarity of the applied voltage, while the 
polarity was reversed in the presence of TMA-β-CD. At 
pH 9.0, no separation of (S)-ambrisentan and its (R)-enan-
tiomer could be achieved with any of the CDs. In contrast, 
partial separation was observed at pH 5.0 in the presence of 
β-CD and HP-γ-CD with the (R)-enantiomer migrating first 
and using M-β-CD with (S)-ambrisentan migrating first. 
Only in the presence of γ-CD as chiral selector at pH 5.0, 
a baseline separation was achieved with the (R)-enantiomer 
migrating before (S)-ambrisentan. Because migration of an 
impurity before the major compound is preferable for CE 
impurity assays, γ-CD was chosen as chiral selector for 
further method development.
Critical Quality Attributes and Critical Process 
Parameters
Method development in the light of the QbD approach 
was performed using experimental design methodologies. 
Resolution (RS) between (S)-ambrisentan and the (R)-enan-
tiomer and the migration time of (S)-ambrisentan as the 
second migrating enantiomer as measure for analysis time 
were defined as critical quality attributes. The target values 
were set as baseline resolution, i.e., RS ≥ 1.5, and migra-
tion time of (S)-ambrisentan ≤10 min. Risk assessment of
experimental factors affecting these attributes was based on 
the initial scouting experiments as well as general experi-
ence in chiral CE methods. Consequently, the instrumental 
parameters, separation voltage and capillary temperature, 
as well as parameters related to the BGE, i.e., pH, electro-
lyte concentration and CD concentration, were considered 
as critical process parameters.
Determination of the Knowledge Space
A fractional factorial Res V+ design was used to gener-
ate a three-level screening matrix for evaluating the effect 
of the critical process parameters using the following 
factor ranges: voltage 15–25 kV, capillary temperature 
15–25 °C, pH of the BGE 3.8–5.5, acetate concentra-
tion 50–200 mM and γ-CD concentration 10–50 mM. 
Peak resolution and migration time were the responses. 
The experiments were performed using a sample solution 
containing 500 μg mL−1 (S)-ambrisentan and 5 μg mL−1 
of the (R)-enantiomer, i.e., at a relative concentration of 
the enantiomeric impurity of 1 %. The design matrix as 
well as the data of the responses are summarized in Table 
S1 (see supplementary material). The data were subse-
quently fitted by multiple linear regression, and the mod-
els were adjusted by deleting non-significant interacting 
factors and adding detected square values to increase the 
Q2 values, which estimate the precision of the predic-
tion, to enhance the validity of the model. Final Q2 values 
were 0.975 and 0.985 for the peak resolution and migra-
tion time models, respectively. Statistical analysis of 
the regression coefficients of RS and migration time are 
shown in Fig. 2. The main factors affecting RS (Fig. 2a) 
were pH and BGE concentration with pH showing a 
negative correlation (RS increased with decreasing pH), 
while BGE concentration displayed a positive effect (RS 
increased with concentration). Smaller effects were seen 
for temperature and applied voltage where increasing RS 
values were observed for decreasing values of the vari-
ables. CD concentration had no significant effect on peak 
resolution within this experimental model. On the other 
hand, migration time of (S)-ambrisentan as a measure 
of run time (Fig. 2b) was mainly affected by the applied 
voltage and capillary temperature as well as BGE concen-
tration. Thus, migration times decreased with increasing 
voltage and temperature, while migration times increased 
with increasing BGE concentrations. The pH of the BGE 
and γ-CD concentration were also significant but with 




Response Surface Methodology and Design Space
In light of the screening results of the critical process parame-
ters, pH exerted a major effect on peak resolution and a minor 
effect on the run time. Thus, to obtain a high RS value, the pH 
of the BGE was fixed at pH 4.0 so that it was not directly set 
at the edge of the screening range. Also, because the CD con-
centration was insignificant for peak resolution and had only 
a minor effect on the run time, it was set at 30 mM, i.e., the 
medium value of the screening range. The remaining param-
eters, voltage, temperature and electrolyte concentration, 
were further investigated by response surface methodology. A 
three-level central composite face-centered design of the vari-
ables, voltage (15–25 kV), capillary temperature (15–25 °C) 
and acetate concentration (50–200 mM), was employed as 
summarized in Table S2 (see supplementary material). A 
sample solution containing 500 μg mL−1 (S)-ambrisentan 
and 5 μg mL−1 of the (R)-enantiomer was used. The data of 
the responses RS and migration time were fitted by multiple 
linear regression and the validity of the models was enhanced 
by deleting non-significant interacting and square factors. 
Q2 values were 0.747 and 0.864 for the peak resolution and 
migration time models, respectively.  The regression coeffi-
cients are shown in (Fig. 3).
Figure 4a shows the sweet plots at three levels of acetate 
concentration of 50, 125, and 200 mM to illustrate the area 
represented by voltage and capillary temperature where 
the target values of the critical quality attributes RS ≥ 1.5
Fig. 2  Regression coefficients 
plot of the screening design 
of the responses a resolution 
and b migration time of (S)-
ambrisentan. V applied voltage, 
Temp capillary temperature, Buf 
acetate buffer concentration in 
the BGE, CD γ-CD concen-
tration in the BGE, pH pH of 
the BGE; x × x represent the
quadratic terms for the respec-
tive parameter and x × y the
interaction terms between two 
parameters
Fig. 3  Regression coefficients 
plot of the response surface 
design of the responses a 
resolution and b migration 
time of (S)-ambrisentan. V 
applied voltage, Temp capillary 
temperature, Buf acetate buffer 
concentration in the BGE, x × x
represent the quadratic terms 
for the respective parameter and 
x × y the interaction terms
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and migration time of (S)-ambrisentan ≤10 min were met.
The largest area was obtained at a buffer concentration of 
50 mM. Subsequent Monte Carlo simulations at the three 
buffer concentrations for the determination of the design 
space are shown in Fig. 4b. The green areas mark the con-
ditions where failure of obtaining a peak resolution ≥1.5
within a run time ≤10 min is less than 1 %. As in the case of
the sweet plots, the area is larger at the lowest buffer concen-
tration. Subsequently, the following analysis conditions were 
chosen as working point: 50 mM sodium acetate buffer, pH 
4.0, containing 30 mM γ-CD as chiral selector, a capillary 
temperature of 25 °C and an applied voltage of 25 kV. The 
pH of the final BGE was equal to the approximate pKa of 
(S)-ambrisentan which illustrates the well-known fact that a 
chiral separation by CE can often be achieved at a pH of the 
BGE close to the pKa of the analyte. An electropherogram 
obtained for the separation of the enantiomers under these 
experimental conditions is shown in Fig. 5.
Robustness Testing
To ensure the detection of a relative concentration of 
0.1 % of the (R)-enantiomer, the sample concentration 
was increased to 700 μg mL−1 for (S)-ambrisentan and 
7 μg mL−1 for (R)-ambrisentan, and the ID of the capil-
lary was increased to 75 μm. Prior to method validation, 
the robustness of the method was verified by deliberately 
changing the critical process parameters within the fol-
lowing ranges: voltage 25 ± 1 kV, temperature 25 ± 1 °C,
buffer pH 4.0 ± 0.1, buffer concentration 50 ± 2 mM and
γ-CD concentration 30 ± 2.5 mM. A Plackett–Burman
design was applied for the robustness test. The matrix as 
Fig. 4  Sweet spot plots (a) and design space plots for risk of fail-
ure (b) at three levels of acetate buffer concentration of 50, 125, 
and 200 mM with the area represented by applied voltage and capil-
lary temperature. a Green areas represent areas where both criteria, 
RS ≥ 1.5 and migration time ≤10 min, are met, while the blue zones
indicate where only the RS criterion is met. b Green areas repre-
sent areas with a risk of failure of less than 1 % to meet the criteria 
RS ≥ 1.5 and migration time ≤10 min
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well as the resulting data for the critical quality attributes RS 
and migration time are summarized in Table S3 (see supple-
mentary material). Statistical analysis revealed no correla-
tion with standard deviations including zero. Furthermore, 
the data were within the acceptance criteria, i.e., RS > 1.5 
and analysis time <10 min. Thus, the method was robust 
and was subsequently validated.
Method Validation
The optimized method was validated according to the 
ICH guideline Q2(R1) [27]. Metformin hydrochloride at 
a concentration of 15 μg mL−1 was selected as internal 
standard. Metformin is a basic compound and, therefore, 
migrates before the EOF so that the total analysis time is 
not affected.
The specificity of the method was demonstrated by the 
resolution between the peaks of (S)-ambrisentan and its 
(R)-enantiomer. A sample containing only (S)-ambrisentan 
at a concentration of 700 μg mL−1 showed no interfering 
peaks at the migration times of the (R)-stereoisomer or 
the internal standard (data not shown). The limit of detec-
tion (LOD) and the limit of quantitation (LOQ) for (R)-
ambrisentan were calculated based on signal-to-noise (S/N) 
ratios of 3 and 10, respectively, and were found to be 0.2 
and 0.7 μg mL−1. An electropherogram of a sample con-
taining 0.7 μg mL−1 of the (R)-enantiomer in the presence 
of 700 μg mL−1 (S)-ambrisentan, corresponding to a rela-
tive concentration of the enantiomeric impurity of 0.1 %, is 
shown in Fig. 5.
The linearity of the method was evaluated by analyz-
ing five sample concentrations in triplicate between 0.7 
and 7.0 μg mL−1 of (R)-ambrisentan in the presence of 
700 μg mL−1 (S)-ambrisentan (relative concentrations of 
0.1–1 %). Linear regression of the ratios of the corrected 
peak areas of (R)-ambrisentan and the internal standard 
yielded the equation y = (0.09085 ± 0.0017)x + (0.04714
± 0.00761) with a coefficient of determination r2 = 0.9955.
Accuracy and precision data are listed in Table 1. Repeat-
ability was estimated using nine determinations covering 















Fig. 5  Electropherograms of a sample containing 700 µg mL−1 (S)-
ambrisentan and 0.7 µg mL−1 of the (R)-enantiomer correspond-
ing to a relative concentration of 0.1 %. Experimental conditions, 
40/50.2 cm, 75 μm ID fused-silica capillary, 50 mM sodium acetate 
buffer, pH 4.0, containing 30 mM γ-CD, 25 kV, 25 °C. S-Amb (S)-
ambrisentan, R-Amb (R)-ambrisentan, IS internal standard metformin 
hydrochloride, concentration 15 µg mL−1
Table 1  Accuracy and 
precision data
a Accuracy is expressed as mean recovery ± confidence interval % (n = 3, α/2 = 0.025)
b Repeatability is evaluated on 9 runs = 3 samples × 3 concentrations and expressed as RSD
c Intermediate precision is evaluated upon 3 consecutive days on 9 runs (3 samples @ 3 concentrations) 









Accuracya 0.14 0.2 97.5 ± 6.9 94.2 ± 3.9
3.85 0.55 101.8 ± 7.0 104.2 ± 2.2
6.3 0.9 99.4 ± 2.9 98.7 ± 0.3
Content repeatabilityb 4.9 4.8
Content intermediate precisionc 6.6 6.6
Resolution repeatability 3.4
Resolution intermediate precision 6.4
Migration time repeatability 1.0
Migration time intermediate precision 5.9
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the specified range for the procedure (three concentrations, 
three replicates each) [27], while data for intermediate 
precision were obtained at the three specified concentra-
tion levels by injecting triplicates of the samples on three 
consecutive days. Overall, acceptable figures of merit with 
RSD values below 10 % were obtained. This also applied 
to peak resolution and migration time of (S)-ambrisentan. 
In addition, intermediate precision was also estimated 
using the normalization approach, i.e., calculating the 
amount of (R)-ambrisentan from the peak area of the enan-
tiomeric impurity relative to the sum of the peak areas of 
(S)-ambrisentan plus its (R)-enantiomer (Table 1). Com-
parable RSD values of repeatability and precision were 
observed, but accuracy was lower in this case illustrating 
the well-known fact that the use of an internal standard in 
CE improves the accuracy of a method. Nonetheless, either 
using an internal standard method or using peak normaliza-
tion is suitable for the determination of the stereoisomeric 
purity of (S)-ambrisentan.
With regard to analysis time and LOQ, the CE method 
was comparable to published chiral HPLC methods uti-
lizing either a cellulose-based stationary phase in the 
reversed-phase mode [16] or an amylose-based stationary 
phase in the normal phase mode [17].
Method Application
The method was subsequently applied to the analysis of a 
sample obtained from a chemical supplier. The concentra-
tion of the (R)-enantiomer was 0.15 ± 0.01 %, calculated
using the internal standard and 0.17 ± 0.01 % when using
peak area normalization. Similar contents of (R)-ambrisen-
tan have been analyzed by HPLC [16]. Thus, the CE 
method can be used for the determination of the enantio-
meric purity of (S)-ambrisentan.
Conclusions
A QbD approach was successfully applied in the devel-
opment and optimization of a capillary electrophoresis 
method for the determination of the chiral purity of (S)-
ambrisentan. Method scouting followed by screening 
of the critical process parameters  led to the selection of 
initial experimental conditions which were further opti-
mized by response surface methodology. This led to the 
determination of the design space from which the experi-
mental conditions of the working point were derived. The 
final validated method proved to be robust and simple 
and allowed the determination of a relative concentra-
tion 0.1 % of the enantiomeric impurity with RSD val-
ues below 10 % and within an analysis time of less than 
10 min. These performance parameters are comparable to 
the reported HPLC methods [16, 17]. The practical appli-
cability of the assay was demonstrated for a commercial 
sample, in which 0.15 ± 0.01 % of the (R)-enantiomer
were found. In conclusion, the method proved to be suit-
able for the determination of the chiral purity of (S)-
ambrisentan and represents another example of the appli-
cability of CE for the determination of the stereoisomeric 
purity of drugs.
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Overview: 
Dextromethorphan is a centrally acting antitussive drug, while its enantiomer levomethorphan is an illicit 
drug with opioid analgesic effects. The present study involves the development of a CE-based limit test 
for levomethorphan. The analytical target profile was defined as a method that should be able to 
determine levomethorphan with acceptable precision and accuracy at the 0.1 % level. From initial 
scouting experiments, a dual selector system consisting of sulfated β-cyclodextrin and methyl-α-
cyclodextrin was identified. Design of experiments methodology was used in method development, 
optimization and validation. The method was validated according to ICH guideline Q2(R1) and applied 
to the analysis of a capsule formulation. Furthermore, the apparent binding constants between the 
enantiomers and the cyclodextrins as well as complex mobilities were determined to understand the 
migration behavior of the analytes. 
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Dextromethorphan is a centrally acting antitussive drug, while its enantiomer lev-
omethorphan is an illicit drug with opioid analgesic effects. As capillary electrophore-
sis has been proven as an ideal technique for enantiomer analysis, the present study
was conducted in order to develop a capillary electrophoresis-based limit test for
levomethorphan. The analytical target profile was defined as a method that should
be able to determine levomethorphan with acceptable precision and accuracy at the
0.1 % level. From initial scouting experiments, a dual selector system consisting of
sulfated β-cyclodextrin and methyl-α-cyclodextrin was identified. The critical pro-
cess parameters were evaluated in a fractional factorial resolution IV design followed
by a central composite face-centered design and Monte Carlo simulations for defin-
ing the design space of the method. The selected working conditions consisted of a
30/40.2 cm, 50 μm id fused-silica capillary, 30 mM sodium phosphate buffer, pH 6.5,
16 mg/mL sulfated β-cyclodextrin, and 14 mg/mL methyl-α-cyclodextrin at 20◦C and
20 kV. The method was validated according to ICH guideline Q2(R1) and applied to
the analysis of a capsule formulation. Furthermore, the apparent binding constants
between the enantiomers and the cyclodextrins as well as complex mobilities were
determined to understand the migration behavior of the analytes.
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Fig. 1) is an N-methyl-D-aspartate receptor antagonist and
σ1 receptor agonist. The compound is widely used as an
Abbreviations: ATP, analytical target profile; CD, cyclodextrin; CPP,
critical process parameter; CQA, critical quality attribute; DS, degree of
substitution; DXM, dextromethorphan; LVM, levomethorphan; M-α-CD,
methyl-α-cyclodextrin; QbD, quality by design; S-β-CD, sulfated
β-cyclodextrin
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antitussive in over-the-counter cough and cold medicines
and in combination with quinidine for the treatment of pseu-
dobulbar affect [1,2]. DXM has an ent-morphinan structure.
The enantiomer levomethorphan ((9R,13R,14R)-3-methoxy-
17-methylmorphinan, (–)-3-methoxy-N-methylmorphinan,
LVM; Fig. 1) displays morphinan structure and is an
opioid analgesic drug with strong respiratory depres-
sion. The compound was never clinically developed
and is classified as a controlled substance worldwide
(www.incb.org/documents/Narcotic-Drugs/Yellow_List/55th_
Edition/YL_-55th_edition_2016.pdf). Severe adverse effects
including cyanosis, respiratory distress, and seizures as
well as about 60 deaths have been reported by the World
Health Organization in different countries after consumption
J Sep Sci 2018;41:1405–1413. © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwww.jss-journal.com
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F I G U R E 1 Structures of dextromethorphan and levomethorphan




xtromethorphan.pdf). As a consequence, chromatographic
tests for the enantiomeric purity of DXM were included
in the United States Pharmacopeia [3] and the Interna-
tional Pharmacopoeia [4], using vancomycin and cellulose
tris(4-methylbenzoate), respectively, as chiral selectors on
the stationary phase. The limit of LVM is 0.1% in both
pharmacopeias. Furthermore, liquid chromatographic enan-
tioseparations of the compounds have been reported using
chiral stationary phases based on β-cyclodextrin (β-CD) [5],
phenylcarbamate β-CD [6], or vancomycin [5,7]. Cellulose
tris(3,5-dimethylphenylcarbamate) proved to be a suitable
selector for the separation of DXM and LVM by SFC [7].
Finally, the indirect separation of the methorphan enan-
tiomers by GC was accomplished after derivatization with
(–)-menthyl chloroformate on a (5–phenyl)-methylpoly-
siloxane stationary phase [8].
Within the last decades, CE has been increasingly used
as a high resolution technique for the analysis of pharma-
ceutical drugs [9–12] including enantioseparations [13–17].
Aumatell et al. reported the enantioseparation of methorphan
by CD-modified MEKC using a BGE composed of 50 mM
SDS in a 50 mM sodium borate buffer, pH 9.05, containing
60 mM β-CD as chiral selector and 20% v/v 1-propanol [18].
Lurie and Cox achieved the separation of DXM and LVM in
a dynamically coated capillary using hydroxypropyl-β-CD as
chiral selector in CElixirۛ buffer, pH 2.5, containing 15% v/v
methanol [19]. Hydroxypropyl-β-CD was also used as chi-
ral selector in 150 mM sodium phosphate buffer, pH 4.4,
containing 20% v/v methanol and a fused-silica capillary
for the analysis of plasma samples in opiate-overdose-related
deaths [20,21]. However, none of these methods were suitable
for the analysis of the enantiomeric purity of DXM due to low
resolution [19–21] or long analysis times of about 1 h [18].
Therefore, the aim of the present study was the development
of a CE method for the determination of the enantiomeric
purity of DXM at the 0.1% level of LVM with acceptable
accuracy and precision implementing quality by design (QbD)
principles.
QbD has been applied increasingly in analytical chemistry
and includes the use of multivariate design of experiments
and risk-assessment tools for identifying the critical process
parameters (CPPs), that is, the experimental factors that influ-
ence the critical quality attributes (CQAs) of the method. Con-
sequently, an in-depth understanding of the analytical process
is provided [22–26].
2 MATERIALS AND METHODS
2.1 Chemicals and reagents
Dextromethorphan hydrobromide monohydrate was from
Fagron (Barsbüttel, Germany). Levomethorphan was from
Cerilliant (Round Rock, USA). Dextromethorphan capsules
from ratiopharm (Ulm, Germany) were obtained from a
local community pharmacy. β-CD and methyl-α-cyclodextrin
(M-α-CD, batch M1, degree of substitution (DS) ∼11)
were from Wacker Chemie (Burghausen, Germany).
Hydroxyethyl-β-CD (DS ∼4.9), γ-CD, sulfated α-CD sodium
salt, sulfated β-CD sodium salt (S-β-CD, batch S1: DS
∼12–15, batch S2: DS ∼7–11), Tris, riboflavin 5′-phosphate
sodium salt hydrate, and procainamide hydrochloride
were from Sigma–Aldrich (Steinheim, Germany). α-CD,
M-α-CD (batch M2, DS ∼11), hydroxypropyl-α-CD
(DS ∼4.5), carboxymethyl-α-CD sodium salt (CM-α-CD,
DS ∼3.5), methyl-β-CD (DS ∼12), hydroxypropyl-β-CD
(DS ∼4.5), carboxymethyl-β-CD sodium salt (CM-β-CD, DS
∼3.5), succinyl-β-CD (DS∼3.5), heptakis(2,6-di-O-methyl)-
β-CD (DS ∼14), carboxymethyl-γ-CD sodium salt (DS ∼3.5),
and hydroxypropyl-γ-CD (DS ∼4.5) were from Cyclolab
(Budapest, Hungary), while sulfobutyl-β-CD sodium salt
(DS ∼6.6) was from CyDex Pharmaceuticals (San Diego,
USA). Boric acid, orthophosphoric acid (85%), glacial
acetic acid, sodium hydroxide, triethanolamine, DMSO,
2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid,
and piperazine-1,4-bis(2-ethanesulfonic acid) were from
Merck (Darmstadt, Germany). Water was purified by a Gen-
Pure system from Thermo Fischer (Waltham, USA). Ethanol
(96%) was from Carl Roth (Karlsruhe, Germany). Methanol
(HPLC grade) was from Fisher Scientific (Loughborough,
UK). All chemicals were obtained at the highest purity
commercially available.
2.2 Instrumentation
All experiments were carried out using a Beckman P/ACE
MDQ CE system (Beckman Coulter, Krefeld, Germany)
equipped with a UV-Vis diode array detector and controlled
by 32 KARAT software (version 8.0) for system control, data
acquisition, and processing. Hydrodynamic sample injection
was performed at a pressure of 0.7 psi (4.8 kPa) for 5 s. UV
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detection was carried out at the cathodic end of the capil-
lary at 200 nm unless otherwise specified. pH measurements
were performed with a WTW Multi-3410 IDS multiparameter
digital pH meter equipped with a SenTix SP-T 900 electrode
(Xylem Analytics Germany Sales, Weilheim, Germany) cali-
brated with buffer solutions at pH 4.00, 7.00, and 9.00 from
Carl Roth.
Fifty micrometer id fused-silica capillaries were from BGB
Analytik (Schloßböckelheim, Germany). A new capillary was
successively rinsed at a pressure of 20 psi (138 kPa) with 1 M
sodium hydroxide for 10 min, followed by water for 15 min.
For the CD screening with BGEs with pH ≤ 6.0, the capil-
lary was rinsed successively with 0.1 M phosphoric acid for
5 min and water for 10 min at the beginning of the day, while
in the case of BGEs with pH > 6.0, the capillary was rinsed
with 0.1 M sodium hydroxide for 5 min and water for 10 min.
Between runs, the capillary was flushed with water for 1 min
and the BGE for 3 min.
Viscosity measurements of buffers containing M-α-CD
were performed in quadruplicate according to Allmendinger
et al. [27] using the CE instrument as viscosimeter
and 0.1% m/v riboflavin-5′-phosphate as the boundary
marker.
2.3 Buffer and sample solutions
The BGEs were prepared by dissolving the CDs in water
followed by addition of the corresponding amount of the
acid component and diluting with water to about 90% of the
required volume. The pH was subsequently adjusted by the
required base and made up to the final volume by water.
Tris/phosphate buffer was prepared by dissolving Tris and
the CD in water and adjusting the pH using phosphoric acid.
All BGEs were filtered through (0.22 μm) polypropylene
syringe filters (BGB Analytik) and sonicated for 10 min before
use.
Stock solutions of DXM hydrobromide equivalent to
2.0 mg/mL of DXM and of LVM at a concentration of
1.0 mg/mL were prepared in 0.01 M HCl. Sample solu-
tions were prepared by dilution in 0.01 M HCl. For prepa-
ration of sample solutions of DXM hydrobromide capsules,
the content of ten capsules was homogenized in a mortar.
An accurately weighed amount equivalent to 20 mg of DXM
was suspended in 5.0 mL 96% v/v ethanol and sonicated for
20 min to yield a solution containing 4.0 mg/mL of DXM.
The suspension was centrifuged at 5000 rpm for 15 min
and 375 μL of the supernatant were transferred to a 1.5 mL
Eppendorf vial and evaporated to dryness using an Eppen-
dorf Concentrator plus (Eppendorf Deutschland, Wesseling-
Berzdorf, Germany). The residue was reconstituted in
970 μL 0.01 M HCl and 30 μL of procainamide hydrochlo-
ride stock solution (1.0 mg/mL) were added as internal
standard.
2.4 Software and data analysis
MODDE 11.0 (Umetrics, Umeå, Sweden) was used for the
experimental design and statistical analysis of the screening,
response surface methodology, and robustness testing. The
data obtained from the respective designs were fitted to a
model using the quadratic polynomial equation [22]:










where y is the predicted response (resolution or migration
time), β0 is the intercept, βi is the coefficient to be opti-
mized (voltage, temperature, buffer pH, and concentration
and/or CD concentration), βij the interaction coefficients, and
βii the quadratic coefficients, with the interaction effect terms
restricted to two-factor interactions.
Microsoft Excel 2007 was used for the statistical analysis
of the validation data. CEval version 0.6 g [28] was used for
calculating CD–enantiomer binding constants and complex
mobilities.
3 RESULTS AND DISCUSSION
Starting point of analytical QbD is the selection of the ana-
lytical technique and definition of the analytical target profile
(ATP). Subsequently, the CPPs are identified and the design
space of the method is established, which refers to the experi-
mental conditions meeting the ATP [23–25]. Design of exper-
iments procedures are employed in the process [22,26]. Thus,
the ATP was defined that the developed CE method should
allow the determination of LVM in DXM in the range of at
least 0.1% up to 1.0% relative to the parent drug with a preci-
sion and accuracy of ≤15% at the 0.1% level and ≤10% above
the 0.1% level in an analysis time of ≤10 min.
3.1 Initial method scouting
Because DXM is a weak base with an estimated pKa value of
about 9.2 [29], the initial selector screening was performed
in a 100 mM sodium phosphate BGE, pH 2.5, using a
40/50.2 cm, 50 μm id fused-silica capillary at a temperature
of 20◦C and an applied voltage of 20 kV. The sample
solution contained 90 μg/mL of DXM and 10 μg/mL of
LVM. Native α-CD, β-CD, and γ-CD as well as neutral
and charged derivatives were studied at a concentration
of approximately 20 mM, or in the case of sulfated or
sulfobutyl CD derivatives at 10 mM based on the average
molecular weight of the CDs. Native and neutral CDs were
evaluated under normal polarity of the applied voltage, while
negatively charged CDs were also studied under reversed
polarity conditions when the analytes could not be detected at
Manuscript 2 27
T A B L E 1 Results of the CD screening in 100 mM sodium phosphate buffer, pH 2.5
CD 𝛂 Migration order Polarity of voltage Comments
α-CD (20 mM) 1.02 LVM > DXM (+) Partial separation
M-α-CD (20 mM) 1.02 DXM > LVM (+) Partial separation
HP-α-CD (20 mM) 1.04 DXM > LVM (+) Baseline separation
HP-γ-CD (20 mM) 1.02 DXM > LVM (+) Partial separation
CM-α-CD (20 mM) 1.05 DXM > LVM (+) Baseline separation
CM-β-CD (20 mM) 1.02 DXM > LVM (+) Partial separation
CM-γ-CD (20 mM) 1.04 DXM > LVM (+) Baseline separation
S-β-CD (10 mM) 1.49 LVM > DXM (-) Baseline separation
Only CDs yielding at least partial enantioseparation are listed.
CM-α-CD, carboxymethyl-α-CD; CM-β-CD, carboxymethyl-β-CD; CM-γ-CD, carboxymethyl-γ-CD;
HP-α-CD, hydroxypropyl-α-CD; HP-γ-CD, hydroxypropyl-γ-CD; S-β-CD, sulfated-β-CD.
normal polarity of the applied voltage. CDs leading to at
least a partial enantioseparation under these conditions are
summarized in Table 1. Good resolution was noted when
using CM-α-CD or S-β-CD but this was associated with
high baseline noise and peak fronting in the case of S-β-CD.
Subsequently, 100 mM triethanolamine-phosphoric acid
buffer, pH 2.5, 100 mM sodium acetate buffer, pH 5.0, and
sodium citrate buffer, pH 6.0, were studied as alternative
BGEs. However, none of these conditions substantially
improved the separation of DXM and LVM, their peak shape
or baseline noise. Therefore, screening was further performed
in sodium phosphate buffer, pH 7.0, and sodium borate buffer,
pH 8.5, under normal polarity of the applied voltage. In the
presence of 10 mM S-β-CD, high resolution was observed
with RS values of about 21 and 24, respectively. DXM
migrated before LVM. However, substantial peak tailing
occurred. Because lower baseline noise was found for the
phosphate-based buffer, different buffer co-ions of phosphate
including triethanolamine and lithium were studied but even
worsened the peak shape. In 2-[4-(2-hydroxyethyl)-1-
piperazinyl]-ethanesulfonic acid buffer, pH 7.0, piperazine-
1,4-bis(2-ethanesulfonic acid) buffer, pH 7.0, or Tris-
phosphoric acid buffer, pH 8.0, no peaks could be detected
within 30 min. Addition of organic solvents up to a concentra-
tion of 20% v/v did not improve peak shape or baseline noise.
Therefore, sodium phosphate buffer, pH 7.0, in combination
with S-β-CD was selected for further evaluation.
Dual CD systems have been applied to drug CE enan-
tioseparations [30,31] and were also employed to improve
the peak shape of basic compounds [32]. Consequently, neu-
tral and charged CDs were tested in combination with S-β-
CD in 50 mM sodium phosphate buffer pH 7.0. Improvement
of peak shape associated with a decrease of resolution was
observed for CM-α-CD and M-α-CD as co-selectors. Thus,
M-α-CD was chosen for further method development because,
as a neutral compound, the CD will not increase the elec-
tric current of the BGE. Figure 2 illustrates the effect of the
F I G U R E 2 Electropherograms of the separation of DXM and
LVM using (A) 20 mg/mL S-β-CD and (B) 20 mg/mL S-β-CD and
10 mg/mL M-α-CD in 50 mM sodium phosphate buffer, pH 7.0. Other
experimental conditions: 30/40.2 cm, 50 μm id fused-silica capillary;
20◦C; 16 kV; detection at 200 nm.
combination of S-β-CD and M-α-CD on the resolution and
peak shape of the separation of the methorphan enantiomers.
3.2 Knowledge space and identification of
critical process parameters
The CQAs of the method were defined as target values of a
resolution of at least 5 and an analysis time of ≤ 10 min so
that the migration time of the second migrating LVM should
not exceed 8 min. Based on the scouting experiments, the
experimental parameters BGE pH and concentration, the con-
centrations of the selectors S-β-CD and M-α-CD, as well as
separation voltage and temperature were studied in further
detail using a fractional factorial resolution IV design in the
ranges of voltage 10–20 kV, capillary temperature 15–25◦C,
pH 6.4–8.0, phosphate buffer concentration 30–100 mM,
S-β-CD concentration 10–24 mg/mL, and M-α-CD concen-
tration 6–20 mg/mL. Due to the relatively high resolution
value achieved in the scouting, the capillary was shortened so
that the experiments were performed in a 30/40.2 cm, 50 μm
id fused-silica capillary. The sample consisted of 1500 μg/mL
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F I G U R E 3 Coefficient plot (scaled and centered) of the screen-
ing design showing the relative effect of the factors on the responses; x
× y represents the interaction terms between two parameters. Note: V,
applied voltage; Temp, capillary temperature; pH, pH of buffer solution;
Buf, buffer concentration; S-β-CD, S-β-CD concentration; M-α-CD, M-
α-CD concentration.
DXM and 15 μg/mL LVM, that is, a relative concentration
of LVM of 1.0%. The design matrix as well as the respec-
tive values of the responses, peak resolution, and migra-
tion time of LVM are summarized in Supporting Information
Table S1. Three experiments were carried out at the center
of the design for estimating the repeatability. The coefficient
plots of the variables as well as their interaction terms are
shown in Fig. 3. Temperature and voltage did not signifi-
cantly affect peak resolution, while migration time of LVM
was not influenced by temperature and buffer concentration.
pH affected both, resolution and migration time. S-β-CD
increased resolution and run time, while M-α-CD decreased
both responses. To better understand the combination terms,
a sweet plot was constructed at low buffer concentration
(30 mM) and a temperature of 20◦C as shown in Supporting
Information Figure S1. Although both CQAs were met for a
large variety of experimental settings, the plot indicated that
low electrolyte pH was favorable. Consequently, BGE con-
centration and pH were fixed at 30 mM and pH 6.5, respec-
tively, and temperature was set at 20◦C. The concentration of
the CDs and separation voltage were considered CPPs and fur-
ther optimized.
3.3 Method optimization and determination
of the design space
The three CPPs voltage (10–20 kV), S-β-CD (10–30 mg/mL),
and M-α-CD (5–15 mg/mL) were optimized in the indicated
ranges using a central composite face-centered design. Cap-
illary dimensions and sample concentration were identical
to the screening design. The design matrix can be found in
Supporting Information Table S2 containing three repetitions
F I G U R E 4 Probability plot of the design space. Notes: Thresh-
old of responses (min/target/max): migration time of LVM (−/−/8 min),
number of theoretical plates of LVM peak (3000/−/−), height of LVM
peak (3000 μAU/−/−) and tailing factor of the DXM peak (0.5/1/3). The
design space (green zone) is identified as the zone where the risk of fail-
ure is ≤ 1%. For the color version of the figure, the reader is referred to
the online version of the article.
at the center of the design for estimation of repeatability. Peak
resolution in all experiments was above the initial threshold of
5 (see Supporting Information Table S2). Therefore, peak res-
olution was not considered a CQA so that optimization efforts
concentrated on analysis time and the peak performance cri-
teria as responses, that is, the tailing factor of the DXM peak
(calculated according to the United States Pharmacopeia by
the instrument software) as well as the number of theoretical
plates and the peak height of the LVM peak.
Setting the migration time of LVM as measure of the anal-
ysis time at ≤ 8 min, the number of theoretical plates and
the peak height of the LVM peak at ≥3000 and ≥3000 μAU,
respectively, as well as the tailing factor of the DXM peak in
the range of 0.5 to 3 with the target value of 1, the design space
of the method was derived by Monte Carlo simulations as
shown in Fig. 4. The level of probability of failure was selected
at ≤ 1%. Because faster analysis was achieved at higher values
of the applied voltage, 20 kV were selected to ensure fast anal-
ysis. The other working point conditions included a sodium
phosphate buffer concentration of 30 mM, a pH of 6.5, a con-
centration of S-β-CD of 16 mg/mL, and a concentration of
M-α-CD of 14 mg/mL. Procainamide hydrochloride was cho-
sen as an internal standard and was added to the sample to
achieve a final concentration of 30 μg/mL. An electrophero-
gram of standards under the optimized experimental condi-
tions is shown in Fig. 5A.
3.4 Method validation and application
3.4.1 Method robustness
Method robustness was estimated using a Plackett-Burman
design with a variation of the experimental conditions around
the center point of the optimized working conditions, that is,
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F I G U R E 5 Electropherograms of a solution of 1.5 mg/mL DXM
spiked with (A) 15 μg/mL LVM (1.0% relative concentration) and
(B) 1 μg/mL LVM (0.067%); (C) electropherogram of DXM hydrochlo-
ride capsules equivalent to a DXM concentration of 1.5 mg/mL.
Notes: X, unknown impurity; IStd, internal standard procainamide
hydrochloride at a concentration of 30 μg/mL. Experimental conditions:
30/40.2 cm, 50 μm id fused-silica capillary; 30 mM sodium phosphate
buffer, pH 6.5, containing 16 mg/mL S-β-CD and 14 mg/mL M-α-CD;
20◦C; 20 kV; detection at 200 nm; hydrodynamic injection at 0.7 psi for
5 s.
voltage 20 ± 1 kV, temperature 20 ± 1◦C, buffer concentra-
tion 30 ± 1 mM, and pH 6.5 ± 0.1, S-β-CD concentration
16 ± 1 mg/mL and M-α-CD concentration 14 ± 1 mg/mL. In
addition, two different batches of S-β-CD and M-α-CD were
included. The design matrix is summarized in Supporting
Information Table S3. Effects of the variations of the param-
eters within the indicated ranges did not significantly affect
the number of theoretical plates of the LVM peak or the tail-
ing factor of the DXM peak. The coefficient plots for migra-
tion time of LVM and height of the LVM peak are shown in
Supporting Information Figure S2. Except for buffer concen-
tration on migration time and S-β-CD concentration on peak
height, all variables were significant including variation of the
CD batch. However, under all experimental conditions eval-
uated, the responses always met the predefined requirements
(Supporting Information Table S3). Thus, migration time of
LVM never exceeded 6 min (threshold ≤ 8 min) and peak
height was higher than 4500 μAU (threshold ≥ 3000 μAU).
Therefore, the method can be considered robust. Nonetheless,
care should be taken in the preparation of the BGE and instru-
mental parameters such as capillary temperature and voltage
should be controlled carefully.
3.4.2 Method validation and application
The optimized method was validated according to the
Q2 (R1) guideline (www.ich.org/fileadmin/Public_Web_Site/
ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1_
Guideline.pdf) in the range of 1.0–10 μg/mL LVM in the
presence of DXM at a concentration of 1.5 mg/mL. Pro-
cainamide hydrochloride at a concentration of 30 μg/mL
served as internal standard. The data are summarized in
Table 2. LOD and LOQ values were estimated based on an
S/N of 3 and 10, respectively. RSD values of repeatability and
intermediate precision of content and migration time were
well below 10% indicating sufficient precision of the method.
Accuracy was estimated by spiking DXM at a concentration
of 1.5 mg/mL with known amounts of LVM. Values ranged
between 88.9 ± 3.6% at the 0.1% level and 99.2 ± 0.9% at
the 0.9% level so that the method can be considered accurate
as well. Absence of a peak at the migration time of LVM
in samples of pure DXM assured selectivity of the method
with regard to LVM. A representative electropherogram of a
DXM sample spiked with LVM at the LOQ (0.07% level) is
shown in Fig. 5B. A small amount of an unknown impurity
was in the drug substance. The amount of the compound was
estimated at about 0.07% based on peak normalization.
The method was subsequently applied to a capsule dosage
form upon extraction of the analytes with ethanol. The elec-
tropherogram is shown in Fig. 5C. LVM could not be detected.
A small amount of the unknown impurity, which was found in
the DXM standard, was also detected in the formulation at an
estimated level of 0.06%. Accuracy was also estimated for the
analysis of the capsules by spiking the content with known
amounts of LVM (Table 2). Values between 93.0 ± 2.8%
(0.1% level) and 105.5 ± 2.9% (0.9% level) indicated satis-
factory accuracy of the method in the case of capsule formu-
lations as well.
3.5 Determination of apparent binding
constants and mobilities
To understand the migration behavior of the analytes in the
applied dual selector system, a mechanistic study determin-
ing the complexation constants and mobilities of the diastere-
omeric CD–analyte complexes was performed in an attempt
to explain the effect of M-α-CD on peak tailing in the S-β-CD-
mediated enantioseparation of methorphan. The data were
obtained as best fit parameters of the dependence of the effec-
tive mobility on the CD concentration assuming the formation
of 1:1 CD–analyte complexes according to Eq. (2) [33]:
μeff =
μf + μc ⋅𝐾 ⋅ [CD]
1 + 𝐾 ⋅ [CD]
, (2)
where μeff is the effective mobility, μc the mobility of the CD–
analyte complex, μf the mobility of the free analyte, K the
complexation constant, and [CD] the molar concentration of
the CDs. CEVal was used for data fitting because this software
allows correction of the migration times in case of strongly
tailing peaks according to the Haarhoff−van der Linde func-
tion [28,34]. In case of S-β-CD, observed mobilities of the
analytes were corrected for the EOF using DMSO as EOF
marker, while in the case of M-α-CD, observed mobilities
were corrected for the increasing viscosity of the buffers due
to the increasing concentrations of the CDs.
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T A B L E 2 Assay validation data
Parameter Level Levomethorphan
Range (μg/mL) 1.0–15 μg/mL (0.1–1.0%)
Coefficient of determination R2 0.9989
LOD (μg/mL; S/N = 3) 0.3 μg/mL (0.02%)
LOQ (μg/mL; S/N = 10) 1.0 μg/mL (0.07%)
Migration time repeatability (RSD) 1.2%
Migration time intermediate precision (RSD) 5.8%
Content repeatabilitya (RSD) 5.3%
Content intermediate precisionb (RSD) 5.7%
Accuracy drug substancec 1.5 μg/mL (0.1%) 88.9 ± 3.6%
7.5 μg/mL (0.5%) 96.1 ± 2.0%
13.5 μg/mL (0.9%) 99.2 ± 0.9%
Accuracy capsulesc 1.5 μg/mL (0.1%) 93.0 ± 2.8%
7.5 μg/mL (0.5%) 101.9 ± 7.0%
13.5 μg/mL (0.9%) 105.5 ± 2.9%
aNine runs of three samples at three concentrations on one day.
bNine runs of three samples at three concentrations on three consecutive days.
cExpressed as mean recovery ± confidence interval % (α/2 = 0.025). DXM samples or capsules were spiked with the indicate amount of LVM.
T A B L E 3 Apparent complexation constants, K, and mobilities of the free analytes, μf, and of the CD–analyte complexes, μc
S-𝛃-CD M-𝛂-CD
DXM LVM DXM LVM




















The numbers in brackets represent the 95% confidence intervals.
In the case of S-β-CD, the mobilities were determined in
the range of 0–12 mg/mL in 30 mM sodium phosphate buffer,
pH 6.5. Because of the strong EOF at pH 6.5, an enantiosepa-
ration could not be observed in the presence of M-α-CD as
selector. Therefore, the data for M-α-CD were determined
in 100 mM sodium phosphate buffer, pH 2.1, using a CD
concentration of 0–50 mg/mL. DXM with a pKa of 9.2 [29]
is essentially fully protonated at both pH values so that the
following discussion assumes that the complexation between
the M-α-CD and the analyte enantiomers is not significantly
altered at pH 6.5 versus pH 2.1. This assumption also applies
to the mobility of the free analytes, μf, and the mobility of
the complexes μc, which are independent of the EOF. The
data are summarized in Table 3. It should be noted that the
data are apparent constants and mobilities rather than ther-
modynamic values because the ionic strength of the buffers
was not determined and concentrations were used instead
of activity. Moreover, S-β-CD is a randomly substituted CD
so that the actual charge of the compound is not known
either.
LVM is complexed much stronger by S-β-CD compared to
DXM. Moreover, the mobility of the S-β-CD–LVM complex
greatly exceeded the mobility of the S-β-CD–DXM complex.
This explains the enantiomer migration order, that is, migra-
tion after the EOF and DXM > LVM, and also the increasing
peak deformation, especially of the LVM peak due to mis-
match of the mobilities of the CD–analyte complexes and
the buffer ions. In the case of M-α-CD, LVM is also bound
stronger than DXM, but complex mobilities are not signif-
icantly different from each other for both enantiomers. Due
to competing effects between both CDs, this results in slow-
ing down the overall mobility of LVM more effectively as
compared to DXM resulting in a reduced peak resolution.
However, the reduced mobility of the analytes also reduced
the extent of the mobility mismatch between analytes and
buffer ions, yielding lower peak deterioration and, conse-
quently, sharper and higher peaks. Improvement of peak shape
by combination of S-β-CD and neutral CD derivatives in the
case of basic drugs has been observed previously [32]. How-
ever, in these cases, the analytes migrated before the EOF and
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addition of the neutral CD enhanced enantioresolution as
reported for most dual CD systems [30,31].
4 CONCLUDING REMARKS
Using a QbD approach, a CE method was developed for the
determination of the stereochemical impurity LVM in DXM
drug substance and pharmaceutical formulations at the 0.1%
level. A dual CD system consisting of the charged derivative
S-β-CD and the neutral derivative M-α-CD was derived from
screening experiments followed by a fractional factorial res-
olution IV design for investigation of the knowledge space.
Setting BGE concentration and pH at low values and temper-
ature of 20◦C, the concentration of the CDs as well as sepa-
ration voltage were further optimized using response surface
methodology to obtain the design space by Monte Carlo sim-
ulation. Selection of the working conditions was followed by
a Placket–Burman design for robustness testing before valida-
tion of the method in the range of 0.07–1.0% LVM relative to
a sample concentration of 1.5 mg/mL DXM.
RSD values of repeatability and intermediate precision of
migration time and content were well below 10%. Accuracy
was ≤15% at the 0.1% level and ≤10% above this level. The
method proved to be suitable for the analysis of a capsule
formulation of DXM. Summarizing, the present method rep-
resents the first CE method for the assessment of the enan-
tiomeric purity of DXM at the 0.1% level as set in drug mono-
graphs of pharmacopeias employing HPLC assays.
In an attempt to understand the improvement of the peak
shape by addition of M-α-CD to the S-β-CD-containing
BGE, apparent complexation constants and mobilities of the
diastereomeric CD–enantiomer complexes were determined.
The stronger tailing of the LVM peak compared to the DXM
peak especially at higher S-β-CD concentrations could be
explained by the high mobility of the CD–LVM complex.
Both enantiomers displayed essentially identical complex
mobilities in the case of M-α-CD, which were also consid-
erably lower than the mobilities of the corresponding S-β-
CD complexes. This reduced the overall mobility of LVM
and DXM, thereby improving the peak shape. A concomitant
decrease of the enantioresolution was observed but proved
negligible for the development of the assay due to the high
resolution obtained in the presence of S-β-CD
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could be applied to the analysis of drug substance.  
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Research Article
Quality by design-assisted development of
a capillary electrophoresis method for the
chiral purity determination of
dexmedetomidine
Dexmedetomidine is a selective 2-adrenergic agonist used for patient sedation, while
its enantiomer levomedetomidine has no sedative effects. As CE has been shown to be a
powerful technique for enantiomer analysis, the aim of the study was the quality by design-
based development of a CE-based limit test for the enantiomeric impurity levomedetomi-
dine. The analytical target profile was defined that the method should be able to determine
levomedetomidine with acceptable precision and accuracy at the 0.1% level. From initial
scouting experiments, sulfated -cyclodextrin was selected as chiral selector. The critical
process parameters were identified in a fractional factorial resolution V+ design, while a
central composite face centered design and Monte Carlo simulations were used for defin-
ing the design space of the method. The selected working conditions were a 21.3/31.5 cm,
50 m id fused-silica capillary, a 50 mM sodium phosphate buffer, pH 6.5, containing
40 mg/mL sulfated -cyclodextrin, a capillary temperature of 17°C and an applied voltage
of 10 kV. Validation according to the ICH guideline Q2(R1) demonstrated repeatability
and intermediate precision of content and migration time between 9.3 and 4.2% with
accuracy in the range of 92.0 and 98.9%.
Keywords:
Capillary electrophoresis / Design of experiments / Dexmedetomidine /
Enantiomeric purity / Quality by design DOI 10.1002/elps.201800100
 Additional supporting information may be found in the online version of thisarticle at the publisher’s web-site
1 Introduction
Dexmedetomidine [(S)-4-[1-(2,3- dimethylphenyl)ethyl]-1H-
imidazole, D-MDT, Fig. 1], is a selective centrally act-
ing 2-adrenergic agonist used as a sedative in anes-
thesia management in surgery and in intensive care
medicine [1, 2]. The advantage of D-MDT over other
sedatives is the absence of respiratory depression [2].
In animal experiments, the compound displayed much
higher activity as compared to its enantiomer levomedeto-
Correspondence: Professor Gerhard K. E. Scriba, Friedrich Schiller
University, Department of Medicinal/Pharmaceutical Chemistry,
Philosophenweg 14, 07743 Jena, Germany
Fax: +49-3641-949802
E-mail: gerhard.scriba@uni-jena.de
Abbreviations: ATP, analytical target profile; CPP, critical
process parameter; CQA, critical quality attribute; D-MDT,
dexmedetomidine; DoE, design of experiments; DS, degree
of substitution; ICH, International Council on Harmonization;
L-MDT, levomedetomidine; MDT, medetomidine; QbD, qual-
ity by design; S--CD, sulfated -cyclodextrin
midine (L-MDT, Fig. 1) [3, 4]. D-MDT was approved
by the US Food and Drug Administration in 1999
[www.accessdata.fda.gov/drugsatfda_docs/label/2013/02103
8s021lbl.pdf], and by the European Medicines Agency in 2011
[www.ema.europa.eu/docs/en_GB/document_library/EPAR
_-_Public_assessment_report/human/002268/WC50011563
2.pdf] for use in humans and is also approved in the




D-MDT is typically prepared by synthesis of racemic
MDT via various synthetic routes and subsequent resolution
of the enantiomers via fractionated crystallization using
enantiomerically pure acids such as (R)-(−)-mandelic acid,
(−)-camphor-10-sulfonic acid, (2R,3R)-(+)-tartaric acid or
derivatives thereof [5]. Consequently, the enantiomeric purity
of D-MDT must be evaluated during quality control. The
HPLC enantioseparation of MDT has been reported using an
Color Online: See the article online to view Fig. 3 in color.
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Figure 1. Structures of dexmedetomidine and
levomedetomidine.
1-acid glycoprotein column and a mobile phase composed
of a phosphate buffer, pH 7.0 and acetonitrile [6, 7]. 0.5%
of L-MDT could be detected in D-MDT [7]. Furthermore,
the United States Pharmacopeia contains a monograph for
D-MDT hydrochloride, limiting L-MDT to 1.0% by a chiral
HPLC method, which also employs an 1-acid glycoprotein
chiral stationary phase and a mobile phase consisting of phos-
phate buffer, pH 7.0 and acetonitrile [8]. Despite the fact that
enantiomeric impurities and their limits are excluded from
the requirements for impurities in drug substances such as
stated in the International Council of Harmonization (ICH)
guideline Q3A(R2) Impurities in New Drug Substances
[www.ich.org/fileadmin/Public_Web_Site/ICH_Products/
Guidelines/Quality/Q3A_R2/Step4/Q3A_R2__Guideline.
pdf], there is general consent that enantiomeric impurities
should be considered in the same manner as other impu-
rities. Consequently, analytical methods should be able to
quantify enantiomeric impurities at the 0.1% level or below.
Capillary electrophoresis (CE) has been increasingly used
for the analysis of pharmaceuticals [9–12] including enan-
tioseparations [13–16] due to the high resolution and experi-
mental flexibility of the technique. Therefore, the aim of the
present study was the development of a CE method for the
determination of the enantiomeric purity of D-MDT allowing
the quantitation of L-MDT at the 0.1% level with acceptable ac-
curacy and precision. In the process, quality by design (QbD)
principles were implemented. QbD has been increasingly
applied in analytical chemistry in recent years [17–21]. This
approach employs multivariate design of experiments (DoE)
and risk-assessment tools for the identification of the critical
process parameters (CPPs), which are the experimental fac-
tors that influence the critical quality attributes (CQAs) of the
method. This methodology results in the understanding of
quantitative effects of the CQAs on the analytical process.
2 Materials and methods
2.1 Chemicals and reagents
D-MDT hydrochloride was from TCI Europe (Zwijndrecht,
Belgium). Racemic MDT hydrochloride was from Car-
bosynth (Compton, UK). -cyclodextrin (-CD) and methyl-
-CD (M--CD, DS 11) were from Wacker Chemie
AG (Burghausen, Germany).  -CD, sulfated -CD sodium
salt, sulfated -CD sodium salt (S--CD, batch S1:
DS 12–15, batch S2: DS 7–11), L-Trp were from
Sigma-Aldrich (Steinheim, Germany). -CD, methyl--CD
(DS 11), hydroxypropyl--CD (DS 4.5), carboxymethyl-
-CD sodium salt (CM--CD, DS 3.5), methyl--CD
(DS 12), hydroxypropyl--CD (DS 4.5), carboxymethyl-
-CD sodium salt (CM--CD, DS 3.5), succinyl--CD
(DS 3.5), heptakis(2,6-di-O-methyl)--CD (DS 14,
50% purity), heptakis(2,6-di-O-methyl)--CD (95% purity),
carboxymethyl- -CD sodium salt (DS 3.5), heptakis(6-O-
sulfo)--CD and hydroxypropyl- -CD (DS 4.5) were from
Cyclolab Ltd. (Budapest, Hungary), while sulfobutyl--CD
sodium salt (DS 6.6) was from CyDex Pharmaceuticals
(San Diego, USA). Orthophosphoric acid (85%), citric acid
monohydrate, glacial acetic acid, sodium hydroxide, and tri-
ethanolamine were from VWR (Darmstadt, Germany). Wa-
ter was purified by a GenPure system from Thermo Fischer
(Waltham, USA). All chemicals were obtained at the highest
purity commercially available.
2.2 Instrumentation
All measurements were carried out on a Beckman P/ACE
MDQ capillary electrophoresis system (Beckman Coulter,
Krefeld, Germany) equipped with a UV-Vis diode array de-
tector and controlled by the 32 KARAT software (version 8.0)
for system control, data acquisition and processing. Hydro-
dynamic sample injection was performed at a pressure of
0.7 psi (4.8 kPa) for 5 s for the CD scouting, while a pres-
sure of 0.7 psi (4.8 kPa) for 7 s was used during screening
and optimization phases, robustness testing, method valida-
tion and sample analysis. UV detection was carried out at
the cathodic end of the capillary at 200 nm unless otherwise
specified. pH measurements were carried out using a WTW
Multi-3410 IDS digital pH meter equipped with a SenTix SP-T
900 electrode (Xylem Analytics Germany GmbH, Weilheim,
Germany) calibrated with buffer solutions at pH 4.00, 7.00,
and 9.00 from Carl Roth (Karlsruhe, Germany).
Fused-silica capillaries with 50 m id were from BGB
Analytik (Schloßböckelheim, Germany). A new capillary was
successively rinsed at a pressure of 20 psi (138 kPa) with
1 M sodium hydroxide for 10 min, followed by water for
15 min. For the CD screening with a background electrolytes
(BGE) at pH  6.0, the capillary was rinsed successively with
0.1 M phosphoric acid for 5 min and water for 10 min at the
beginning of the day. When using a BGE with pH  6.0, the
capillary was rinsed with 0.1 M sodium hydroxide for 5 min
and water for 10 min. Between runs, the capillary was flushed
with water for 1 min and the BGE for 3 min.
2.3 Background electrolyte and sample solutions
The BGEs were prepared by dissolving the respective CD in
water followed by addition of the corresponding amount of
C© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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the acid component and diluting with water to about 90% of
the required volume. The pH was subsequently adjusted and
the water was added to the final volume. All BGEs were fil-
tered through polypropylene syringe filters (0.22 m, BGB
Analytik, Schloßböckelheim, Germany) and sonicated for
10 min prior to use.
Stock solutions of D-MDT hydrochloride equivalent to
4.0 mg/mL of D-MDT and racemic MDT hydrochloride equiv-
alent to 4.0 mg/mL of MDT were prepared in 0.01 M hy-
drochloric acid. Sample solutions were prepared by dilution
of the stock solutions with 0.01 M HCl. Samples contain-
ing L-MDT were obtained by mixing appropriate volumes of
solutions of racemic MDT with solutions of D-MDT.
2.4 Software and data analysis
MODDE 11.0 (Umetrics, Umeå, Sweden) was used for the
experimental design and statistical analysis of the screening,
response surface methodology and robustness testing. The
data obtained from the respective designs were fitted to a
model using the quadratic polynomial equation [21]:










where y are the predicted response (separation selectivity ,
migration time or current), 0 the intercept, i the coeffi-
cients, which were optimized (voltage, temperature, buffer
pH and concentration and CD concentration), ij the interac-
tion coefficients (restricted to two-factor interactions) and ii
the quadratic coefficients. Statistical analysis of the validation
data was performed using Microsoft Excel 2013.
3 Results and discussion
The first step in developing an analytical method following
the QbD methodology is the choice of the technique and the
definition of the analytical target profile (ATP). Subsequently,
the CPPs are identified in initial experiments followed by the
establishment of the design space of the method. The latter
refers to experimental conditions where the ATP is fulfilled
[18–21]. In the process, DoE methodology is employed.
With regard to the stereoselective D-MDT assay, the ATP
was defined that the CE method should allow the determina-
tion of L-MDT in the presence of D-MDT in the range of at
least 0.1% up to 1.5% relative to the concentration to the par-
ent drug with precision and accuracy of 10% in an analysis
time of 10 min.
3.1 Initial method scouting
CDs as the most widely used chiral selectors in CE [13,16,22]
were evaluated as chiral selectors for the assay. MDT is a weak
base with a pKa value of about 7.08 [23]. Thus, the selector
screening was performed in a 50 mM sodium phosphate
buffer, pH 2.5, using a 40/50.2 cm, 50 m id fused-silica
capillary at 20°C and an applied voltage of 20 kV. The sample
solution contained 100 g/mL of D-MDT and 50 g/mL of
L-MDT. Native -CD, -CD and  -CD as well as neutral and
charged derivatives were studied at concentrations of about
5 and 20 mM. Uncharged CDs were evaluated under normal
polarity of the applied voltage, while negatively charged CDs
were also studied at reversed polarity. The best resolution was
observed in the presence of sulfated -CD and sulfated -CD
(S--CD) with -values 1.2. Because the highest -value was
found for S--CD and the price of this CD is relatively low,
S--CD was selected for further evaluation.
Using a sample containing 0.7 mg/mL of D-MDT and
7 g/mL of L-MDT (i.e. 1% relative concentration), sev-
eral phosphate-based buffers, pH 2.5, in combination with
sodium or triethanolamine as counter ions and S--CD
concentrations, 50 mM sodium citrate buffer, pH 2.5, and
50 mM sodium acetate buffer, pH 4.8, containing S--CD
were studied. In addition, short end injection was evaluated.
However, under all conditions severe peak tailing was ob-
served for D-MDT due to the high sample concentration.
Subsequently, 50 mM sodium phosphate buffer, pH 7.0, at
normal polarity of the applied voltage was investigated. These
conditions led to improved peak shape. Moreover, under
these conditions, L-MDT migrated before D-MDT, which is
favorable when a minor impurity has to be determined in the
presence of a large excess of a drug. Using triethanolamine as
counter ion resulted in higher background noise. Therefore,
sodium phosphate buffer, pH 7.0, in combination with S--
CD as selector was chosen for method development. Shorten-
ing of the capillary to an effective length of 21.3 cm resulted
in reduced analysis time. Figure 2 shows a comparison of
the enantioseparation in 50 mM sodium phosphate buffer,
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Figure 2. Electropherograms of the S--CD-mediated separation
of D-MDT and L-MDT at (A) pH 2.5 and (B) pH 7.0. Experimental
conditions: (A) 10.2/50.2 cm, 50 m id fused-silica capillary (short
end injection); 50 mM sodium phosphate buffer, pH 2.5; 30 mg/mL
S--CD; 20°C; −20 kV and (B) 21.3/31.5 cm, 50 m id fused-silica
capillary; 50 mM sodium phosphate buffer, pH 7.0; 50 mg/mL
S--CD; 20°C; 6 kV; UV detection at 200 nm. Sample concentration:
700 g/mL D-MDT and 7 g/mL L-MDT.
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3.2 Knowledge space and identification of critical
process parameters
The CQAs of the method were defined to comprise peak res-
olution expressed as separation selectivity  of at least 1.05, a
current 100 A and a migration time of D-MDT of 10 min
so that the analysis time would not exceed 12 min. Consid-
ering the scouting experiments, BGE pH and concentration,
concentration of the S--CD, as well as separation voltage and
temperature were studied in detail using a fractional factorial
resolution V+ design. The ranges were BGE pH 6.3 to 8.5,
phosphate buffer concentration 50 to 100 mM, S--CD con-
centration 30 to 50 mg/mL, voltage 6 to 10 kV and capillary
temperature 15 to 25°C. The sample consisted of 1.0 mg/mL
D-MDT and 10 g/mL L-MDT (i.e., relative concentration of
1.0%).
The design matrix as well as the respective values of
the CQAs as responses, i.e. -value, current and migration
time of D-MDT are summarized in Supporting Information
Table 1. The coefficient plots of the variables as well as
their interaction terms are shown in Supporting Information
Fig. 1. Significant effects were detected for all parameters
and for most interaction terms. Increasing the pH of the
BGE negatively affected separation selectivity in addition to
increasing the current. Thus, low pH seems favorable, al-
though this leads to increased migration times. Similarly,
increasing phosphate buffer concentration results in lower
-values and increased currents but with a smaller effect
on migration times. Voltage and temperature affected mi-
gration time and current more significantly than separation
selectivity . Increasing S--CD concentrations increased all
responses. Consequently, the concentration and pH of the
phosphate buffer were fixed at 50 mM and pH 6.5, respec-
tively, to achieve high separation selectivity and short mi-
gration times as well as low current. The concentration of
S--CD, the capillary temperature and the separation voltage
were considered CPPs and further optimized.
3.3 Method optimization and design space
The CPPs voltage (6–10 kV), S--CD concentration (30–
50 mg/mL) and capillary temperature (15–25°C) were further
optimized in the indicated ranges using a central compos-
ite face centered design and keeping the responses as above.
The design matrix is summarized in Supporting Information
Table 2.
Setting the CQA limits at   1.05, current  100 A
and migration time 10 min, the design space was obtained
by Monte Carlo simulations setting the level of probability
of failure at 1%. Figure 3 shows the plots for concentra-
tions of S--CD of 30, 40 and 50 mg/mL. Because the larger
space was found at a selector concentration of 40 mg/mL,
this concentration was chosen for S--CD. Moreover, voltage
was set at 10 kV in order to achieve a short analysis time.
Temperature was set at 17°C so that the final experimental
conditions included a 21.3/31.5 cm, 50 m id fused-silica
capillary, a BGE composed of a 50 mM sodium phosphate
buffer, pH 6.5, containing 40 mg/mL S--CD, a capillary
temperature of 17°C and an applied voltage of 10 kV. These
conditions resulted in currents of approximately 75 A.
L-Trp was selected as internal standard to compensate for in-
jection errors. An electropherogram of standards under the
optimized experimental conditions is shown in Fig. 4A.
3.4 Method robustness
In order to achieve the desired limit of 0.1% L-MDT in
D-MDT the sample concentration was set at 2.0 mg/mL of D-
MDT and 20 g/mL of L-MDT (0.1% relative concentration)
containing 60 g/mL L-Trp as internal standard. Method ro-
bustness was estimated using a Plackett-Burman design by
varying the experimental conditions around the center point
of the working conditions, i.e. buffer concentration 50 ± 2.5
mM and pH 6.5 ± 0.1, S--CD concentration 40 ± 2 mg/mL,
voltage 10 ± 1 kV and temperature 17 ± 1°C. In addition,
two batches of S--CD were included. The design matrix is
summarized in Supporting Information Table 3. In addition
to the three optimized responses, the quantitative robustness
was assessed using the ratio of the corrected peak areas of L-
MDT and the internal standard as a measure. The regression
analysis of the model indicated that the responses -value,
current and the ratio of corrected peak areas were not sig-
nificantly affected by the small variations of the experimen-
tal parameters (data not shown). This included the different
batches of S--CD tested. In contrast, in the case of migration
time, a significant although minor effect of all variables on
this response was detected (Supporting Information Fig. 2).
However, none of the conditions led to a migration time above
8.2 min, which is well below the threshold of 10 min set
in the ATP. Therefore, the method can be considered robust.
Nonetheless, the BGE should be prepared carefully and the
instrumental parameters voltage and capillary temperature
should be strictly controlled.
3.5 Method validation and application
The optimized method was validated according to the
Q2 (R1) guideline (www.ich.org/fileadmin/Public_Web_
Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_
R1__Guideline.pdf) in the range of 2.0 - 30 g/mL L-MDT
in the presence of D-MDT at a concentration of 2.0 mg/mL
(relative concentration of L-MDT 0.1 to 1.5%). L-Trp at a
concentration of 60 g/mL served as internal standard. The
data are summarized in Table 1. LOD and LOQ values were
estimated at 0.6 g/mL (0.03%) and 2.0 g/mL (0.1%),
respectively, based on a signal-to-noise ratio of 3 and 10.
Repeatability and intermediate precision of content and
migration time were well below 10%, which indicated
sufficient precision of the method. Accuracy was estimated
by spiking a solution containing 2.0 mg/mL D-MDT with
L-MDT to yield concentration levels of 4, 16 and 28 g/mL
C© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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Figure 3. Probability plot of
the design space obtained by
Monte Carlo simulations. The
design space (green zone) de-
fines combinations of param-
eters where the risk of failure
is  1%, to meet the three cri-
teria, -value> 1.05, Current
 100 A, and migration time
of D-MDT 10 min. For the
color version of the figure, the
reader is referred to the online








































A B C Figure 4. Electropherograms
of a solution of 2 mg/mL
D-MDT spiked with
(A) 20 g/mL L-MDT (1.0%
relative concentration) and
(B) 2 g/mL L-MDT (0.1% rela-
tive concentration). (C) Anal-
ysis of a commercial D-MDT
hydrochloride sample at a
concentration equivalent to
2 mg/mL D-MDT. Experimen-
tal conditions: 21.3/31.5 cm,
50 m id fused-silica capillary;
50 mM sodium phosphate
buffer, pH 6.5; 40 mg/mL S--
CD; 17°C; 10 kV; UV detection
at 200 nm.
and ranged between 92.0 ± 6.4% and 98.9 ± 1.7%. Thus, the
method can be considered accurate. Because no peak at the
migration time of L-MDT was detected in samples of D-MDT
the method can also be considered selective. A representative
electropherogram of D-MDT spiked with L-MDT at the LOQ
(0.1% level) is shown in Fig. 4B.
The method was subsequently applied to a sample of
D-MDT hydrochloride substance obtained from a commercial
source. The electropherogram is shown in Fig. 4C. L-MDT
was below the LOD.
4 Concluding remarks
A CE method was developed for the determination of the
stereochemical purity of D-MDT drug substance using a sys-
tematic QbD approach. S--CD was chosen as chiral selec-
tor from screening experiments. Separation after the EOF
in a BGE pH 6.5 resulted in the desired migration order so
that the minor impurity L-MDT migrated before the large
peak of D-MDT. A fractional factorial resolution V+ design
was used for the investigation of the knowledge space and
the identification of the CQAs. Because separation selectiv-
ity and migration time decreased with increasing pH and
concentration of the BGE, these parameters were set at low
values while S--CD concentration as well as the instrumen-
tal parameters separation voltage and capillary temperature
were further optimized using response surface methodology.
The design space was derived by Monte Carlo simulations fol-
lowed by selection of the working conditions. The method was
robust as assessed by a Plackett-Burman design. Subsequent
validation in the range of a relative L-MDT concentration of
0.1 to 1.5% indicated repeatability and intermediate precision
10% with an accuracy of 90%. Analysis time was 10 min.
In summary, the present method is the first CE method for
the determination of the enantiomeric purity of D-MDT at
the 0.1% level.
L-MDT could not be detected in a commercial batch of
D-MDT. Therefore, the limit of L-MDT of 1.0% stated in the
C© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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Coefficient of determination R2 0.9897
LOD (S/N = 3) 0.6 g/mL
(0.03%)












Accuracyc) 4 g/mL (0.2%) 92.0 ± 6.4%
16 g/mL (0.8%) 96.8 ± 3.0%
28 g/mL (1.4%) 98.9 ± 1.7%
a) nine runs, three samples at three concentrations on one day.
b) nine runs, mean of three samples at three concentrations on
three consecutive days.
c) Expressed as mean recovery ± confidence interval% (/2 =
0.025). D-MDT samples were spiked with the racemic MDT
solution to yield the indicated amount of L-MDT.
monograph of D-MDT hydrochloride of United States Phar-
macopeia [8] could be questioned. It may be speculated that
the high limit of L-MDT is due to the chromatographic as-
say in the monograph, which utilizes an 1-acid glycoprotein
chiral stationary phase. However, this would have to be inves-
tigated by direct comparison of the chromatographic method
with the CE-based method, which was out of the scope of the
present study.
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The manuscript describes the first detailed study on the complexation of the enantiomers of 
medetomidine by CDs. In CE experiments reversal of the enantiomeric migration order depending on 
the applied CD was noted. Specifically, reversal or the migration order was observed for the pairs β-CD 
and γ-CD as well as for randomly substituted sulfated β-CD and single isomer HS-β-CD. In order to 
understand this migration behavior, complexation constants and complex mobilities were determined by 
CE. The structures of the analyte-CD complexes were derived from ROESY NMR experiments, which 
agreed with the CE data. Finally, molecular modeling and molecular dynamics simulations were applied 
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The migration order of the enantiomers of medetomidine in the presence of  cyclodextrins studied  by
capillary  electrophoresis in phosphate buffer, pH 2.5, depended on the  cavity size and the substitution
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CD)  and -cyclodextrin (-CD) as well as randomly sulfated -CD (S--CD) and heptakis(6-O-sulfo)--CD
(HS--CD).  This could be  rationalized by the fact  that dexmedetomidine formed more stable  complexes
with  -CD and S--CD, while  levomedetomidine interacted stronger with -CD and  HS--CD. The  struc-














omer  migration order
lar modeling
r  magnetic resonance
-CD,  -CD and HS--CD. In the 
cavity  through the  wider secondar
inside  the  CD cavity interacting w
calculations  also suggested opposi
troduction
clodextrins (CDs) are cyclic oligosaccharides, which consist of
linked d-glucopyranose units. -CD contains six glucose units,
 seven and -CD eight. CDs can be topologically described as
w toroids with a lipophilic cavity and a hydrophilic outside.
ider rim contains the secondary 2- and 3-hydroxyl groups,
 the narrower rim features the primary 6-hydroxyl groups.









demnumber of derivatives, many of which are commercially avail-
Due to their ability to form complexes with a large variety
pounds, CDs have found numerous pharmaceutical, chemi-
io)technological, food, cosmetic or textile applications [1–3].
 regard to separation sciences, CDs have been applied as chiral
ors in GC [4], HPLC [5] and especially CE [6–9].
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673/© 2018 Elsevier B.V. All rights reserved.f the  native CDs, the phenyl ring  of medetomidine entered the
of  the CDs, whereas the protonated imidazole ring was positioned
e sulfate groups  of HS--CD. Furthermore, molecular dynamics
nities of the medetomidine enantiomers toward -CD and  -CD.
© 2018 Elsevier B.V. All  rights  reserved.
lexation of guest molecules often occurs via their inclu-
 the CD cavity either from the narrower or the wider side
rus, displacing solvent molecules from the cavity. Van der
d hydrophobic interactions as well as hydrogen bonding
 hydroxyl groups on the rims and steric factors are consid-
 driving forces. In the case of charged CD derivatives, ionic
ons also play a role [10–12]. While most selector-selectand
es were shown to be of the inclusion type, several studies
rated that so-called external complexes can also be formed
o effective CE enantioseparations [13–15]. Due to the fact
selector-selectand complexes are mobile, two enantios-
principles govern enantioseparations in CE [16,17]. The
ographic enantioselective principle (also referred to as
modynamic mechanism) is based on the different affini-
e selector toward the solute enantiomers, which can be
d as complexation constants. The electrophoretic enan-
ive principle is due to differences in the mobilities of
tiomer-selector complexes, for example as a result of
es in the hydrodynamic radii of the complexes or the
 complexation-induced pKa shift [18]. Consequently, the
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e binding strength between the selector and the enan-
 as it is the case in HPLC where the selector is immobile
for the rarely used technique of a chiral mobile phase addi-
tural information on the complexes can be obtained by
copic techniques such as NMR  and X-ray analyses. Nuclear
ser effect-based NMR  methods, in particular rotating frame
Overhauser effect spectroscopy (ROESY), allow the deter-
n of correlation of spatially close nuclei and proved to
uable tool to elucidate the structure of selector-selectand
es [19–22]. Furthermore, as NMR  is a solution technique,
ents can be carried out under conditions comparable to
ed in CE with regard to the composition of the electrolyte
, pH and temperature.
cular  dynamics (MD) simulations also yield 3-dimensional
ive structures of the CD-solute complexes [23–27]. In addi-
D  approaches allow the calculation of binding energies,
annot be experimentally determined at present. Further-
D simulations can provide information on the interactions
 selectors and solutes as well as on the different steps
 in the chiral recognition process. These may  include the
h of solutes and selector, displacement of solvent molecules
D cavity or the establishment of specific van der Waals
trostatic interactions in the complex, including direct and
ridged hydrogen bonds.
etomidine (4-[1-(2,3- dimethylphenyl)ethyl]-1H-
le) is an 2-adrenoreceptor agonist, which is used as
esic and anesthetic drug in veterinary medicine [28]. The
cological activity has been attributed mainly to the dex-
y (S)-enantiomer dexmedetomidine [29], which has been
ed for human use as a sedative in anesthesia management
ry and in intensive care medicine [30]. In the process
evelopment of a CE-based assay for the determination
stereochemical purity of dexmedetomidine using CDs
l selectors [31], different enantiomer migration orders
ng on the CD were observed. The aim of the present study
 investigation of the complexation of the medetomidine
mers by CDs and a detailed characterization of selected CD
es by CE, NMR  spectroscopy and MD simulations.
rimental
micals and reagents
edetomidine hydrochloride was from TCI Europe (Zwi-
t, Belgium). Racemic medetomidine hydrochloride was
rbosynth (Compton, UK). -CD and methyl--CD (degree
titution (DS) ∼11) were from Wacker Chemie AG
usen, Germany). -CD, hydroxyethyl--CD (DS ∼4.9), sul-
-CD sodium salt (DS ∼12), sulfated -CD sodium salt
, DS ∼12-15) and riboflavin 5′-phosphate sodium salt
 were from Sigma-Aldrich (Steinheim, Germany). -CD,
propyl--CD (DS ∼4.5), carboxymethyl--CD sodium salt
5), methyl--CD (M--CD,  DS ∼12), hydroxypropyl--CD
5), carboxymethyl--CD sodium salt (DS ∼3.5), succinyl-
S ∼3.5), heptakis(2,3,6-tri-O-methyl)--CD (TM--CD),
(2,6-di-O-methyl)--CD (DM--CD, 95% isomeric purity),
(6-O-sulfo)--CD (HS--CD), carboxymethyl--CD sodium
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_______ (Budapest, Hungary), while sulfobutyl--CD sodium salt
6) was  from CyDex Pharmaceuticals (San Diego, CA, USA).
-CD (DS ∼13-16) and sulfated -CD sodium salt (DS
) were from Cyclodextrin-Shop (Tilburg, The Netherlands).
osphoric acid (85%) and sodium hydroxide were from VWR




were run at 
NOVA softw
de Compost98–210 199
o Fischer (Waltham, MA,  USA). All chemicals were
the highest purity commercially available. Deuterium
 99% atom D) and deuterated phosphoric acid (D3PO4,
2O, 98 atom D) were from Sigma-Aldrich (Saint-Louis,
dium deuteroxide (NaOD, 40% w/w in D2O, 99.5% atom
 Deutero GmbH (Kastellaun, Germany).
riments
urements were performed on a Beckman P/ACE
ry electrophoresis system (Beckman Coulter, Krefeld,
quipped with a UV–vis diode array detector and con-
 the KARAT software (version 8.0) for system control,
tion and processing. Hydrodynamic sample injection
ed at a pressure of 0.7 psi (4.8 kPa) for 5 s. Sepa-
e carried out in 40/50.2 cm,  50 m I.D. fused-silica
BGB Analytik, Schloßböckelheim, Germany) at 20 ◦C.
llary was  successively rinsed at a pressure of 20 psi
ith 1 M sodium hydroxide for 10 min, followed by
 min. At the beginning of each day the capillary was
 0.1 M orthophosphoric acid for 10 min  followed by
 min. Between analyses, the capillary was flushed with
phosphoric acid for 1 min, water for 2 min, and the
 electrolyte for 2 min. Background electrolytes for CD
d determination of the complexation constants in the
D, S--CD and HS--CD consisted of 50 mM sodium
uffer, pH 2.5 obtained by addition of the appropriate
rthophosphoric acid to water and adjustment of the pH
odium hydroxide solution. In the case of -CD as selec-
s  added for solubilization of the CD. Thus, screening
ed in 50 mM sodium phosphate buffer containing 2 M
omplexation parameters were determined in 150 mM
sphate buffer, pH 2.0, containing 2 M urea. Both buffers
repared from orthophosphoric acid and 0.1 M sodium
lution. The following concentrations of the CDs for the
on of the complexation parameters: -CD (0, 10, 20, 30,
D (0, 10, 20, 30, 40, 50 mM),  S--CD (0, 8, 16, 20, 24, 28,
 HS--CD (0, 15, 20, 25, 30, 40, 50 mM).
] was used for the calculation of the complexation con-
omplex mobilities. Viscosity measurements of buffers
ed in quadruplicate according to Allmendinger et al.
the CE instrument as viscosimeter and 0.1% (m/v)
′-phosphate as boundary-marker.
periments
 INNOVA 500 NMR  system (Varian, Palo Alto, CA, USA),
n inverse 5 mm HCX 1H/13C/15N/31P probe head, gra-
e and variable temperature unit was  used for all NMR
. The spectrometer resonance frequency for 1H was
. The 1H 90◦ hard pulse width was optimized for each
1H spectral width was  set to 8012.8 Hz. All NMR signals
ed based on COSY, TOCSY and HSQC data, where appro-
ignal of residual HDO (4.65 ppm) was used as internal
r the 1D ROESY experiments, all excitation windows
d manually depending on the comparative isolation of
tem to study, with which the duration and potency of
ective) excitation pulses were automatically adjusted
mrJ software (version 3.2 revision A, Agilent Technolo-
___________
43 
_____________________lara, CA, USA). The number of transients in each 1D
riment was  set to 512. The duration of the low power
xing was  400 ms  in every case. All NMR experiments
25 ◦C. All NMR  spectra were processed with the Mestre
are (version 12.0.0, Mestrelab Research S. L., Santiago
ela, Spain).










































































_____________________Fig. 1. Structure of medetomidine e
e concentration of the analytes in the NMR  samples was about
ld higher than that in the CE experiments so that reproducible
 spectra were obtained. Samples were prepared by weighing
nts of medetomidine spiked with dexmedetomidine with -
-CD or HS--CD and dissolving in 0.7 mL  50 mM  D3PO4 in D2O,
ted to an apparent pH 2.5 with sodium deuteroxide in D2O
 w/v). In the case of -CD the samples also contained 2 mM
 All samples were vortexed for 1 min  and filtered through
m polypropylene filters prior to data acquisition.
Molecular modeling and MD  simulations
e 3D structures of -CD, -CD and dexmedetomidine were
ved from Cambridge Structural Database (CSD) [34] entries
OX [35], KOHBUE [36] and UQODEL [37], respectively.
-CD was built using CSD entry MEZWIZ (heptakis(6-O-
propylsilyl)--CD) [38] as a template and replacing the
propylsilyloxy groups with sulfate substituents in all glucopy-
se units with the aid of the builder module implemented in the
cular graphics program PyMOL [39]. Geometry optimization of
olecules and point charge derivation were achieved by means
e AM1-BCC method [40], as implemented in the sqm program
contained in the AMBER Tools [42] distribution. The standard
10 and ff14SB force field parameter sets in AMBER 14 [43]
 used for all atoms. PyMOL was also employed for visualization
D trajectories and 3D figure generation.
e three pairs of complexes between the two medetomidine
tiomers (S and R) and the three CDs were modelled upon man-
 docking each analyte into the CD cavity in orientations that
tatively agreed with the 1D ROESY NMR  results. Each complex
hen immersed in a box of TIP3P water molecules that extended
































 the simulated systems, the positive charge of medetomidine
e complexes with -CD and -CD was neutralized by substi-
g one chloride ion for a water molecule located close to the
 positive electrostatic potential region. The excess of nega-
harges in the inclusion complexes with the sulfated CDs was




CDs inclumers and CDs.
atically favored regions. Upon reorientation of all solute
s and water molecules, each complex was relaxed by per-
500 steps of steepest-descent followed by 5000 steps of
e-gradient energy minimization. The resulting geometry-
d coordinates were used as input for unrestrained MD
ns at 300 K and a constant pressure of 1 atm running
ER pmemd.cuda [44] code in parallel on 4 GeForce Nvidia
raphics processing units (GPUs). The application of SHAKE
ds allowed an integration time step of 2 fs to be used. A cut-
ce of 9 Å was  used for the nonbonded interactions and the
bonded pairs was  updated every 25 steps. Periodic bound-
itions were applied and electrostatic interactions were
ted using the smooth particle mesh Ewald method [45]
id spacing of 1 Å. The coupling constants for the tempera-
pressure baths were 1.0 and 0.2 ps, respectively. The water
s and the counterion were first equilibrated around the
lly restrained solute for an initial heating period lasting
hereafter each inclusion complex was allowed to evolve
 a 100-ns period during which coordinates collected every
subjected to a simulated annealing procedure [46] that
 in cooling down the system from 300 to 273 K over
riod. The geometry of each “frozen” snapshot was fur-
larized by carrying out an energy minimization until the
n-square of the Cartesian elements of the gradient was
 0.01 kcal mol1 Å1. The resulting set of 100 representative
s for each complex was analyzed with the cpptraj module
 [47] to measure relevant distances and angles. Solvent-
 binding energies, as well as their decomposition into van
s, Coulombic, apolar and desolvation contributions were
 by use of our in-house MM-ISMSA program [48].
ts and discussionediated CE enantioseparation of medetomidine
ructure of the medetomidine enantiomers and the CDs,
re used in the present study, are summarized in Fig. 1. The
ded CDs differing in the cavity size, i.e., -CD, -CD and -
S. Krait et al. / J. Chromatogr. A 1567 (2018) 198–210 201
Table  1
Enantioseparation of medetomidine using CDs as chiral selectors in 50 mM sodium phosphate buffer, pH 2.5.
CDa  Migration orderb Polarity of voltage Comments
-CD 1.000 – + no separation
M--CD 1.009  L-MDT > D-MDT + partial separation
HP--CD  1.009 D-MDT > L-MDT + partial separation
CM--CD  1.033 L-MDT > D-MDT + baseline separation
S--CD  1.243 L-MDT > D-MDT + baseline separation
-CD  1.009 L-MDT > D-MDT + partial separation
M--CD  1.009 L-MDT > D-MDT + partial separation
DM--CD  (95 %) 1.000 – + no separation
TM--CD 1.005  L-MDT > D-MDT + partial separation
HE--CD  1.008 L-MDT > D-MDT + partial separation
HP--CD  1.000 – + no separation
CM--CD  1.061 L-MDT > D-MDT + baseline separation
Suc--CD  1.000 – + no separation
SBE--CD  1.000 – – no separation
S--CD  1.579 L-MDT > D-MDT – baseline separation
HS--CD  1.031 D-MDT > L-MDT – baseline separation
-CD  1.022 D-MDT > L-MDT + baseline separation
M--CD 1.016  L-MDT > D-MDT + partial separation
HP--CD  1.015 D-MDT > L-MDT + partial separation
CM--CD  1.028 L-MDT > D-MDT + baseline separation
S--CD  1.072 L-MDT > D-MDT 
a M--CD, methyl--CD; HP--CD, hydroxypropyl--CD; CM--CD,  carboxymethyl--CD; S--CD, s
methyl)--CD  (95%); TM--CD,  heptakis(2,3,6-tri-O-methyl)--CD; HE--CD, hydroxyethyl--CD; HP-
CD, succinyl--CD; SBE--CD, sulfobutylether--CD; S--CD, sulfated -CD; HS--CD, heptakis(6-O-su
CM--CD;  carboxymethyl--CD; S--CD, sulfated -CD. The CD concentration was 20 mM except fo
substituted CDs was calculated using their average molecular weight.
b Migration order as observed at the cathodic end of the capillary.
Fig. 2. Electropherograms of the separation of the medetomidine enantiomers

























































--CD, the apparent complexation constants and the mobil-





_____________________-CD, (B) -CD, (C) S--CD and (D) HS--CD. Experimental conditions:
,  50 m I.D. fused silica capillary; 50 mM sodium phosphate buffer, pH
 detection at 200 nm.  Other conditions: (A) 20 mM -CD, 2 M urea, 20 kV;
 -CD, 20 kV; (C) 20 mM S--CD, –20 kV; (D) 20 mM HS--CD, –20 kV. The
nsisted of 100 g/mL dexmedetomidine and 50 g/mL medetomidine.
exmedetomidine; L-MDT, levomedetomidine.
ell as different uncharged and charged substituents. Except
ative CDs, HS--CD and TM--CD,  all other CDs were ran-
ubstituted so that they consisted of a number of compounds
 in the substitution pattern. The results of the separation
nantiomers of medetomidine in 50 mM phosphate buffer,
are summarized in Table 1. In the presence of most CDs
a partial separation could be observed using concentra-
 20 mM.  For those CDs where no separation was observed
tandard conditions, CD concentrations were decreased to
 well as increased to 50 or 80 mM.  However, none of these
ns resulted in enantioresolutions, except for sulfated -CD,
nantioseparation was only observed at a concentration of
he enantiomer migration order shown in Table 1 as deter-
t the cathodic end of the capillary depended on the type




















and HSe of -CD and -CD (Fig. 2A and B), indicating an effect of
 of the cavity on analyte complexation. This applied only to
ve CDs, while in the case of all substituted CDs, whether
ed or charged, the enantiomer migration order is inde-
 of the cavity size. Opposite enantiomer migration order
ities of the d
The data we
ity as a funct
complexes b
(1) [51]:− baseline separation
ulfated -CD; M--CD, methyl--CD; DM--CD,  heptakis(2,6-di-O-
-CD, hydroxypropyl--CD; CM--CD,  carboxymethyl--CD; Suc--
lfo)--CD; M--CD, methyl--CD; HP--CD, hydroxypropyl--CD;
r S--CD, where it was  5 mM.  The concentration of the randomly
tive CDs, i.e. as a function of the cavity size, has been
 a number of analytes including dipeptides, ketoprofen,
thetimide, as summarized in [49].
ase of sulfated -CDs, the enantiomer migration
epended on the substitution pattern. Thus, the levo-
 migrated before dexmedetomidine in the presence of
omer HS--CD, while opposite enantiomer migration
served with randomly substituted S--CD (Fig. 2C and
 be noted that the migration order in Table 1 is listed
 at the cathode so that it is opposite to the migration
 in the figures, which were obtained under reversed
he applied voltage, i.e. with detection at the anodic
apillary. The migration behavior can be explained by
 S--CD is in fact a mixture of CDs with different sub-
tterns as stated above resulting in different effective
f the enantiomers as compared to HS--CD. More-
 enantioresolution was  observed in the presence of the
bstituted S--CD compared to the single isomer HS-
 is also an often observed phenomenon [50]. Another
bservation refers to the methylated -CDs. Randomly
M--CD  as well as the trisubstituted TM--CD  partially
 medetomidine enantiomers under the experimental
pplied for the screening, while in the presence of the
tuted DM--CD  no enantioseparation was observed.
 be speculated that the enantioseparation observed in
andomly substituted M--CD  is accomplished by CDs
itution pattern differing from the 2,6-disubstitution.
ination of apparent complexation constants and
ilities
to understand the opposite migration behavior of the
s in the presence of -CD and -CD as well as S--CDiastereomeric CD-solute complexes were determined.
re obtained as best fit parameters of the effective mobil-
ion of CD concentration assuming the formation of 1:1
etween the selectors and the solutes according to Eq.
202 S. Krait et al. / J. Chromatogr. A 1567 (2018) 198–210
Table 2




























































































_____________________mM  sodium phosphate buffer, pH 2.0, containing 2 M urea.
M sodium phosphate buffer, pH 2.5.
f + c • K • [CD]
1 + K • [CD] (1)
e eff is the effective mobility, c the mobility of the CD-
te complex, f the mobility of the free analyte, K the
lexation constant and [CD] the molar concentration of the
The observed mobilities were corrected for the increasing vis-
y in the buffers due to the increasing CD concentrations. The
was assumed to be negligible at pH 2.5 and was  not consid-
because it could not be observed within 60 min. -CD was
tigated in the concentration range of 0–40 mM,  while -CD
S--CD were studied in the range of 0–50 mM and S--CD
e range of 0–32 mM.  In the case of the randomly substituted
D, the average molecular weight corresponding to a DS of
sulfate groups was used for the calculations. Due to the rela-
 poor enantioseparation in the case of -CD in 50 mM sodium
phate buffer, pH 2.5, the concentration of the phosphate buffer
increased to 150 mM and the pH lowered to pH 2.0 in order
tain sharp peak allowing the determination of the mobilities
e enantiomers. The data are summarized in Table 2. These are
rent constants and mobilities rather than thermodynamic data
use the ionic strength of the buffers was not determined and
r concentrations were used instead of activities. In the case of
omly substituted S--CD, the data are not only apparent but
averaged over all CD isomers.
 the case of -CD and -CD, the opposite enantiomer migra-
order can be explained by opposite affinities of the analyte
tiomers toward the respective CDs. Dexmedetomidine bound
ger to -CD compared to the levo-enantiomer, while the
site was found for -CD (Table 2). As expected, the stronger
d enantiomer migrates second. The small difference between
omplexation constants of the enantiomers with -CD could
in the lower resolution observed for this CD versus -CD.
estingly, in both cases, the mobility of the levomedetomidine-
omplex exceeds the mobility of the diastereomeric complex
ining dexmedetomidine (Table 2). This counteracts the enan-
paration by -CD but no significant deterioration of the
ution was observed with increasing CD concentrations. This
e attributed to the relatively small and insignificant differ-
s between the complex mobilities and the somewhat larger






































be dasing mobility of the complex with increasing CD concentra-
 does not significantly affect the overall enantioseparation.
, in the case of -CD as well as -CD the enantiosepara-
is governed by the complexation constants. Recent studies of
eversal of the enantiomer migration order based on opposite





case of si[27], phenylalanine derivatives [52] or ketoprofen [53].
xamples have been summarized in [49].
ite recognition of the medetomidine enantiomers was
nd for S--CD and HS--CD. Dexmedetomidine is
d stronger than its enantiomer by S--CD, while lev-
midine is complexed stronger than dexmedetomidine
-CD (Table 2). The limiting mobility of the stronger
tomidine–S--CD complex also significantly exceeded
lity of the complex between the CD and levomedetomi-
lting in the large resolution between the enantiomers
 However, higher complex mobility was  observed for the
ound dexmedetomidine in the case of HS--CD (Table 2),
sults in the deterioration of the enantioseparation at
S--CD concentrations. Thus, in contrast to -CD and -
separation of the medetomidine enantiomers with the
y charged S--CD and HS--CD is governed by both, the
tion constants and the complex mobilities. For S--CD,
ntioselective principles in CE cooperate leading to a large
solution while they counteract each other in the case of
 resulting in a loss of enantioseparation at higher CD con-
ns. A detailed discussion of the effect of complex mobility
antiomer migration order in CE including several exam-
be found in [49,54].
 studies
 NMR  resonances of the medetomidine-CD complexes as
e chemical shifts of -CD, -CD and HS--CD are summa-
able 3. The signals were assigned based on COSY, TOCSY
 data, where appropriate. S--CD and the respective com-
e not studied because unequivocal signal assignment of a
 substituted CD is not possible. Because these CDs are a
of many isomers differing in the substitution pattern as
e position of the substituents, overlap of signals occurs so
ningful conclusions from irradiation experiments cannot
. 1D ROESY experiments were preferred over 2D ROESY
of easier interpretation of intramolecular nuclear Over-
fects (NOEs). Moreover, enantiomeric bias, i.e. the stronger
onse of one enantiomer over the other enantiomer, can
d directly from the comparison of the 1D ROESY spec-h the 1H NMR  spectrum. Racemic drug was used for ROESY
nts, while non-racemic mixtures (racemic medetomidine
ith dexmedetomidine) were applied in a second experi-
rder to assign the signals of the respective enantiomer in
gnal splitting.
S. Krait et al. / J. Chromatogr. A 1567 (2018) 1
Table  3
1H NMR  chemical shifts of medetomidine-CD complexes. In case of signal splitting
upon  complexation, the resonance of dexmedetomidine is indicated by (+), while
the shift of the levomedetomidine protons are characterized by (−). For assignment
of  the medetomidine protons see also Fig. 1.
Position Medetomidine
-CD complex -CD complex HS--CD complex
aliphatic CH 4.48 4.46 4.49














Ph H-4 7.07 6.87 (−)
6.90  (+)
7.03
Ph H-5 7.08s 6.94 (−)
6.96  (+)
7.04






Ph 2-Me 2.17 2.11 2.15 (+)
2.16 (−)
Ph 3-Me 2.17 2.05 (−)
2.08 (+)
2.18
-CD  -CD HS--CD




































































































ith the aliphatic and phenyl protons as well as a small effect










1H NMR  spectrum of the mixture of racemic medetomi-
ked with dexmedetomidine and -CD is shown in Fig. 3A
 and Fig. 3B for medetomidine. All signals appeared sharp
l resolved, although some overlapping was  found, in par-
or the aromatic protons of medetomidine (6.94–7.14 ppm)
e -CD hydrogens (H-3, H-5 and both H-6, between 3.60
0 ppm). In some cases, splitting of signals was  observed
 medetomidine resonances upon complexation with -CD
). However, the splitting was too small to attempt selective
on experiments for each enantiomer.
D ROESY experiments showed intermolecular NOE inter-
between almost all medetomidine hydrogens with the
 H-3 and H-5 protons of -CD (Fig. 3A). Selective irradiation
4,5 (7.09 ppm) and at 2,3-Me (2.17 ppm) resulted in NOEs
 and H-5 of -CD (3.71 and 3.65 ppm, respectively). A weak
as also observed for H-6 (3.74 ppm). In contrast, excitation
-6 of medetomidine (6.98 ppm) and the aliphatic CH and
tons (4.48 and 1.55 ppm, respectively) resulted primarily
 with H-3 of -CD. In our hands, no intermolecular NOEs
served upon irradiation of the imidazole hydrogens. These
ndicated that the phenyl ring of medetomidine is inserted
 -CD cavity through the larger, secondary rim, while the
ated) imidazole moiety remained outside the cavity and is
 to the solvent.
iation  at the hydrogens of -CD corroborated these find-
en though some signal overlapping occurred (Fig. 3B).
on at 3.73 ppm (H-3 and H-6 of -CD) gave NOEs with all
midine hydrogens, including those of the imidazole moiety.
atic representation of the tentative medetomidine–-CD





































tions wnoteworthy, that a slight enantiomeric bias was observed
OEs with the aromatic Ph H-6 and Im H-5, as dexmedeto-
seemed to give a slightly larger NOE response than the
antiomer when compared to the parent 1H NMR  spectrum






,  where a stronger complexation of dexmedetomidine
pared to the levo-enantiomer was found (Table 2).
Complex
MR  spectrum of a sample containing racemic medeto-
ed with dexmedetomidine in the presence of -CD is
. 5A for -CD and in Fig. 5B for medetomidine. All sig-
sharp, well resolved and easily identifiable, although
of H-3 and H-6 of -CD were close (3.71 ppm). All sig-
tomidine split upon complexation, with the exception
CH and CH3 protons (1.48 and 4.46 ppm, respectively;
e NOE interaction pattern was  quite similar to that
 the medetomidine–-CD complex, as all the observed
lar NOEs involved the internal hydrogen atoms of
A). Selective irradiation at medetomidine imidazole
m) seemed to give a NOE exclusively with -CD H-3
while excitation at medetomidine phenyl and aliphatic
ulted in NOEs with both, H-3 and H-5 of -CD. This
 suggest the formation of an insertion complex, in
enyl ring of the drug is accommodated inside the -CD
e imidazolium moiety was situated closer to the larger
xposed to the solvent. Additional ROESY experiments,
 -CD protons were selectively irradiated, were consis-
is conclusion (Fig. 5B). A tentative schematic complex
shown in Fig. 4B.
eric bias was also found. Thus, irradiation at -CD H5
esulted in a stronger NOE response for the phenyl pro-
levomedetomidine (Fig. S2, supplementary material)
at this enantiomer is complexed stronger by -CD as
o dexmedetomidine. This is opposite to the observa-
n the case of -CD, yet consistent with the CE data
omplexation constant was derived between -CD and
midine compared to dexmedetomidine (Table 2). Due
high plate numbers, CE allows to observe very tiny
in the recognition pattern while even quite powerful
ic techniques do not allow to find a structural rationale
erences.
CD complex
MR  spectrum of the mixture of a sample containing
detomidine spiked with dexmedetomidine and HS--
 in Fig. 6A for HS--CD and in Fig. 6B for medetomidine.
revious cases, all signals appeared sharp and were well
hough some overlapping occurred (medetomidine Ph
H-5 at 7.04 ppm). Most of the medetomidine signals
omplexation (Table 3).
n at medetomidine Im H-5 (7.15 ppm) resulted in a
S--CD H-3 (3.78 ppm). Irradiation at the aliphatic CH
f medetomidine also resulted in a NOE with HS--CD
er, when the aliphatic methyl group (1.51 ppm) was
xcited only comparatively small NOE responses with
5 (3.82 ppm) and H-6 (4.10 and 4.15 ppm) were found.
t medetomidine phenyl H-4 and H-5 resulted in NOEs
D H-3 and H-5, perhaps more intensely with H-5. Irra-
enyl H-6 (6.86 ppm) gave a NOE with HS--CD H-3 and
 minor extent, with both H-6 protons of HS--CD. Irra-
e aromatic methyl groups of medetomidine (2.17 ppm)
OE with HS--CD H-5 and H-3 as well as a small effect
-6 atoms (Fig. 6A).
 irradiation at HS--CD H-5 resulted in NOE interac-
___________
47 
_____________________dazole H-5, but not with imidazole H-2. Selective irra-
S--CD H-3 gave essentially an identical interaction
, irradiation at the HS--CD H-6 protons (centred at
as particularly relevant (Fig. 6B) because NOE inter-
 all medetomidine hydrogens except the aliphatic CH
204 S. Krait et al. / J. Chromatogr. A 1567 (2018) 198–210
Fig. 3. 1H NMR  reference spectra and 1D ROESY spectra of the complex between -CD and medetomidine upon irradiation of medetomidine protons (A) and upon irradiation
of  -CD protons (B). The sample contained 3.8 mg  racemic medetomidine spiked with dexmedetomidine and 25 mg -CD in 0.7 mL 50 mM D3PO4 in D2O, adjusted to an
apparent  pH 2.5 with sodium deuteroxide in D2O.
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_____________________ematic representation of the structures of the medetomidine-CD complexes derived fr
mplex with HS--CD.
und. This implies proximity of medetomidine to the pri-
m of HS--CD. Interestingly, albeit those NOEs were not
ong, NOE responses of the imidazole protons were slightly
an those of the phenyl hydrogens of medetomidine. This
s a structure of the HS--CD complex different from the
es of the respective -CD and -CD complexes. With HS-
e protonated imidazolium moiety seems to be positioned
 down” in the cavity close to the primary ring interact-
ably through water-mediated hydrogen bonds with the
ly charged sulfate groups. The phenyl ring would there-
d itself inside the CD cavity as shown schematically in
iation at the HS--CD H-6 protons also evidenced an enan-
 bias as a larger response was noted for the protons of
etomidine (Fig. S3, supplementary material). This sug-
ighter complexation of the levo-enantiomer with HS--CD
ed to dexmedetomidine, which is consistent with the com-
n data derived by CE (Table 2).
lecular modeling and MD  simulations
 the NMR  spectroscopy study, randomly substituted S--
not included because of the fact that the CD is a mixture
onal and substitution isomers. Molecular modeling would
possible for the individual CD isomers but this would not
 deduce meaningful data of the overall complexation pro-
ween S--CD and medetomidine.
tructures of the CD complexes between the respective CDs
medetomidine enantiomers as derived by molecular mod-
e summarized in Fig. 7. In both -CD inclusion complexes
), each medetomidine enantiomer is bound with the imi-
 moiety pointing towards the rim formed by the 2- and
xyl groups and essentially exposed to the solvent so that
ed direct hydrogen bonds were not observed. On the con-
e xylene group is buried in the hydrophobic environment
d by C5 and C6 glucopyranose atoms thus explaining the
lecular NOEs arising from the proximity of phenyl H-5 and
ons of the drug with the H-5 and H6 protons of the glucopy-
nits of -CD. Essentially the same orientation is observed
-CD-medetomidine complexes (Fig. 7B). The hydrophobic
roup is found within the cavity, whose bottom is defined
5 and C6 atoms of the glucopyranose subunits. As a con-
e, the shortest inter-proton distances are also observed
 the H-5 and H-6 protons of several glucose units in -CD










































ful dataod agreement with the reported NOEs. The imidazolium
tes freely compared to the phenyl ring and its protonated
s engage in hydrogen bonding interactions with surround-
r molecules as well as with 2- and 3-hydroxyl groups of the





and H-6 of t
contrast, lev
HS--CD ane NMR  ROESY data. (A) complex with -CD, (B) complex with -CD
st, in the HS--CD complexes the imidazolium appears
 inside the cavity and surrounded by the sulfate groups
he O6 atom of each glucose unit (Fig. 7C). This favorable
 interaction is quite strong but direct hydrogen bonds
ntly in competition with similar interactions with sol-
olecules. In this orientation, Ph-5 and Ph-6 protons of
ne face protons on H-3 and H-5 of the CD, hence the
Es.
 binding energies of the CD complexes with the medeto-
tiomers derived from 100 representative structures
imulations are shown as a box-and-whisker plot in
te the expected heterogeneities in the respective pop-
 proposed binding modes were conclusive and led to
rajectories for all the inclusion complexes studied. As
lier for several clenpenterol CD complexes [26], some
olecular hydrogen bonds were mediated by bridging
ules. Compared to the CE data (Table 2), opposite bind-
s between the CDs and the medetomidine enantiomers
uggested by MD  simulations (Fig. 8). In accordance
medetomidine formed a stronger complex with -CD,
red binding of levomedetomidine by -CD could also
rom the respective binding energies.
e of the HS--CD complexes, similar distribution of the
gies of 100 simulations were found for both medetomi-
mers (Fig. 8). This may  reflect incomplete sampling for
 charged complexes and/or entrapment into some local
 also noted that repulsion between the sulfate groups
ents direct simultaneous binding of any two  sulfates
ed imidazolium group of the drug enantiomers. It may
d that an incomplete sulfate substitution pattern may
 rise to enhanced binding energies. In addition, distinct
ated hydrogen-bonding patterns (data not shown) may
 observed migration differences in the electric field.
ons
ent study investigated the complexation of the enan-
edetomidine by various CDs. Specifically, the opposite
der observed in the presence of -CD and -CD as well
D and HS--CD was studied in detail by CE, NMR  spec-
 molecular modeling. S--CD was not included in NMR
lar modeling because this randomly substituted CD is
 positional and substitution isomers so that meaning-
ld not be obtained by these techniques. CE and NMR good agreement. Thus, dexmedetomidine was bound
-CD than levomedetomidine, which was also reflected
oselective NOE of the resonance of the imidazole H-5
he phenyl moiety of the drug in ROESY experiments. In
omedetomidine was  complexed stronger by -CD and
d a stronger NOE was observed for the phenyl H-6 in
206 S. Krait et al. / J. Chromatogr. A 1567 (2018) 198–210
Fig. 5. 1H NMR  reference spectra and 1D ROESY spectra of the complex between -CD and medetomidine upon irradiation of medetomidine protons (A) and upon irradiation
of -CD protons (B). The sample contained 4.2 mg  racemic medetomidine spiked with dexmedetomidine and 23.3 mg  -CD in 0.7 mL 50 mM D3PO4 in D2O, adjusted to an
apparent pH 2.5 with sodium deuteroxide in D2O.
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Fig. 6. 1H NMR  reference spectra and 1D ROESY spectra of the complex between HS--CD and medetomidine upon irradiation of medetomidine protons (A) and upon
irradiation of HS--CD protons (B). The sample contained 3.6 mg  racemic medetomidine spiked with dexmedetomidine and 22.1 mg HS--CD in 0.7 mL 50 mM D3PO4 in D2O,
adjusted to an apparent pH 2.5 with sodium deuteroxide in D2O.
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Fig. 7. Molecular modeling structures of the medetomidine enantiomers with (A) -CD, (B) -CD and (C) HS--CD. The complexes with dexmedetomidine (D-MDT) are
presented in the top layer, while the complexes with levomedetomidine (L-MDT) are shown in the bottom layer.
Fig. 8. tiome
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_____________________ Box-and-whisker plot of the complexes between the CDs and the medetomidine enan
side each box represent the mean for the 100 calculated values whereas the vertical w
e those whiskers were considered outliers. DMD, dexmedetomidine, LMD, levomedetom
resence of both CDs as well as the imidazole protons when
lexed with HS--CD.
olecular  modeling supported the structures derived from
 experiments. In the case of -CD and -CD, the phenyl moi-
f medetomidine entered the cavity from the wider secondary
f the CDs, while the protonated imidazole ring was  exposed
e bulk solvent. In the complex with HS--CD, the proto-
 imidazolium moiety appears to be positioned inside the CD
y interacting with the sulfate groups in position 6 of the glu-
molecules. Compared to CE and NMR  data, enantioselective
nition of the medetomidine enantiomers by the CDs was also
ested by MD simulations and reflected the observed reversal
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The manuscript describes a phenomenon hitherto unknown for cyclodextrins as hosts in CE which is 
the simultaneous formation of complexes with different stoichiometries between γ-cyclodextrin and the 
antiviral drug daclatasvir. In addition, the complexes displayed unexpected electrophoretic migration 
behavior as the complex migrated faster than the non-complexed analyte. Finally, the 2:1 complex was 
extremely stable so that it was detectable using cyclodextrin-free background electrolytes.  
Various techniques were applied in the study including capillary electrophoresis, HPLC, NMR 
spectroscopy and mass spectrometry to understand the phenomenon. Solution structure of daclatasvir 
and some analogs, structure of the complexes formed between daclatasvir as well as analogs with γ-
cyclodextrin were derived.  
The complexes of a daclatasvir diastereomer and two related substances were also elucidated. 
 
Unusual Complexation Behavior between Daclatasvir and -
Cyclodextrin. A Multiplatform Study
Sulaiman Krait a†, Antonio Salgado b†, Claudio Villani c, Lukas Naumann d, Christian Neusüß d, Bezhan 
Chankvetadze e, and Gerhard K.E. Scriba *a
During a screening of cyclodextrins (CDs) as chiral selectors for the separation of daclatasvir (DCV) and its enantiomer by 
capillary electrophoresis (CE), an unprecedented phenomenon for CDs was observed, that is two peaks with a plateau in 
between using -CD as chiral selector. The same result was encountered when enantiopure DCV was injected or when 
analyzing a sample containing enantiopure DCV and -CD in a CD-free background electrolyte. Peak coalescence was 
observed at 45 °C and at a pH above 3.5. Two peaks with a plateau were also observed for DCV stereoisomers as well as a 
structural analog. However, only a single peak was detected if one or both amino acid moieties of DCV were lacking. Nuclear 
magnetic resonance (NMR) experiments including Nuclear Overhauser effect-based methods showed that in solution DCV 
adopted a folded conformation in which the isopropyl side chain of the valine residues pointed toward the aromatic rings 
of DCV. Moreover, NMR unequivocally demonstrated the simultaneous formation of DCV--CD inclusion complexes with 1:1 
and 2:1 stoichiometry, which was corroborated by mass spectrometry. In both complexes, DCV also adopted a folded 
structure. The RSSR-diastereomer of DCV as well as an analog lacking one of the amino acid moieties also formed 1:1 and 
2:1 complexes with -CD although a plateau was only observed in the case of the RSSR-diastereomer. As shown by CE-MS, 
both DCV–-CD complexes surprisingly comigrated as the first peak, while the second migrating peak represents non-
complexed DCV.
Introduction
Daclatasvir (DCV, dimethyl N,N'-([1,1'-biphenyl]-4,4'-diylbis{1H-
imidazole-4,2-diyl-[(2S)-pyrrolidine-2,1-diyl][(2S)-3-methyl-1-
oxobutane-1,2-diyl]})dicarbamate, Figure 1) is an inhibitor of 
the hepatitis C nonstructural protein 5A replication complex.1 
The drug is used in combination with sofosbuvir for the 
treatment of infections with hepatitis C virus genotypes 1 – 4.2,3 
DCV is a biphenyl with two identical halves each containing two 
stereogenic centers each. The compound possesses S,S,S,S 
configuration. Due to the four stereogenic centres, there are 
also other diastereomers including meso forms of the com-
pound beside the R,R,R,R-configured enantiomer (RRRR-DCV).
Capillary electrophoresis (CE) is considered an effective method 
for stereoisomer separations, especially enantioseparations, 
due to the high-resolution ability as well as the flexibility of the 
technique.4-6
Other advantages include low consumption of chemicals and 
analytes and the availability of several operation modes. 
Furthermore, CE can be applied to study the complexation 
between high- and low-molecular weight compounds.7-10 In CE, 
the chiral selector is added to the background electrolyte (BGE). 
Enantioseparations are based on the formation of transient 
diastereomeric complexes between the chiral selector and the 
analyte enantiomers, which differ in their binding 
thermodynamics.11,12 Moreover, the diastereomeric complexes 
may differ in their electrophoretic mobility, so that 
enantioseparations can be also based on this phenomenon, 
even in the case of equal complexation constants.12,13 With 
regard to chiral selectors, cyclodextrins (CDs) are by far the 
most often applied selectors for enantioseparations in CE.14-16 
When screening different CDs in sodium phosphate buffer, pH 
2.5, as BGE for their ability to separate DCV and its enantiomer 
it was noted, that some CDs such as methyl-β-CD (M-β-CD) or 
hydroxypropyl-β-CD yielded an enantioseparation, while in the 
case of other CDs such as -CD or sulphated β-CD two peaks with 
a plateau be-tween them were observed. This indicates a slow 
dynamic equilibrium with regard to the CE timescale. Moreover, 
the same behaviour, i.e. two peaks with a plateau in between, 
was also encountered when enantiopure DCV was analysed in a 
-CD containing BGE at pH 2.5.
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Figure 1. Structures of DCV, RSSR-DCV, mono-DCV and half-DCV. For the structures of 
further compounds see Figure S1.
To the best of our knowledge, such a phenomenon has not yet 
been de-scribed for CDs as chiral selectors. Therefore, the 
present study was conducted in order to obtain some insight 
into the complexation between DCV and -CD.
Materials and methods
Chemicals




methyl ester) were a gift from Mylan Laboratories Ltd. 
(Hyderabad, India), while RRRR-DCV dihydrochloride, the RSSR-
diastereomer dihydrochloride (RSSR-DCV), the RSSS-
diastereomer dihydrochloride (RSSS-DCV) and the mono 




methylbutyl]carbamic acid methyl ester) were kindly supplied 




biphenyl, BOC-BPIB) and 4,4'-bis(2-((S)-pyrrolidin-2-yl)-1H-
imidazol-5-yl)-1,1'-biphenyl tetrahydrochloride (bis-
pyrrolidinyl-imidazolyl biphenyl, BPIB) were from abcr GmbH 
(Karlsruhe, Germany). N-[(1S)-2-methyl-1-[[(2S)-2-(5-phenyl-
1H-imidazol-2-yl)-1-pyrrolidinyl]carbonyl]propyl]-carbamic acid 
methyl ester (half-DCV) was synthesized as described in the 
supporting information.
Capillary electrophoresis 
CE experiments were performed on a Beckman P/ACE MDQ 
capillary electrophoresis system (Beckman Coulter, Krefeld, 
Germany) equipped with a UV-Vis diode array detector and 
controlled by the 32 KARAT software (version 8.0) for system 
control, data acquisition and processing. Polymicro® fused-silica 
capillaries 40/50.2 cm, 50 µm i.d. were from CM Scientific 
(Silsden, UK). A new capillary was rinsed at a pressure of 20 psi 
(138 kPa) with 1 M sodium hydroxide for 20 min, followed by 
water for 10 min. Before each run, the capillary was flushed 
with water for 2 min followed by the background electrolyte 
(BGE) for 2 min. If not stated otherwise, experiments were 
carried out at 20 °C and an applied voltage of 25 kV. The 
detection wavelength was 305 nm, except for half-DCV, which 
was detected at 250 nm. Samples were injected 
hydrodynamically at a pressure of 0.7 psi (4.8 kPa) for 5 s. The 
background electrolytes BGEs containing -CD were prepared 
by dilution the appropriate amount of the acid component to 
approx. 80 % of the final volume. -CD was added, and the pH 
was adjusted with the base component before making up to the 
final volume. Selector-free electrolyte solutions were prepared 
accordingly.
Capillary electrophoresis-mass spectrometry 
CE-MS experiments were carried out on an Agilent G1600X CE 
System coupled with an Agilent 6510 QTOF (Agilent, Santa 
Clara, CA, U.S.A.) using a fused-silica capillary (60 cm effective 
length, 50 µm i.d.) and a separation voltage 30 kV. Injections 
were performed for 9 s at a pressure of 5 kPa. A new capillary 
was rinsed according to the CE-UV experiments. The BGE 
consisted of 100 mM ammonium formate adjusted to pH 2.6 by 
addition of 2 % ammonia solution. Experiments in the presence 
of -CD were carried out at a concentration of 50 mM of the CD. 
The MS instrument settings were the same as for the direct 
infusion experiment. A tri-axial sheath flow CE-MS sprayer was 
used for coupling CE with MS. Therefore, a 
methanol/water/formic acid (50/49/1, v/v) sheath liquid was 
used for grounding and the separation capillary had a 
protrusion of 0.05 mm.
NMR spectroscopy
NMR spectra were recorded with a Varian NMR System (Varian 
Inc, Palo Alto, CA, USA), fitted with a CHX 1H/13C/15N-31P probe 
head, gradient module and variable temperature unit. The 
spectrometer resonance frequency for 1H was 499.61 MHz. The 
90º hard pulse for proton was optimized for each sample. The 
signal due to residual HDO (4.65 ppm) was used as internal 
standard. 1H signals were assigned upon COSY, HSQC and 1D 
TOCSY results when appropriate. For the 1D TOCSY 
experiments, the spinlock (mixing) time was set to 80 ms. The 
structures of supramolecular aggregates and the conformation 
of DCV in solution, either in the complexed or in the free form, 





















































(200, 300 and 400 ms). All NMR data were processed with the 
MestReNova software (v. 14.1.0, Mestrelab Research, S.L., 
Santiago de Compostela, Spain). Samples were prepared by 
weighing about 12 to 13 mg γ-CD and/or 2 to 3 mg of the 
compound and dissolution in 0.6 to 0.8 mL of 50 mM D3PO3 in 
D2O adjusted to an apparent pH 2.5 or 4.0 by NaOD.
Results and Discussion
Unusual electrophoretic migration, dependence on solute 
structure and variables
Screening of CDs as chiral selectors for the CE separation of DCV 
and its enantiomer was carried out in 50 mM sodium phosphate 
buffer, pH 2.5, containing the CDs at concentrations of 5 mM 
and 20 mM. The results are summarized in Table S1. Partial 
enantioseparations were observed using carboxymethyl-α-CD 
and 2-hydroxypropyl-β-CD, while baseline separations could be 
found for M-β-CD, carboxymethyl-γ-CD and sulfated γ-CD. 
Surprisingly, two peaks with a plateau in between were 
observed in the presence of sulfated β-CD and γ-CD. Figure 2 
shows representative electropherograms of the analysis of a 
non-racemic mixture of DCV and its enantiomer in the presence 
of M-β-CD (Figure 2A) and γ-CD (Figure 2B) as examples of 
baseline separations and the plateau phenomenon, 
respectively. Moreover, two peaks with a plateau in between 
were also observed when enantiopure DCV or the enantiomer 
RRRR-DCV were analyzed in the presence of γ-CD (Figure 2C and 
2D, respectively). In contrast, a single peak was detected for 
DCV or RRRR-DCV when M-β-CD was added to the BGE (data not 
shown). Therefore, the plateau phenomenon indicates an 
equilibrium, which is slow on the CE time scale and apparently 
not related to an enantiodifferentiation. Typically, 
complexation equilibria between analytes and CDs in CE 
enantioseparations are very fast on the CE timescale so that 
separate peaks are not detected for the free and complexed 
analyte. Consequently, further experiments were conducted in 
order to investigate the slow equilibrium phenomenon.
The plateau was observed in the γ-CD concentration range up 
to 100 mM and could be detected at CD concentrations as low 
as 0.1 mM (Figure S2A). In addition, the area of the first 
migrating peak slightly increased with the γ-CD concentration.
Figure 2. Electropherograms (A) a nonracemic mixture of DCV and RRRR-DCV in the 
presence of 7 mg/mL M-β-CD in the BGE, (B) a nonracemic mixture of DCV and RRRR-
DCV in the presence of 20 mM γ-CD in the BGE, (C) DCV in the presence of 20 mM γ-CD 
in the BGE, (D) RRRR-DCV in the presence of 20 mM γ-CD in the BGE and (E) sample 
containing DCV and γ-CD analyzed in a CD-free BGE.
Similar data were observed as a function of the phosphate 
buffer concentration (20 to 200 mM) (Figure S2B). The effects 
of the capillary temperature between 15°C and 45 °C (Figure 
S3A) showed a dynamic behavior indicating in-capillary 
equilibria with two well separated peaks at slow exchange 
regimes at lower temperatures and progressive coalescence at 
higher temperatures. The plateau area between the resolved 
peaks became more pronounced under fast exchange regimes 
between 20 and 35 °C, eventually leading to complete 
coalescence at 45°C. Computer simulation of the exchange-
broadened peaks (Figure S4) 17-20 gave the rate constants for the 
in-capillary process leading from the first to the second 
migrating species spanning between 0,7·10-3 s-1 at 15°C and 
1.38·10-3 s-1 at 40°C. The averaged value of the free energy 
barriers was calculated as ΔGǂ = 20.97 kcal/mol. This value 
indicates a significantly slower process than those reported for 
other CD complexations. Linear regression of the Eyring plot (ln 
(k/T) vs 1/T) yielded activation enthalpy ΔHǂ = 20.80 kcal/mol 
and entropy ΔSǂ = -0.6 cal/mol·K, indicating the process is 
enthalpy controlled, with only a minor entropic contribution. 
Upon increasing the pH of the BGE from 2.5 to 4.5 peak 
coalescence around pH 4 was observed (Figure S3B). DCV 
possesses two basic imidazole nitrogen atoms with pKa values 
of 5.6 and 4.9. 21 Thus, protonation of both imidazole nitrogen 
atoms appears to be a prerequisite for the observation of the 
slow equilibrium leading to the plateau in the CE experiments.
In addition, two diastereoisomers of DCV, a structural analog 
containing Ile instead of Val as one of the amino acid moieties, 
mono-DCV, which lacks one MOC-Val moiety, two synthetic 
precursors, BPIB (lacking both MOC-Vals side chains) and the 
BOC-protected derivative BOC-BPIB, as well as the 
“monomeric” half-DCV were analyzed by CE (Figures 1 and S1). 
In analogy to DCV, two peaks with a plateau in between were 
also observed for the R,S,S,R- and R,S,S,S-configured 
diastereomers as well as Ile-DCV (Figure S5). In contrast, only a 
single peak was observed for mono-DCV, half-DCV or the 
pyrrolidine derivatives BPIB and BOC-BPIB (Figure S5). 
Therefore, a structural prerequisite for the appearance of the 
plateau seems to be a "symmetrical" structure containing two 
MOC-amino acid moieties, which may, however, differ to some 
extent. The stereochemistry at the chiral centers did not play an 
important role as this behavior was seen with all available 
stereoisomers of DCV.
In order to exclude the very unlikely enantiomerization of DCV 
in the presence of γ-CD under the CE conditions, a sample 
containing DCV and γ-CD (kept at room temperature for 30 min) 
was analyzed by HPLC on a Lux i-Cellulose-5 column. This system 
effectively separates the enantiomers of DCV (Figure S6A). Only 
a single peak at the retention time of DCV was detected for the 
γ-CD-containing DCV sample (Figure S6B) so that 
enantiomerization in the presence of γ-CD could be excluded. 
Surprisingly, when this sample was analyzed by CE using a CD-
free phosphate buffer-based BGE, pH 2.5, two peaks with a 
plateau in between were also observed (Figure 2E). The plateau 
was independent of parameters for the preparation of the γ-CD-
containing DCV sample solution. A temperature study revealed 
coalescence of the peaks also at about 45 °C. Computer 






simulations (Figure S7) yielded rate constants for the conversion 
of the first into the second migrating species spanning one 
order of magnitude from 0.57·10-3 s-1 at 20°C to 5.7·10-3 s-1 at 
35°C. The averaged value of the free energy barriers was 
calculated as Gǂ = 21.33 kcal/mol, a value that is of the same 
order of magnitude of that obtained for the -CD containing BGE 
system.
With regard to the observation of a plateau between two peaks 
in CE, the "complete" DCV structure, i.e. a symmetrical 
biphenyl-imidazole-pyrrolidine molecule with two MOC-Val 
side chains seems to be required. The appearance of the 
plateau is independent of the stereochemistry of DCV as well as 
minor modifications in the amino acid moiety. Furthermore, the 
molecule must be fully protonated as peak coalescence was 
observed at about pH 4. The phenomenon is not generally 
observed for all CDs because a "true" enantioseparation and, 
consequently, no plateau could be obtained in the screening 
experiments (Table S1). The cavity size of the CD does not 
appear to be a prerequisite, because the plateau was found for 
-CD containing 8 glucopyranose units and sulfated β-CD, which 
is formed by 7 glucopyranose units, while it was not found in 
the case of sulfated -CD and M-β-CD.
Structure of dynamic supramolecular complexes
The structures of the complexes of -CD with DCV, the RSSR 
diastereomer, mono-DCV as well as half-DCV were further 
studied in deuterated sodium phosphate buffer by 1H-NMR 
experiments because nuclear Overhauser effect (NOE) based 
NMR methods, in particular rotating frame nuclear Overhauser 
effect spectroscopy (ROESY) techniques, allow the analysis of 
spatially close nuclei also in CD-based complexes. 22-25 Signals 
were assigned based on COSY, TOCSY and HSQCED data.
DCV. The 1H-NMR spectrum of DCV recorded in deuterated 
phosphate buffer is shown in Figure 3 and the resonances are 
reported in Table S2. Surprisingly, two sets of signals were 
observed for most resonances. Based on the well resolved 
signals for the two pyrrolidine H-2 protons, two conformers 
were identified. The major one showed a triplet at 5.14 ppm (J 
= 7.6 Hz), while the minor one featured a double doublet at 5.61 
ppm (J1 = 7.6 Hz and J2 = 1.5 Hz). Assuming an envelope-type 
conformation of the pyrrolidine ring, the H-2 in the pyrrolidine 
ring in the major conformer had axial configuration and 
equatorial configuration in the minor one. The molar ratio of 
the conformers was 1.0:0.14 as concluded from the respective 
integrals of the H-2 protons as well as the signals of the methoxy 
groups at 3.53 and 3.23 ppm. This ratio did not change 
significantly when heating the probe to 60 °C (data not shown). 
Moreover, in a 2D ROESY experiment, NOEs between the 
methyl groups of the valine side chain with the aromatic 
protons of the phenyl and imidazole rings were observed 
(Figure S8) indicating that DCV existed in a folded structure in 
solution where the valine side chains were close to the aromatic 
rings of the molecule, while the MOC moieties pointed away 
from it. Such a folded structure has been also reported in 
modelling studies26 and when DCV is complexed to the 
nonstructural protein 5A replication complex. 27 Moreover, a 
NOE interaction between the methyl protons of the isopropyl 
side chain and the pyrrolidine H-2 proton was observed for the 
minor conformer, so that the methyl groups appear to be 
located closer to the pyrrolidine ring in the folded structure of 
this conformer as compared to the major conformer.
DCV and -CD. The 1H-NMR spectrum of a sample containing 
DCV and -CD is shown in Figure 3C in comparison to the spectra 
of -CD (Figure 3A) and DCV (Figure 3B). Details of signal 
assignment are summarized in Table S3. Unlike most reported 
cases in the literature where usually only a single set of signals 
for the analyte and another one for the CD are observed, [22-25] 
three sets of 1H resonances were seen for DCV and two sets of 
signals for -CD. As to the -CD resonances, the more intense set 
if signals coincided with the resonances of pure -CD, while the 
less intense signals were shifted upfield. Considerable shifts 
were also seen for the signals related to DCV, particularly in the 
aromatic region (insert Figure 3C). The "minor" set of DCV 
resonances encountered minor downfield shifts, while the two 
other sets of "major" signals were shifted upfield com-pared to 
DCV in the absence of -CD. By comparing the integrals of 
signals, the two “major” DCV sets seemed to be equimolar 
(same integral values), while the “minor” DCV signals integrated 
for less, so that a 1.0:1.0:0.24 ratio (mol/mol/mol) was 
determined at 25°C. The integrals of the aromatic protons of the 
two “major” DCV species and the integral of the anomeric H-1 
signal of the “minor” -CD yielded a molar ratio of 1:1:1.
A 2D ROESY experiment (Figure S9) yielded evidence for the 
presence of two structurally different complexes. All observed 
intermolecular NOE responses involved the inner hydrogens of 
-CD (H-3 and H-5) and the aromatic pro-tons of DCV. A NOE 
between the inner protons of the "major" -CD and the "minor" 
DCV species indicated the presence of a 1:1 inclusion complex, 
which is often reported for CDs. 22-24 However, a second 
supramolecular structure was identified based on the NOEs 
between the inner protons of the "minor" -CD and the 
aromatic protons of both "major" DCV species. This indicated 
the formation of a 2:1 complex (DCV:-CD) in which two DCV 
molecules are inserted into the CD cavity. A 1D ROESY 
experiment further corroborated this assumption because 
selective irradiation at the resonance at 7.25 ppm representing 
the phenyl protons H-2 and H-6 of one of the "major" DCV 
species resulted in a NOE with the same protons of the other 
"major" DCV at 7.17 ppm (Figure S10). Likewise, irradiation at 
the resonance of 7.17 ppm showed a NOE response for the 
signals at 7.25 ppm (data not shown). Therefore, the aromatic 
rings of the two DCV molecules in the 2:1 complex appear to be 
in close vicinity. The complex stoichiometry also explains the 
upfield shift of the protons of the "minor" -CD due to the 
anisotropic ring current effect generated by the aromatic 
moieties of the DCV molecules, which are spatially closer in the 
2:1 complex than in the 1:1 complex. Further evidence of the 
two coexisting complexes was provided by a DOSY experiment, 
because the diffusion coefficient of H-1 of the “minor” species 
involved in the 2:1 complex was smaller than that of H-1 of its 
“major” counterpart (representing the 1:1 complex as well as 
non-complexed -CD).






Figure 3. 1H-NMR spectra of (A) γ-CD, (B) DCV and (C) DCV plus γ-CD in 50 mM deuterated phosphate buffer in D2O, apparent pH 2.5. The insert shows the expanded region of the 
aromatic protons. For signal assignments see Tables S2 and S3 (supplementary electronic material). Experimental conditions: (A) 3.6 mg DCV·2HCl in 0.7 mL 50 mM D3PO4 in D2O (6.4 
mM), pH 2.5, 25 °C; (B) 13.0 mg γ-CD in 0.7 mL 50 mM D3PO4 in D2O (14.3 mM), pH 2.5, 25 °C; (C) 3.0 mg DCV·2HCl and 13.0 mg γ-CD in 0.7 mL 50 mM D3PO4 in D2O (5.3 mM, 14.3 
mM), pH 2.5, 25 °C.
Intramolecular NOEs were also observed for the DCV molecules. 
Cross peaks between the methyl groups of the valine side chains 
(0.70 - 0.80 ppm) and the aromatic hydrogens (7.35 - 7.50 ppm) 
indicated that DCV adopts the same folded structure in the 
complexes as it had been observed for the solution structure in 
the absence of γ-CD. This applies to both, the 1:1 and the 2:1 
complexes. Information on the conformation of the pyrrolidine 
ring in the complexes from coupling constants of the pyrrolidine 
H-2 signal could not be derived because of significant signal 
overlapping. A schematic illustration of the tentative structures 
of both complexes is shown in (Figure 4). The ratio of the 1:1 
versus the 2:1 complex was about 0.24:1.0 based, for example, 
on the integrals of the imidazole H-5 of the minor DCV at 7.59 
ppm and the doublet of the phenyl H-2,6 protons at 7.18 ppm. 
Measuring the spectra at 40 °C, 60 °C and 80 °C resulted in ratio 
between the complexes of about 0.39:1.0, 0.9:1.0 and 2.3:1.0, 
respectively. Thus, the 2:1 complex is more abundant at lower 
temperatures, while the 1:1 complex is the major species at 80 
°C with inversion of the ratio above 60 °C. Therefore, the peak 
coalescence at about 40 °C observed in the CE experiments is 
not based on the equilibrium between the complexes. 
Figure 4. Schematic representation of the 1:1 and 2:1 complexes formed between DCV 
and γ-CD. The intermolecular NOEs derived from ROESY experiments are indicated by 
arrows; red: intramolecular NOEs, blue: intermolecular NOEs between DCV and γ-CD, 
green: intermolecular NOEs between DCV molecules in the 2:1 complex.






Upon cooling the sample to 25 °C, the 1:1 versus 2:1 complex 
ratio returned to the original value of 0.24:1.0. Because pH-
dependent peak coalescence was observed in CE at pH 4.0, 
NMR experiments were also performed at this apparent pH. The 
1H-NMR spectra of DCV in the absence and presence of -CD at 
pH 4.0 (Figure S11) were essentially identical to the spectrum 
recorded at pH 2.5 (Figure 4). COSY, TOCSY as well as 1D and 2D 
ROESY data also clearly demonstrated the presence 1:1 and 2:1 
complexes at pH 4.0 (data not shown). The molar ratio was 
about 0.23:1.0, i.e. identical to pH 2.5. Moreover, NOE 
interactions did not differ significantly to those at pH 2.5 so that 
identical structures of the complexes can be concluded at both 
pH values. This clearly indicated that the plateau observed in CE 
is not due to an equilibrium between the two complexes.
The presence of both complexes in solution was confirmed by 
direct infusion ESI-TOF-MS of a solution containing DCV and -
CD in ammonium formate buffer, pH 2.6. Control experiments 
employed the linear oligosaccharide maltoheptaose as well as 
α-CD, in order to avoid misinterpretation as supramolecular 
associates may be formed in the gas phase, which do not exist 
in solution. 28,29 α-CD did not yield an enantioseparation or a 
plateau with DCV in the screening experiments.
In the presence of -CD, the resulting mass spectrum (Figure 
S12) shows two intensive signals at m/z 739.4 and m/z 370.2 
corresponding to singly and doubly charged DCV. The low-
intensity signal at m/z 1017.4 is consistent with the doubly 
charged 1:1 DCV--CD complex, while the signals at m/z 1387.1 
and m/z 925.7 are in accordance with the doubly and triply 
charged 2:1 complex between DCV and -CD. Calculated and 
observed masses were in good agreement (Table S4). Only the 
DCV signals at m/z 739.4 and m/z 370.2 could be detected in the 
presence of -CD or maltoheptaose (data now shown). 
Therefore, the signals representing the 1:1 and 2:1 DCV--CD 
complexes are not artefacts created in the ion source and 
confirm the NMR results on the concomitant formation of 
complexes with 1:1 and 2:1 stoichiometry between DCV and -
CD in solution.
The most commonly reported stoichiometry for CD complexes 
is 1:1 (solute:CD) 30-32 although higher order aggregates have 
also been published. The composition 1:2 is the second most 
abundant.[31] In contrast, stoichiometries of 1:3, 2:1 and 2:2 
have been rarely reported. Furthermore, ternary CD complexes 
including additional background electrolyte components such 
as SDS in addition to the analytical solute with a ratio of 1:1:1 
were described.33,34 Unless NMR has been employed, the 
nature of the complexes (inclusion or "external" complex) 
cannot be concluded. With regard to 2:1 complexes involving 
CDs, several reports demonstrated their formation. 35-38 In most 
cases the stoichiometry of the complexes was derived from 
Job´s plots, while the orientation and stacking of both solutes 
within the CD cavity was derived from molecular modeling. 35-37 
There are also reports of 2:1 complexes, in which one solute 
molecule was included in the CD cavity, while the second one 
was coordinated externally. 39,40 Neither these studies nor the 
abovementioned publications on 2:1 aggregates provided 
evidence for the presence of two complexes with different 
stoichiometries in solution. To the best of our knowledge only 
one publication reported the simultaneous presence complexes 
with different stoichiometry (1:1 and 2:1) between dimetindene 
and carboxymethyl-β-CD, 41 but the structures could not be 
unequivocally resolved in that study. In contrast, the presence 
of the two complexes between DCV and -CD including their 
stoichiometry was unequivocally demonstrated based on NMR 
and MS data.
In addition, the structures of the complexes of the 
diastereomeric RSSR-DCV as well as mono-DCV and half-DCV 
with -CD were determined by 1H-NMR spectroscopy. A 
detailed discussion can be found in the Supporting Information. 
Table 1 compares the CE behaviour as well as complex 
stoichiometries, their ratios and structures of the guest 
molecules of DCV and the three analogues studied in more 
detail. Although the number of analytes is limited, a biphenyl 
structure appears to be required for the formation of a 2:1 
complex. The stereochemistry of the amino acid moiety does 
not affect the simultaneous formation of two complexes but 
might change the ratio between them. 
Migration order
In order to confirm the role of interaction between DCV and -
CD, the CE capillary was used as a microreactor. Individual plugs 
of DCV and -CD were injected in a capillary containing CD-free 
BGE, pH 2.5, which were separated by a short plug of buffer to 
prevent contact between the plugs due to diffusion. The results 
are shown in Figure 5. When DCV was injected as the first plug 
so that die not migrate through the -CD plug only a single peak 
was detected at the migration time of DCV (Figure 5A), while 
two peaks with a plateau was found when DCV was injected as 
the second plug so that it had to migrate through the -CD plug 
on the way to the detector (Figure 5B).





Structure of guest molecule(s) in complex(es)
DCV Plateau 1:1 and 2:1 ~ 0.24:1 Folded conformation of MOC-Val residues
RSSR-DCV Plateau 1:1 and 2:1 ~ 1:1 Extended conformation of MOC-Val residues in complexes
Mono-DCV – 1:1 and 2:1 [a] ~ 0.4:1 Folded conformation of MOC-Val residue in complexes 
Half-DCV – 1:1 – Folded conformation of MOC-Val residue in complex
[a] no unequivocal proof of a 2:1 complex by NOEs but presence likely






Figure 5. Plug-plug CE experiments. The order of the injected plugs is schematically 
shown above the electropherograms. Injection sequence: (A) DCV > γ-CD, (B) γ-CD > DCV, 
(C) DCV + γ-CD, (D) DCV > DCV + γ-CD. The BGE consisted of 50 mM sodium phosphate 
buffer, pH 2.5. The direction of migration is toward the cathode.
Injecting a mixture of DCV and γ-CD also resulted in two peaks 
with a plateau (Figure 5C). Moreover, the area of the second 
migrating peak increased significantly when a DCV-plug was 
injected before a plug of a mixed DCV plus γ-CD sample (Figure 
5D), indicating that the first migrating peak represents the 
unresolved mixture of the 1:1 and 2:1 DCV-γ-CD complexes, 
while the second peak is due to free DCV.
This was confirmed by CE-MS experiments (Figure 6). When 
analyzing pure DCV in a CD-free BGE, only a single peak with m/z 
739.4 at the migration time of DCV is observed (Figure 6A). Mass 
traces corresponding to complexes with γ-CD could not be 
detected above baseline noise. In contrast, two peaks with the 
plateau were detected in the analysis of a sample containing 
DCV and γ-CD using a CD-free BGE (Figure 6B).
Figure 6. CE-MS experiments of (A) pure DCV and (B) a sample containing DCV and γ-CD 
using 50 mM ammonium formate buffer pH 2.6 as BGE. (C) CE-MS analysis of DCV using 
50 mM ammonium formate buffer pH 2.6, containing 50 mM γ-CD as BGE.
The trace of m/z 739.4 proved that DCV is present in the peaks 
as well as the plateau, while the mass traces m/z 925.4 and m/z 
1018.4 representing the 2:1 and 1:1 complex, respectively, were 
only detected in the first migrating peak. When γ-CD is present 
in the BGE (Figure 6C), the mass traces of the 1:1 and 2:1 
complexes at m/z 925.4 and m/z 1018.4 as well as free DCV (m/z 
739.4) were detected, while in the second migrating peak free 
DCV dominated. In contrast to the analysis of the DCV plus γ-CD 
sample analyzed in a CD-free BGE (Figure 6B), the plateau is also 
formed by the complexes in addition to non-complexed DCV. 
This difference can be explained by the presence of γ-CD in the 
BGE. Free DCV resulting from the dissociation of the complexes 
can be complexed again if the CD is present in the BGE, while 
this is not possible in the absence of γ-CD in the BGE because in 
the latter case γ-CD and DCV are electrophoretically separated.
The CE-MS data show that both complexes exhibit the same 
mobility so that they are not separated independent of the 
presence or absence of γ-CD in the BGE. This is also unexpected 
considering the theoretical difference in the mass-to-charge 
ratios of both complexes. Taking into account the low 
abundance of the ion representing the 1:1 complex in the 
experiments obtained in the absence of γ-CD in the BGE (Figure 
6B) it could be hypothesized that the 2:1 complex possesses a 
higher stability, which results in the fact that the complex can 
still be observed in a CD-free BGE injecting a sample containing 
DCV and γ-CD. Upon dissociation of one DCV molecule, the 
resulting 1:1 complex is considerably less stable and quickly 
liberates DCV, which cannot form a complex again because γ-
CD and DCV are electrophoretically separated. In contrast, 
when γ-CD is present in the BGE, the complexes can be 
reestablished upon dissociation into γ-CD and DCV so that the 
plateau between the peaks is composed of all three species, i.e. 
both complexes as well as free DCV (Figure 6C).
The faster migration of the complexes compared to free DCV as 
demonstrated by the plug-plug as well as CE-MS data is 
unexpected, because non-complexed DCV should have a higher 
charge density (charge-to-mass ratio) than the complex based 
on the molecular weight of the species and, consequently, 
migrate first. It has been described for CE enantioseparations of 
peptides that the enantiomer migration order can be based on 
a complexation-induced pKa shift translating into a faster 
mobility of the stronger complex between one of the 
enantiomers and a CD. 42,43 However, at pH 2.5, a pH about 2 - 
3 orders of magnitude below the pKa value of DCV, the 
compound would be fully protonated in the free as well as the 
complexed form. Therefore, the reason for a higher mobility of 
the complex due to a pKa shift upon complexation of DCV can 
be excluded. A speculative explanation could be based on 
differences in the solvation shell of the molecules/complexes 
assuming a larger shell in the case of free DCV. It is known that 
small inorganic ions such as Li+ migrate slower than larger ions 
in CE44 because of a much larger solvation shell.45
Furthermore, the CE capillary was used as a microreactor for the 
analysis of the equilibrium between DCV and γ-CD applying the 
so-called nonequilibrium capillary electrophoresis of 






equilibrium mixtures (NECEEM).46,47 Applying a sample 
containing 6 mM -CD and 0.1 mM DCV (n = 3) gave the 
equilibrium dissociation rate constant KD = 1.32·10-2 M (RSD = 
4.4 %) the complex formation rate constant kon = 9.36·10-2 M-
1·s-1 (RSD = 9.5 %) and the complex dissociation constant koff = 
1.23·10-3 s-1 (RSD = 7.1 %). The approximate proportions of free 
DCV, the complex and the decay (plateau) in this equilibrium 
mixture were about 69 %, 17 % and 14 % (mol/mol/mol), 
respectively.
Conclusions
Two peaks with a plateau in between were observed in CE when 
DCV was analyzed in a -CD-containing BGE and also when a 
sample composed of DCV and -CD using a CD-free BGE. This is 
an unprecedented phenomenon for CDs in CE. Equilibria 
between peptides and ligands are slow on the CE timescale so 
that two peaks with a plateau can be observed, where the peaks 
represent the complex and the free ligand, respectively, while 
the plateau is formed by the dissociating ligand.10,47 In contrast, 
equilibria involving CDs are typically very fast on the CE 
timescale so that only a single peak is observed when 
enantiopure (or achiral) compounds are analyzed in the 
presence of CDs in the BGE. The process was dependent on the 
pH of the BGE and the temperature, peak coalescence was 
observed above pH 3.5 and at about 45 °C, respectively.
Furthermore, the simultaneous presence of 1:1 and 2:1 
complexes formed between either DCV, RSSR-DCV or mono-
DCV and -CD was demonstrated by NMR and MS experiments. 
According to NMR data, DCV or the analogs are included in the 
cavity of the CD. In the case of the 2:1 complexes the solutes 
appear to be stacked. The equilibrium between the complexes 
with different stoichiometry were not the reason for the 
formation of the plateau as unequivocally shown by CE-MS. 
Surprisingly, the complexes displayed identical mobility so that 
they were not separated in CE. In addition, they migrated faster 
than non-complexed DCV which implies a higher charge-density 
than DCV probably due to differences in the solvation shells.
Although the number of investigated compounds is limited, the 
plateau phenomenon was only observed for “complete” 
derivatives with a symmetrically substituted biphenyl-
imidazole-pyrrolidine structure containing MOC-amino acid 
moieties at both pyrrolidine “ends”. Mono-DCV did not display 
two peaks with a plateau although 1:1 and 2:1 complexes are 
most likely present in solution. No indication for a 2:1 complex 
could be found for half-DCV. Thus, it may be hypothesized that 
upon accommodation of two stacked DCV molecules in the 
cavity of -CD, the molecules are “locked” because of the amino 
acid residues at both ends. This results in a highly stable 2:1 
complex that dissociates only slowly so that it can still be 
detected in CD-free BGE. The stereochemistry of the chiral 
centers does not seem to play a role. However, if one of the 
MOC-Val moieties is missing (mono-DCV) the compounds are 
not locked, so that the equilibrium of complex formation is fast 
and only a single peak is observed in CE.
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4. General discussion 
 
This work includes three main themes. The main one is the determination of chiral purity of three drugs 
using experimental design approaches for method development (manuscripts 1,2,3). The second one 
is connected to the first one and comprises the elucidation of the chiral separation mechanism of two 
substances (manuscripts 2,4). The last theme involves clarifying an unusual complexation behavior of 
γ-CD and daclatasvir, which was observed in CE and studied with multiple analytical approaches 
(manuscript 5). 
 QbD-assisted development of CE methods for the chiral purity determination of drugs 
(manuscripts 1,2,3) 
4.1.1. ATP, Initial method scouting and identification of chiral selectors 
As mentioned in the introduction, cyclodextrins are the most widely applied selectors in chiral CE due 
to their versatility, stability, UV-transparency, commercial availability, and the affordability of most 
derivatives [60]. Many screening strategies were described in the literature for the enantiomeric 
separation methods in CE [110–114]. Native and neutral CDs are usually screened as possible chiral 
selectors for ionizable analytes in CZE mode and even for neutral compounds when using MEKC or 
MEEKC modes. Charged CDs proved high efficiency as chiral selectors, especially the sulfated CDs 
[115; 116]. The chiral separation with charged CDs has a higher opportunity when the electrophoretic 
mobility of the CD is opposite that of the analyte [115; 117]. The general rule would be using anionic 
CDs for basic and neutral analytes, and cationic CDs with acidic drugs, but this is also pH dependent 
since acidic analytes that are not ionized at low pH values, may also be separated with anionic CDs, 
especially the sulfated derivatives which were recently reported as the most commonly used chiral 
resolving agents in CE [61].  
The first step in developing an analytical method following the QbD methodology is the and the definition 
of the analytical target profile. For the three drugs, the ATP was defined as a method allowing the precise 
determination of the enantiomeric impurity at a relative concentration of 0.1 % with acceptable precision 
and accuracy at the 0.1% level and within an analysis time of less than 10 minutes. 
In order to identify the suitable chiral selectors, a phosphate buffer pH 2.5 was used as BGE for the 
initial screening of cyclodextrins in case of the basic compounds DXM and MDT. This insured both 
sample solubility and a slow EOF which would lead to a better enantioresolution in case of chiral bias. 
For the acidic compound ambrisentan Amb, cyclodextrins were screened in a basic borate buffer pH 9.0 
and an acetate buffer pH 5.0, to ensure the solubility since the pKa of Amb is approximately 4.0. 
However, the higher resolution was obtained in this case with lower pH due to the slower EOF. 
Different native and neutral cyclodextrins and their derivatives were screened as possible chiral 
selectors in all three methods. In addition to the latter, the cationic 2-hydroxy-3-N,N,N-
trimethylamino)propyl-β-CD was screened with Amb, while anionic CDs were screened with DXM and 




MDT. The polarity of voltage was reversed when no peaks were detected after 60 minutes when 
evaluating ionic CDs.  
γ-CD was chosen as chiral selector for Amb further method development because it yielded the highest 
resolution of the screened CDs.  
The best enantiomeric resolution at pH 2.5 was obtained by applying the reversed polarity of voltage 
and sulfated β‐cyclodextrin (S‐β‐CD) as a chiral selector in case of DXM and MDT.  
 
4.1.1.1. Improving the peak shape through adjustment of the experimental conditions 
MDT. Despite the high chiral resolution obtained with S‐β‐CD, a severe tailing affected the peak shapes 
of D-MDT and L-MDT, which couldn’t be improved by changing the counter ions of the phosphate buffer, 
or even trying other buffer substances at pH 2.5 or 4.8 with the same selector. Short end injection did 
not help either. Upon investigating a sodium phosphate buffer pH 7.0 at normal polarity of the applied 
voltage the peak shape was improved. A comparison of the initial and the improved peak shape is shown 
in Fig. 7. 
 
Figure 7 Electropherograms of the S-β-CD-mediated separation of D-MDT and L-MDT at (A) pH 2.5 and (B) pH 
7.0. Experimental conditions: (A) 10.2/50.2 cm, 50 μm ID fused-silica capillary (short end injection); 50 mM 
sodium phosphate buffer, pH 2.5; 30 mg/mL S-β-CD; 20°C; −20 kV and (B) 21.3/31.5 cm, 50 μm ID fused-silica 
capillary; 50 mM sodium phosphate buffer, pH 7.0; 50 mg/mL S-β-CD; 20°C; 6 kV; UV detection at 200 nm. Sample 
concentration: 700 μg/mL D-MDT and 7 μg/mL L-MDT. 
 
DXM. The chiral resolution of DXM and LVM using S‐β‐CD was associated with high baseline noise and 
peak fronting. Subsequently, 100 mM triethanolamine‐phosphoric acid buffer, pH 2.5, 100 mM sodium 
acetate buffer, pH 5.0, and sodium citrate buffer, pH 6.0, were studied as alternative BGEs. However, 
none of these conditions improved the chiral separation, the peak shape of the analytes or baseline 
noise. Therefore, S‐β‐CD was further screened in sodium phosphate buffer, pH 7.0, and sodium borate 
buffer, pH 8.5, under normal polarity of the applied voltage. In the presence of 10 mM S‐β‐CD, high 
resolution was observed with R S values of about 21 and 24, respectively. DXM migrated before LVM, 
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buffer, different buffer co‐ions of phosphate including triethanolamine and lithium were studied but even 
worsened the peak shape. In 2‐[4‐(2‐hydroxyethyl)‐1‐piperazinyl]‐ethanesulfonic acid buffer, pH 7.0, 
piperazine‐1,4‐bis(2‐ethanesulfonic acid) buffer, pH 7.0, or Tris‐phosphoric acid buffer, pH 8.0, no peaks 
could be detected within 30 min. Addition of organic solvents up to a concentration of 20% v/v did not 
improve peak shape or baseline noise. Therefore, sodium phosphate buffer, pH 7.0, in combination with 
S‐β‐CD was selected for further evaluation. 
Dual CD systems have been successfully applied to drug CE enantioseparations [118; 119] and were 
also employed to improve the peak shape of basic compounds [120]. Therefore, neutral and charged 
CDs were tested in combination with S‐β‐CD in 50 mM sodium phosphate buffer pH 7.0. The peak 
shape was substantially improved with an associated decrease of resolution upon using carboxymethyl‐
α‐CD sodium salt (CM‐α‐CD) or methyl‐α‐CD sodium salt (M‐α‐CD) as a co‐selector.  
Being a neutral compound, M‐α‐CD was chosen for further method development because it will not 
increase the electric current of the BGE. Fig. 8 illustrates the effect of the combination of S‐β‐CD and 
M‐α‐CD on the resolution, peak shape, and baseline noise during the separation of the methorphan 
enantiomers. 
 
Figure 8 Electropherograms of the separation of DXM and LVM using (A) 20 mg/mL S-β-CD and (B) 
20 mg/mL S-β-CD and 10 mg/mL M-α-CD in 50 mM sodium phosphate buffer, pH 7.0. Other experimental 
conditions: 30/40.2 cm, 50 μm ID fused-silica capillary; 20°C; 16 kV; detection at 200 nm. 
 
4.1.1.2. The role of the enantiomeric migration order (EMO) in the separation 
It is favorable for the quantitative determination of impurities in CE/chromatographic methods that a 
minor impurity migrates/elutes before the main analyte when it is to be determined in the presence of a 
large excess of a drug, especially when they are detected close to each other. This was already the 
case with ambrisentan with γ-CD and the acetate buffer pH 5.0 used for the initial screening. In the case 
of D-MDT, changing the pH from 2.5 to 7.0 and reversing the polarity were necessary to reverse the 
EMO so that L‐MDT migrated before D‐MDT (Fig. 7). Nonetheless, a similar change of pH and polarity 
reversed the migration order of DXM and LVM so that the chiral impurity migrated afterwards, but the 
enantioresolution was large enough so this did not affect the subsequent quantification (Fig. 8). 










4.1.2. Knowledge space and initial screening of factors 
The CPPs and the CQAs were identified considering the predefined ATP and the initial scouting 
experiments. For all three methods, similar factors were defined as CPPs for the initial screening using 
a fractional factorial design (table 2). Nevertheless, the enantioresolution, and the analytical run time 
were considered CQAs in all three methods, but the current was added as a third response in the case 
of MDT due to the relatively high amount of the charged cyclodextrin S‐β‐CD. 
 
Table 2 Comparison of the QbD approaches used for screening of the three chiral purity methods for 
Amb, DXM, and D-MDT 
Identification of the knowledge space 
  Method 













X both X 
Buffer concentration X X X 
Buffer pH X X X 
Voltage X X X 
Capillary Temperature X X X 
 
Responses 
Enantioresolution X X X 
Analytical run time X X X 
Current - - X 
 
 
Amb. pH of the BGE exerted a major effect on peak resolution and a minor effect on the run time (Fig. 
9). Thus, to obtain a high RS value, the pH was fixed at pH 4.0 so that it was not directly set at the edge 
of the screening range. Also, because the CD concentration was insignificant for peak resolution and 
had only a minor effect on the run time, it was set at 30 mM, i.e., the medium value of the screening 
range. Voltage, temperature and BGE concentration, were considered CPPs for the RSM.  
DXM. Although both CQAs were met for a large variety of experimental settings, the plot indicated that 
low electrolyte pH was favorable (Fig. 10). Consequently, BGE concentration was fixed at the lowest 
value of the screened range and pH was fixed at 6.5, and temperature was set at the center point 20°C. 
The concentration of the CDs and separation voltage were further optimized by RSM. 
 

















Figure 10 Coefficient plot (scaled and centered) of the screening design of DXM. V, applied voltage; Temp, 
capillary temperature; pH, pH of buffer solution; Buf, buffer concentration; S‐β‐CD, S-β-CD concentration; M‐α‐
CD, M-α-CD concentration. 
 
MDT. Significant effects were detected for all parameters and for most interaction terms (Fig. 11). 
Increasing the pH of the BGE negatively affected separation selectivity in addition to increasing the 
current. Thus, low pH seems favorable, although this leads to increased migration times. Similarly, 
Resolution 
Migration time 
Figure 9 Regression coefficients plot of the screening design of Amb. V applied voltage, Temp capillary 
temperature, Buf acetate buffer concentration in the BGE, CD γ-CD concentration in the BGE, pH pH 
of the BGE 
 




increasing phosphate buffer concentration results in lower enantioresolution and increased current but 
with a smaller effect on migration times. Voltage and temperature affected migration time and current 
more significantly than separation selectivity. Increasing S‐β‐CD concentrations increased all 
responses. Consequently, the concentration and pH of the phosphate buffer were fixed at 50 mM and 
pH 6.5 (i.e. lowest values), respectively, to achieve high separation selectivity and short migration times 
as well as low current. The concentration of S‐β‐CD, the capillary temperature and the separation 
voltage were considered CPPs and further optimized. 
 
 
Figure 11 Coefficient plot of the screening design for D-MDT. V, Applied voltage; Temp, capillary temperature; 
pH, pH of BGE; Buf, BGE concentration; SB, S-β-CD concentration. 
 
4.1.3. Design space definition by RSM 
Considering the screening results some experimental parameters were fixed in each method while the 
remaining parameters were considered CPPs and further optimized with response surface 
methodology. The same responses of the screening design were further considered CQAs in the 
optimization of Amb and D-MDT methods. Nevertheless, with DXM, the enantioresolution was above 
the initial threshold in all experiments, therefore, it was not considered a CQA. The optimization 
concentrated on analysis time and the peak performance criteria as responses, that is, the of the DXM 
peak (calculated according to the United States Pharmacopeia by the instrument software) as well as 
the number of theoretical plates and the peak height of the LVM peak. This was necessary to improve 
the peak shapes which leads to better quantification. A quick comparison of the CPPs and the CQAs 
for the RSM of the three methods is shown in Table 3. 




Table 3 Comparison of the QbD approaches used for optimization of the three chiral purity methods for 
Amb, DXM, and D-MDT 
Design space definition by response surface methodology 
  Method 
  Amb DXM D-MDT 
CQAs 











Buffer pH - - - 
Voltage 15–25 kV 10–20 kV 6–10 kV 
Capillary Temperature 15–25 °C - 15–25°C 
     
CPPs 
Enantioresolution RS ≥ 1.5 - α > 1.05 
Analytical run time* ≤10 min ≤ 8 min ≤10 min 
Current - - < 100 μA 
Drug peak asymmetry (USP tailing 
factor) 
- 0.5 to 3 - 
Impurity peak height - ≥3000 μAU - 
Theoretical plate count of impurity 
peak 
- ≥3000 - 
* The analytical run time was marked by the migration time of the last peak of interest 
 
For the three compounds, a three-level central composite face-centered design of the assigned factors 
in their respective ranges was used for further investigation. Subsequently, Monte-Carlo simulations 
were carried out for defining the design space of each method. The design space represents a map for 
the risk of failure to meet the predefined CPPs. An example of a design space representing the 
probability map of DXM is shown in Fig. 12. In this case the migration time of LVM was set as measure 
of the analysis time at ≤ 8 min, the number of theoretical plates and the peak height of the LVM peak at 
≥3000 and ≥3000 μAU, respectively, as well as the tailing factor of the DXM peak in the range of 0.5 to 
3 with the target value of 1, the design space of the method was derived by Monte Carlo simulations.  
In light of the results, an optimized working point was chosen for each method. The final working 
conditions of each method are summarized in Table 4. An internal standard was chosen for each method 
for the calibration of the impurity.  





Figure 12 Probability plot of the design space. Notes: Threshold of responses (min/target/max): migration time 
of LVM (−/−/8 min), number of theoretical plates of LVM peak (3000/−/−), height of LVM peak (3000 μAU/−/−) 
and tailing factor of the DXM peak (0.5/1/3). The design space (green zone) is identified as the zone where the 
risk of failure is ≤ 1%.  
 




Amb DXM D-MDT 
Chiral selector 30 mM γ-CD 
16 mg/mL S‐β‐CD 
+ 14 mg/mL M‐α‐CD 
40 mg. mL-1 S‐β‐CD 
Buffer 
50 mM sodium 
acetate buffer, pH 4.0 
30 mM sodium 
phosphate buffer, 
pH 6.5 
50 mM sodium 
phosphate buffer, 
pH 6.5 
Voltage +25 kV +20 kV +10 kV 
Capillary 
Temperature 




40/50.2 cm, 75 μm ID 
fused-silica capillary 
30/40.2 cm, 75 μm ID 
fused-silica capillary 
21.3/31.5 cm, 50 μm ID 
UV detection 
wavelength 
200 nm   
hydrodynamic 
injection 








Fig. 13 shows the electropherograms of the optimized methods with the corresponding enantiomeric 
impurity spiked in each sample. 
 
 
Figure 13 Electropherograms of the three compounds each spiked with the relevant enantiomeric impurity. (A) 
700 µg/ mL (S)-ambrisentan and 0.7 µg/mL of the (R)-enantiomer (0.1%) with metformin hydrochloride 15 µg/mL 
as internal standard; (B) 1.5 mg/mL DXM spiked 1 μg/mL LVM (0.067%) with procainamide hydrochloride 30 
μg/mL as internal standard; (C) 2 mg/mL D-MDT spiked with 2 μg/mL L-MDT (0.1%) 60 μg/mL L -Tryptophan as 
internal standard. 
 
4.1.4. Robustness testing 
The robustness of the three methods was also estimated with a QbD approach using a Plackett‐Burman 
design with a variation of the experimental conditions around the center point of the optimized working 
conditions. The design matrices are summarized in the corresponding supplementary information 
appendix of each method.  
Amb. Statistical analysis revealed no correlation with standard deviations including zero. Furthermore, 
the data were within the acceptance criteria, i.e., RS > 1.5 and analysis time <10 min.  
DXM. In addition to the factors initially screened as CPPs, the effect of different batches of different 
batches of S‐β‐CD and M‐α‐CD was investigated, since they are both randomly substituted. The 
variations of the parameters did not significantly affect the number of theoretical plates of the LVM peak 
or the tailing factor of the DXM peak. Except for buffer concentration on migration time and S‐β‐CD 
concentration on peak height, all variables were significant including variation of the CD batch. However, 
under all experimental conditions evaluated, the responses always met the predefined requirements 
and hence, the method can be considered robust. Nonetheless, care should be taken in the preparation 
of the BGE and instrumental parameters such as capillary temperature and voltage should be controlled 
carefully. 
D-MDT. As with DXM, two batches of S‐β‐CD were included as additional factor to the screening CPPs. 
In addition to the three optimized responses, the quantitative robustness was assessed using the ratio 
of the corrected peak areas of L‐MDT and the internal standard as a measure. The responses α‐value, 
current and the ratio of corrected peak areas were not significantly affected by the small variations of 




the experimental parameters. In contrast, in the case of migration time, a significant although minor 
effect of all variables on this response was detected. However, none of the conditions led to a migration 
time above 8.2 min, which is well below the threshold of ≤10 min set in the ATP. Therefore, the method 
can be considered robust. Nonetheless, the BGE should be prepared carefully and the instrumental 
parameters voltage and capillary temperature should be strictly controlled. 
 
4.1.5. Method validation 
The developed methods were validated according to ICH guideline Q2(R1) [90]. Table 5. Represents a 
comparison of the developed methods in terms of validation parameters. The limit of quantitation (LOQ) 
of the chiral impurity corresponded to 0.1% relative concentration of the enantiomeric impurity in cases 
of both Amb and D-MDT, while it was possible to reach 0.07% in the case of DXM. This was mainly 
possible due to the higher enantioresolution in case of DXM (Fig. 13). The USP [36] and the Ph. Eur. 
[38] deploy chiral HPLC methods for the chiral purity of DXM with 0.1% as a specification limit of the 
impurity LVM. D-MDT has also a HPLC test for the enantiomeric purity in its USP monograph where the 
maximum limit of L-MDT is specified as 1.0%. 
  




Table 5 Comparison of the validation parameters of the chiral purity methods for Amb, DXM, and D-MDT 
Parameter Amb DXM D-MDT 







































13.5 µg/mL  
(0.9 %) 




98.9 ±  
1.7 % 
Migration time repeatability 
(RSD) 
1.0 % 1.2 % 4.2 % 
Migration time intermediate 
precision (RSD) 
5.9 % 5.8 % 9.3 % 
Content repeatability 3 (RSD) 4.9 % 5.3 % 4.7 % 
Content intermediate 
precision 4 (RSD) 
6.6 % 5.7 % 5.4 % 
Range 1 
0.7 - 7 µg/mL  
(0.1 - 1.0 %) 
1.0 - 15 µg/mL 
 (0.1 - 1.0 %) 
2.0 - 30 µg/mL  
(0.1 - 1.5 %) 
Coefficient of determination 
R2 
0.9955 0.9989 0.9897 
LOD (S/N = 3) 0.2 µg/mL (0.03 %) 0.3 µg/mL (0.02 %) 0.6 µg/mL (0.03 %) 
LOQ (S/N = 10) 0.7 µg/mL (0.1 %) 1.0 µg/mL (0.07 %) 2.0 µg/mL (0.1 %) 
1 The percentage represents the relative concentration of the spiked enantiomeric impurity in the sample 
solution 
2 Mean recovery ± confidence interval % (α/2 = 0.025). Amb and DXM samples were spiked with the 
indicated amount of the corresponding enantiomeric impurity, while D-MDT samples were spiked with the 
racemate. 
3 Nine runs, three samples at three concentrations on one day. 
4 Nine runs, mean of three samples at three concentrations on three consecutive days. 
 
  




 Elucidation of the chiral separation mechanism (manuscripts 2,4) 
Mechanistic studies were performed in order to understand the migration interaction of the enantiomers 
with the selector(s). The study served in case of DXM to explain the effect of M‐α‐CD on peak tailing in 
the S‐β‐CD‐mediated enantioseparation of methorphan (Fig. 8). In the case of MDT enantiomers, an 
opposite EMO was observed at pH 2.5 in the presence of the two native CDs β-CD and γ-CD, which 
differ in the cavity size (Fig. 14A and B). MDT enantiomers also exhibited an opposite EMO at pH 2.5 in 
the presence of sulfated CDs S-β-CD and HS-β-CD (Fig. 14C and D), which have the same cavity size 
but differ in the substitution pattern (Table. 1). Consequently, the apparent complexation parameters of 
MDT enantiomers with the four CDs were determined by CE, in order to understand the migration 
behavior. In addition to CE, the complexation of MDT enantiomers with β-CD, γ-CD , and HS-β-CD was 
also studied in detail by NMR spectroscopy and molecular modeling. 
 
 
Figure 14 EMO reversal of MDT enantiomers using (A) β-CD, (B) γ-CD, (C) S-β-CD and (D) HS-β-CD. Experimental 
conditions: 40/50.2 cm, 50 μm I.D. fused silica capillary; 50 mM sodium phosphate buffer, pH 2.5; 20 °C; detection 
at 200 nm. Other conditions: (A) 20 mM β-CD, 2 M urea, 20 kV; (B) 20 mM γ-CD, 20 kV; (C) 20 mM S-β-CD, –20 
kV; (D) 20 mM HS-β-CD, –20 kV. 
 
4.2.1. Determination of the apparent complexation constants and complex mobilities by CE 
The apparent complexation constants and complex mobilities of the diastereomeric CD–analyte 
complexes were determined by preparing a series of BGEs containing ascending concentrations of the 
relevant CDs and plotting the effective mobilities against the CD concentrations. The data were obtained 
as best fit parameters of the dependence of the effective mobility on the CD concentration assuming the 
formation of 1:1 CD–analyte complexes according to equation 6 [53]. 
CEVal is a helpful tool for the evaluation of experimental results obtained by CZE and affinity CE [121]. 
It was used for data fitting because this software allows correction of the migration times in case of 
strongly tailing peaks according to the Haarhoff−van der Linde function [122; 121].  




Methorphan enantiomers. The mobilities were determined in 30 mM sodium phosphate buffer, pH 6.5 
in the case of S‐β‐CD, i.e. the pH and buffer concentration of the optimized method. Meanwhile, in the 
presence of M‐α‐CD as selector because of the strong EOF at pH 6.5, an enantioseparation could not 
be observed. Therefore, the data for M‐α‐CD were determined in 100 mM sodium phosphate buffer, 
pH 2.1. DXM has a pKa of 9.2 [123] which means it is fully protonated at both pH values so it can be 
assumed that the mobility of the free analytes, μf, the mobility of the complexes μc, and the complexation 
between the M‐α‐CD and the analyte enantiomers are not significantly altered at pH 6.5 versus pH 2.1 
which are independent of the EOF. The obtained data are summarized in Table 6.  
 
Table 6 Complexation constants, K, and mobilities of the free analytes, µf, and of the CD-analyte complexes, µc. 
The ranges in brackets represent the 95 % confidence intervals. 
 
S-β-CD M-α-CD 
DXM LVM DXM LVM 
























LVM is complexed much stronger by S‐β‐CD compared to DXM, and the mobility of the S‐β‐CD–LVM 
complex is much higher than the mobility of the S‐β‐CD–DXM complex. This explains the enantiomer 
migration order, i.e. that DXM migrates faster than LVM (after the EOF), and the increasing peak 
deformation, especially of the LVM peak due to mismatch of the mobilities of the CD–analyte complexes 
and the buffer ions. In the case of M‐α‐CD, LVM is also bound stronger than DXM, but complex mobilities 
are not significantly different from each other for both enantiomers. The competing effects between both 
CDs, results in slowing down the overall mobility of LVM more effectively as compared to DXM resulting 
in a reduced peak resolution. However, the reduced mobility of the analytes also reduced the extent of 
the mobility mismatch between analytes and buffer ions, yielding lower peak deterioration and, 
consequently, sharper and higher peaks.  
 
MDT enantiomers. The measurements were made in 50 mM sodium phosphate buffer, pH 2.5, where 
the EOF and was not considered because it could not be observed within 60 min. Due to the relatively 
poor enantioseparation in the case of β-CD in 50 mM sodium phosphate buffer, pH 2.5, the 
concentration of the phosphate buffer was increased to 150 mM and the pH lowered to pH 2.0 in order 
to obtain sharp peak allowing the determination of the mobilities of the enantiomers. The data are 
summarized in Table 7.  
 




Table 7 Apparent complexation constants, K, and mobilities of the free analytes, µf, and of the CD-analyte 
complexes, µc. The numbers in brackets represent the confidence interval (α/2 = 0.025). 
 
β-CD γ-CD 
D-MDT L-MDT D-MDT L-MDT 
µf (10-9 m2 s-1 V-1) 19.54 (19.34, 19.74) 
23.70 
(23.33, 24.07) 





















D-MDT L-MDT D-MDT L-MDT 
µf (10-9 m2 s-1 V-1) 25.03 (24.77, 25.29) 
25.35 
(25.13, 25.58) 















The opposite EMO In the case of β-CD and γ-CD can be explained by opposite affinities of the analyte 
enantiomers toward the respective CDs. D-MDT bound stronger to β-CD compared to L-MDT, while the 
opposite was found for γ-CD (Table 6), and thus the stronger bound enantiomer migrates second. The 
lower resolution observed for β-CD versus γ-CD is due to the small difference between the complexation 
constants of MDT enantiomers with this CD. Interestingly, in both cases, the mobility of the (L-MDT)-CD 
complex exceeds the mobility of the diastereomeric complex of MDT. This counteracts the 
enantioseparation by γ-CD, but no significant deterioration of the resolution was observed with 
increasing CD concentrations. This can be attributed to the relatively small and insignificant differences 
between the complex mobilities and the relatively larger difference between the complexation constants 
of γ-CD so that the increasing mobility of the complex with increasing CD concentrations does not 
significantly affect the overall enantioseparation. Thus, in the case of β-CD as well as γ-CD the 
enantioseparation is governed by the complexation constants. Examples of EMO reversal based on 
opposite affinities of CDs toward the analyte enantiomers are summarized in [124]. 
Opposite recognition of the medetomidine enantiomers was also found for S-β-CD and HS-β-CD.  
D-MDT is complexed stronger than its enantiomer by S-β-CD, while L-MDT is complexed stronger than 
D-MDT by HS-β-CD. The limiting mobility of the stronger D-MDT–S-β-CD complex also significantly 
exceeded the mobility of the complex between the CD and L-MDT resulting in the large resolution 
between the enantiomers (Fig. 14C). However, higher complex mobility was observed for the weaker 
bound D-MDT in the case of HS-β-CD, which causes the deterioration of the enantioseparation at higher 
HS-β-CD concentrations. Thus, contrary to β-CD and γ-CD, the separation of the MDT enantiomers with 




the negatively charged S-β-CD and HS-β-CD is governed by both, the complexation constants and the 
complex mobilities. For S-β-CD, both enantioselective principles in CE cooperate leading to a large 
enantioresolution while they counteract each other in the case of HS-β-CD resulting in a loss of 
enantioseparation at higher CD concentrations.  
 
4.2.2. NMR and molecular dynamics studies 
The complexation of MDT enantiomers (Fig. 15) with β-CD, γ-CD, and HS-β-CD was studied in detail 
by NMR spectroscopy and molecular modeling. S-β-CD was excluded from both the NMR studies 
molecular modeling because this randomly substituted CD is a mixture of positional and substitution 
isomers so that meaningful data could not be obtained by these techniques.  
 
4.2.2.1. NMR studies 
The 1H NMR resonances of the MDT-CD complexes were recorded by measuring samples containing 
MDT (alone or spiked with D-MDT) mixed with each of β-CD, γ-CD or HS-β-CD in a deuterated sodium 
phosphate buffer pH 2.5. The samples also contained 2 mM urea in the case of β-CD. 
 
 
Figure 15 Structures of MDT enantiomers with the proton numbering on the imidazole and phenyl rings 
 
1D ROESY experiments were performed and the intramolecular nuclear Overhauser effects (NOEs) 
were  interpreted. Enantiomeric bias is indicated through the stronger NOE response of one enantiomer 
over the other. Racemic MDT was used for ROESY experiments, while non-racemic mixtures (MDT 
spiked with D-MDT) were applied in a second experiment in order to assign the signals of the respective 
enantiomer in case of signal splitting. 
 
β-CD complex. The 1D ROESY experiments showed intermolecular NOE interactions between almost 
all medetomidine hydrogens with the internal H-3 and H-5 protons of β-CD. However, selective 
irradiation at the proton resonances of the MDT and β-CD indicated that the phenyl ring of MDT is 
inserted into the β-CD cavity through the larger rim, while the imidazole moiety remained outside the 








Figure 16 Schematic representation of the structures of the medetomidine-CD complexes derived from the NMR 
ROESY data. (A) complex with β-CD, (B) complex with γ-CD and (C) complex with HS-β-CD 
 
A slight enantiomeric bias was observed in the NOEs with the aromatic Ph H-6 and Im H-5, as D-MDT 
seemed to give a slightly larger NOE response than the L-MDT. This is consistent with the CE 
experiments, where a stronger complexation of D-MDT by β-CD compared to L-MDT was found (Table 
7). 
 
γ-CD Complex. The NOE interaction pattern was similar to that observed for the MDT–β-CD complex, 
since all the observed intermolecular NOEs involved the internal hydrogen atoms of γ-CD. Once again, 
selective irradiation suggested the formation of an insertion complex, where the phenyl ring of MDT is 
positioned inside the γ-CD cavity and the imidazolium moiety is situated closer to the larger CD rim and 
exposed to the solvent. A tentative complex structure is shown in (Fig. 16B). 
Enantiomeric bias was also found with γ-CD. Thus, irradiation at γ-CD H5 resulted in a stronger NOE 
response for the phenyl proton H-6 of L-MDT indicating it is complexed stronger by γ-CD as compared 
to D-MDT. This complexation pattern is opposite to that observed in the case of β-CD, yet consistent 
with the CE data as a larger complexation constant was derived between γ-CD and L-MDT compared 
to D-MDT (Table 7).  
 
HS-β-CD complex. NOE interactions with all MDT hydrogens except the aliphatic CH were found. This 
implies proximity of MDT to the primary rim of HS-β-CD. Although those NOEs were not very strong, 
NOE responses of the imidazole protons were slightly larger than those of the phenyl hydrogens of 
MDT. This supports a structure of the HS-β-CD complex different from the structures of the respective 
β-CD and γ-CD complexes. With HS-β-CD, the protonated imidazolium moiety seems to be positioned 
inside the cavity close to the primary ring interacting probably through water-mediated hydrogen bonds 
with the negatively charged sulfate groups. The phenyl ring would therefore find itself inside the CD 
cavity as shown schematically in (Fig. 16C). 




Irradiation at the HS-β-CD H-6 protons proved an enantiomeric bias as a larger response was noted for 
the protons of L-MDT. This suggests a tighter complexation of the L-MDT with HS-β-CD compared to 
D-MDT, which is consistent with the complexation data derived by CE (Table 7). 
In conclusion, the results of the NMR studies were concordant with the CE data for the three CDs. 
 
4.2.2.2. Molecular modeling 
The structures of complexes formed between β-CD, γ-CD, and S-β-CD and MDT enantiomers as derived 
by molecular modeling are summarized in (Fig. 17). In both β-CD inclusion complexes (Fig. 17A), each 
MDT enantiomer is bound with the imidazolium moiety pointing towards the secondary rim and 
essentially exposed to the solvent, while the phenyl group is positioned in the hydrophobic CD cavity.   
Essentially the same orientation is observed in the γ-CD-MDT complexes (Fig. 17B). The hydrophobic 
phenyl group is positioned inside the CD cavity.  
In the HS-β-CD complexes, the imidazolium appears to be buried inside the cavity and surrounded by 
the sulfate groups attached to the O6 atom of each glucose unit (Fig. 17C). This favorable electrostatic 
interaction is quite strong but direct hydrogen bonds are permanently in competition with similar 
interactions with solvent water molecules. In this orientation, Ph-5 and Ph-6 protons of medetomidine 
face protons on H-3 and H-5 of the CD, hence the observed NOEs. 
 
 
Figure 17 Molecular modeling structures of the medetomidine enantiomers with (A) β-CD, (B) γ-CD and (C) HS-
β-CD. The complexes with dexmedetomidine (D-MDT) are presented in the top layer, while the complexes with 
levomedetomidine (L-MDT) are shown in the bottom layer. 
 
This shows that the complex structures derived from molecular modeling (Fig. 17) are in good 
agreement with the tentative structures deduced from NMR experiments (Fig 16).  




 Unusual complexation behavior between daclatasvir and γ-CD (manuscript 5) 
Daclatasvir (DCV) is an inhibitor of the hepatitis C nonstructural protein 5A replication complex [125]. 
DCV is a biphenyl with two identical halves each containing two stereogenic centers each. The 
compound possesses S,S,S,S configuration while the enantiomer (RRRR-DCV) is R,R,R,R configured. 
Due to the four stereogenic centers, there are also other diastereomers including meso forms of the 




Figure 18 Structures of the DCV with 3 stereoisomers, the synthetic impurities BPIB, BOC-BPIB, Ile-DCV, mono 
DCV, and half-DCV 
 
When screening CDs in sodium phosphate buffer, pH 2.5, as BGE for their ability to separate DCV and 
its enantiomer it was noted, that some CDs such as methyl-β-CD (M-β-CD) (Fig. 16A) or hydroxypropyl-
β-CD yielded an enantioseparation, while two peaks with a plateau between them were observed in the 
case of other CDs such as γ-CD (Fig. 16B) or sulfated β-CD.  
 
4.3.1. Unusual electrophoretic migration, dependence on solute structure and experimental 
conditions 
4.3.1.1. Solute structure  
The two peaks with a plateau in between, were also observed when enantiopure DCV or the enantiomer 
RRRR-DCV were analyzed in a γ-CD containing BGE at pH 2.5 (Fig. 19C and 19D), while a single peak 




was detected for DCV or RRRR-DCV when M-β-CD was added to the BGE. Therefore, the plateau 
phenomenon is apparently not related to an enantiodifferentiation, and indicates an equilibrium, which 
is slow on the CE time scale since complexation equilibria between analytes and CDs in CE 




In addition, two diastereoisomers of DCV (RSSR-DCV and RSSS-DCV), a structural analogue 
containing Ile instead of Val as one of the amino acid moieties (Ile-DCV), a derivative that lacks one 
MOC-Val moiety (mono-DCV), two synthetic precursors, BPIB (lacking both MOC-Vals side chains) and 
the BOC-protected derivative BOC-BPIB, as well as the “monomeric” half-DCV were analyzed by CE 
(Fig. 18). Similarly to DCV, two peaks with a plateau in between were also observed for the R,S,S,R- 
and R,S,S,S-configured diastereomers as well as Ile-DCV (Fig 20), while only a single peak was 
observed for mono-DCV, half-DCV or the pyrrolidine derivatives BPIB and BOC-BPIB. Therefore, a 
structural prerequisite for the appearance of the plateau seems to be a "symmetrical" structure 
containing two MOC-amino acid moieties, which may, however, differ to some extent (as in Ile-DCV). 
The stereochemistry at the chiral centers did not play an important role as this behavior was seen with 
all available stereoisomers of DCV. 
 
 
Figure 20 Electropherograms of the analysis of (A) RSSR-DCV, (B) RSSS-DCV, (C) Ile-DCV, using 50 mM sodium 
phosphate buffer, pH 2.5, containing 20 mM γ-CD as BGE. 
 
Figure 19 Electropherograms of (A) a nonracemic mixture of DCV and RRRR-DCV in the presence of 7 
mg/mL M-β-CD in the BGE, (B) a nonracemic mixture of DCV and RRRR-DCV in the presence of 20 mM γ-
CD in the BGE, (C) DCV in the presence of 20 mM γ-CD in the BGE, (D) RRRR-DCV in the presence of 20 mM 
               




4.3.1.2. Experimental CE conditions 
The plateau was observed in the γ-CD concentration range up to 100 mM and could be detected at CD 
concentrations as low as 0.1 mM. The effects of the capillary temperature between 15°C and 45 °C (Fig. 
21A) showed a dynamic behavior indicating in-capillary equilibria with two well separated peaks at slow 
exchange regimes at lower temperatures and progressive coalescence at higher temperatures. The 
plateau area between the resolved peaks became more pronounced under fast exchange regimes 
between 20 and 35 °C, eventually leading to complete coalescence at 45°C.  
 
Figure 21 Electropherograms showing the effect of (A) temperature and (B) pH of the BGE using a 50 mM 
sodium phosphate buffer, pH 2.5, containing 20 mM γ-CD.  
 
Upon increasing the pH of the BGE from 2.5 to 4.5 peak coalescence around pH 4 was observed (Fig. 
21B). DCV possesses two basic imidazole nitrogen atoms with pKa values of 5.6 and 4.9 [126]. Thus, 
protonation of both imidazole nitrogen atoms appears to be a prerequisite for the observation of the slow 
equilibrium leading to the plateau in the CE experiments. 
Surprisingly, when a sample of DCV mixed with γ-CD was analyzed by CE using a CD-free phosphate 
buffer-based BGE, pH 2.5, two peaks with a plateau in between were also observed (Fig. 19E). The 
plateau was independent of parameters for the preparation of the γ-CD-containing DCV sample solution. 
A temperature study revealed coalescence of the peaks also at about 45°C.  




So far, such a phenomenon has not been described for CDs as chiral selectors. Therefore, a deep 
investigation was conducted to obtain some insight into the complexation between DCV and γ-CD. In 
addition to CE experiments, NMR, electrospray ionization mass spectrometry (ESI-MS) and CE-ESI-MS 
studies were conducted in order to obtain information on the structures involved in the equilibrium. 
 
4.3.2. Structure of dynamic supramolecular complexes 
The structures of the complexes of γ-CD with DCV, the RSSR diastereomer, mono-DCV as well as half-
DCV were studied in deuterated sodium phosphate buffer pH 2.5 by 1H-NMR experiments because 
nuclear Overhauser effect (NOE) based NMR methods, in particular ROESY techniques, allow the 
analysis of spatially close nuclei also in CD-based complexes [98; 100; 127; 128]. Signals were assigned 
based on COSY, TOCSY and HSQCED data. The following discussion is focused on the structures of 
DCV: γ-CD complexes. 
The 1H-NMR spectrum of a sample containing DCV and γ-CD was compared with the spectra of γ-CD 
and DCV. The interpretation of the additional sets of 1H resonances and the chemical shifts together 
with a 2D ROESY experiment demonstrated the presence of two structurally different complexes in the 
solution. All observed intermolecular NOE responses involved the inner hydrogens of γ-CD (H-3 and H-
5) and the aromatic protons of DCV, and indicated the presence of a 1:1 inclusion complex in addition 
to a 2:1 complex (DCV: γ-CD) in which two DCV molecules are inserted into the CD cavity. Further 2D 
and 1D ROESY experiments affirmed this assumption. Fig. 22. represents a schematic illustration of the 
tentative structures of both complexes. 
 
 
Figure 22 Schematic representation of the 1:1 and 2:1 complexes formed between DCV and γ-CD. The 
intermolecular NOEs derived from ROESY experiments are indicated by arrows; red: intramolecular NOEs, blue: 
intermolecular NOEs between DCV and γ-CD, green: intermolecular NOEs between DCV molecules in the 2:1 
complex. 




The ratio of the 1:1 versus the 2:1 complex was about 0.24:1.0 based on the integrals of NMR signal. 
Measuring the spectra at 40 °C, 60 °C and 80 °C resulted in ratio between the complexes of about 
0.39:1.0, 0.9:1.0 and 2.3:1.0, respectively. Thus, the 2:1 complex is more abundant at lower 
temperatures, while the 1:1 complex is the major species at 80 °C with inversion of the ratio above 60 
°C. Therefore, the peak coalescence at about 40 °C observed in the CE experiments is not based on 
the equilibrium between the complexes. Upon cooling the sample to 25 °C, the 1:1 versus 2:1 complex 
ratio returned to the original value of 0.24:1.0.  
Because pH-dependent peak coalescence was observed in CE at pH 4.0, NMR experiments were also 
performed at this apparent pH. The 1H-NMR spectra of DCV alone and mixed with γ-CD at pH 4.0 were 
essentially identical to the spectrum recorded at pH 2.5. Moreover, the data obtained from further NMR 
studies (as studied with the pH 2.5 buffer) also demonstrated the presence of identical 1:1 and 2:1 
complexes at pH 4.0, with the molar ratio being 0.23:1.0 which is similar to pH 2.5. This proved that the 
plateau observed in CE is not due to an equilibrium between the two complexes. 
The presence of both complexes in solution was confirmed by direct infusion ESI-TOF-MS of a solution 
containing DCV and γ-CD in ammonium formate buffer, pH 2.6, which confirms the NMR results on the 
concomitant formation of complexes with 1:1 and 2:1 stoichiometry between DCV and γ-CD in solution. 
Several literature examples reported different stoichiometries of the cyclodextrins with guest molecules 
using different analytical approaches [105; 107; 106; 108], but the nature of the complexes 
(inclusion or "external" complex) cannot be concluded, unless NMR has been employed. Several 
reports demonstrated the formation of to 2:1 complexes involving CDs [129–132]. In most cases 
the stoichiometry of the complexes was derived from Job´s plots, while the orientation and 
stacking of both solutes within the CD cavity was derived from molecular modelling [129–131]. 
There are also reports of 2:1 complexes, in which one solute molecule was included in the CD 
cavity, while the second one was coordinated externally [39; 40; 133; 134]. Neither these studies 
nor the abovementioned publications on 2:1 aggregates provided evidence for the presence of 
two complexes with different stoichiometries in solution.  
So far, only one publication could be found in the literature which reported the simultaneous presence 
of complexes with different stoichiometry (1:1 and 2:1) between dimetindene and carboxymethyl-β-CD 
[134], but the structures could not be unequivocally resolved in that study. In contrast, the presence of 
the two complexes between DCV and γ-CD including their stoichiometry was unequivocally 
demonstrated based on NMR and MS data. 
In addition, the structures of the complexes of the diastereomeric RSSR-DCV as well as mono-DCV and 
half-DCV with γ-CD were determined by 1H-NMR spectroscopy. Table 1 compares the CE behavior as 
well as complex stoichiometries, their ratios and structures of the guest molecules of DCV and the three 
analogues studied in more detail. Although the number of analytes is limited, a biphenyl structure 
appears to be required for the formation of a 2:1 complex. The stereochemistry of the amino acid moiety 
does not affect the simultaneous formation of two complexes but might change the ratio between them. 





Table 8 CE behavior, stoichiometry and structure of γ-CD complexes with DCV and analogues 
Compound CE Complex stoichiometry 
Complex 
ratio Structure of guest molecule(s) in complex(es) 
DCV Plateau 1:1 and 2:1 ~ 0.24:1 Folded conformation of MOC-Val residues 
RSSR-DCV Plateau 1:1 and 2:1 ~ 1:1 Extended conformation of MOC-Val residues in complexes 
Mono-DCV – 1:1 and 2:1* ~ 0.4:1 Folded conformation of MOC-Val residue in complexes  
Half-DCV – 1:1 – Folded conformation of MOC-Val residue in complex 
* no unequivocal proof of a 2:1 complex by NOEs but presence likely 
 
4.3.3. Migration order 
In order to confirm the role of interaction between DCV and γ-CD, the CE capillary was used as a 
microreactor. Individual plugs of DCV and γ-CD were injected in a capillary containing CD-free BGE, pH 
2.5, which were separated by a short plug of buffer to prevent contact between the plugs due to diffusion. 
The results are shown in Fig. 23.  
 
 
When DCV was injected as the first plug so it did not migrate through the γ-CD plug only a single peak 
was detected (Fig. 23A), while two peaks with a plateau were found when DCV was injected as the 
second plug so that it had to migrate through the γ-CD plug on the way to the detector (Fig. 23B). 
Injecting a mixture of DCV and γ-CD also resulted in two peaks with a plateau (Fig. 23C). Moreover, the 
area of the second migrating peak increased significantly when a DCV-plug was injected before a plug 
Figure 23 Plug-plug CE experiments. The order of the injected plugs is schematically shown above the 
electropherograms. Injection sequence: (A) DCV > γ-CD, (B) γ-CD > DCV, (C) DCV + γ-CD, (D) DCV > DCV + γ-
CD. The BGE consisted of 50 mM sodium phosphate




of a mixed DCV plus γ-CD sample (Fig. 23D), indicating that the first migrating peak represents the 
unresolved mixture of the 1:1 and 2:1 DCV-γ-CD complexes, while the second peak is due to free DCV. 
This was confirmed by CE-MS experiments (Fig. 24). When analyzing pure DCV in a CD-free BGE, only 
a single peak with m/z 739.4 at the migration time of DCV is observed (Fig. 24A). In contrast, two peaks 
with the plateau were detected in the analysis of a sample containing DCV and γ-CD using a CD-free 
BGE (Fig. 24B). The trace of m/z 739.4 proved that DCV is present in the peaks as well as the plateau, 
while the mass traces m/z 925.4 and m/z 1018.4 representing the 2:1 and 1:1 complex, respectively, 
were only detected in the first migrating peak. When γ-CD is present in the BGE (Fig. 24C), the mass 
traces of the 1:1 and 2:1 complexes at m/z 925.4 and m/z 1018.4 as well as free DCV (m/z 739.4) were 
detected, while in the second migrating peak free DCV dominated. In contrast to the analysis of the DCV 
plus γ-CD sample analyzed in a CD-free BGE (Fig. 24B), the plateau is also formed by the complexes 
in addition to non-complexed DCV. This difference can be explained by the presence of γ-CD in the 
BGE. Free DCV resulting from the dissociation of the complexes can be complexed again if the CD is 
present in the BGE, while this is not possible in the absence of γ-CD in the BGE because in the latter 
case γ-CD and DCV are electrophoretically separated. 
 
 
Figure 24 CE-MS experiments of (A) pure DCV and (B) a sample containing DCV and γ-CD using 50 mM ammonium formate 
buffer pH 2.6 as BGE. (C) CE-MS analysis of DCV using 50 mM ammonium formate buffer pH 2.6, containing 50 mM γ-CD 
as BGE. 




The CE-MS data show that both complexes exhibit the same mobility so that they are not separated 
independent of the presence or absence of γ-CD in the BGE. This is also unexpected considering the 
theoretical difference in the mass-to-charge ratios of both complexes. Taking into account the low 
abundance of the ion representing the 1:1 complex in the experiments obtained in the absence of γCD 
in the BGE (Fig. 24B) it could be hypothesized that the 2:1 complex possesses a higher stability, which 
results in the fact that the complex can still be observed in a CD-free BGE injecting a sample containing 
DCV and γ-CD. Upon dissociation of one DCV molecule, the resulting 1:1 complex is considerably less 
stable and quickly liberates DCV, which cannot form a complex again because γ-CD and DCV are 
electrophoretically separated. In contrast, when γ-CD is present in the BGE, the complexes can be 
reestablished upon dissociation into γ-CD and DCV so that the plateau between the peaks is composed 
of all three species, i.e. both complexes as well as free DCV (Fig. 24C). 
The faster migration of the complexes compared to free DCV as demonstrated by the plug-plug as well 
as CE-MS data is unexpected, because non-complexed DCV should have a higher charge density 
(charge-to-mass ratio) than the complex based on the molecular weight of the species and, 
consequently, migrate first. A speculative explanation could be based on differences in the solvation 
shell of the molecules/complexes assuming a larger shell in the case of free DCV. It is known that small 
inorganic ions such as Li+ migrate slower than larger ions in CE [135] because of a much larger solvation 
shell [136]. 






The stereochemistry of the drugs plays in important in their pharmacological effects since the 
enantiomers of chiral drugs interact in a stereoselective way with the targets, which may lead to different 
activity or even undesirable effects. An increased awareness of the importance of the chiral purity of 
single isomer drugs led the development of separation methods for the quantitative determination of the 
chiral purity.  
CE is a microanalytical technique that has been increasingly used in pharmaceutical analysis due to its 
advantages such as small sample volume, high resolution, low cost, and reduced use of organic 
solvents. In addition, chiral CE proved its efficiency as an established method analytical 
enantioseparations of drugs in the last decades with many examples in the literature. The development 
of chiral CE methods is particularly flexible due to the large number of available chiral selectors 
especially cyclodextrins, which have many neutral and charged derivatives in addition to the native α-
CD, β-CD and γ-CD.  
QbD methodology approach is the state-of-the-art strategy for method development in analytical 
separations including CE, due to the systematic approach which allows the understanding of the relative 
effects of the experimental factors and their interaction within a lower number of experiments compared 
to testing one factor each time. QbD employs multivariate DoE and risk‐assessment tools for the 
identification of CPPs, which are the experimental factors that influence the CQAs of the method. 
Subsequently the knowledge space is identified by screening designs which provides an initial 
understanding of quantitative effects of the CQAs on the analytical process. This leads to fixing some 
experimental factors and the selection of other factors as CPPs to be further optimized using response 
surface designs. This allows the definition of the design space and selecting a working point. The 
robustness of the working point is tested by assessing the effects of deliberate small variations of the 
experimental parameters on the method. The assessment is made within QbD approach using a 
fractional factorial design (e.g. Plackett‐Burman design). Considering this all, the risk based QbD 
framework was followed in analytical method development, optimization, and validation.  
Consequently, three methods were developed for the determination of the enantiomeric purity of three 
drug substances Amb, DXM, and D-MDT using cyclodextrin-mediated capillary electrophoresis. All 
methods were validated according to the requirements of the ICH Q2(R1) guideline and proved robust 
with acceptable precision and accuracy for the determination of the chiral impurities. The methods were 
simple, cost effective, and had short run times which enables using them for routine analysis. 
The working point conditions of chiral purity determination of Amb included a BGE of 50-mM sodium 
acetate buffer, pH 4.0, containing 30 mM γ-CD, in a 40/50.2 cm, 75 μm ID fused-silica capillary at an 
applied voltage of 25 kV and a capillary temperature of 25 °C. The method allowed the determination of 
a relative concentration of the (R)-enantiomer of 0.1 % within less than 10 minutes of run time and was 
subsequently applied to the analysis of an Amb sample obtained from a chemical supplier 




The chiral purity method of DXM employed a 30/40.2 cm, 50 μm ID fused‐silica capillary with a BGE 
consisting of 30 mM sodium phosphate buffer, pH 6.5, 16 mg/mL S‐β‐CD, and 14 mg/mL M‐α‐CD at 
20°C and 20 kV. The method allowed the determination of LVM with acceptable precision and accuracy 
at the 0.1 % level within ca. 5 minutes of run time and was applied to the analysis of a capsule dosage 
form of DXM.  
Furthermore, the apparent complexation constants and mobilities of the diastereomeric CD-enantiomer 
complexes were determined, in order to explain the chiral separation mechanisms for DXM, which led 
to the improvement of the peak shape by addition of M‐α‐CD to the S‐β‐CD‐containing BGE. The 
stronger tailing of the LVM peak compared to the DXM peak especially at higher S‐β‐CD concentrations 
could be explained by the high mobility of the CD-LVM complex. Both enantiomers displayed essentially 
identical complex mobilities in the case of M‐α‐CD, which were also considerably lower than the 
mobilities of the corresponding S‐β‐CD complexes. This reduced the overall mobility of LVM and DXM, 
thereby improving the peak shape.  
S‐β‐CD was chosen as chiral selector for the determination of the stereochemical purity of D-MDT. 
Separation after the EOF in a BGE pH 6.5 resulted in the desired migration order so that the minor 
impurity L‐MDT migrated before the large peak of D‐MDT. The working conditions were a 21.3/31.5 cm, 
50 μm ID fused‐silica capillary, a BGE composed of 50 mM sodium phosphate buffer, pH 6.5, containing 
40 mg/mL sulfated β‐CD, with a capillary temperature of 17°C and an applied voltage of 10 kV. The 
analysis time was less than 10 min, and this was the first CE method for the determination of the 
enantiomeric purity of D‐MDT with acceptable precision and accuracy at the 0.1% level. 
Moreover, the role of the cavity size and the substitution pattern of the cyclodextrins in the migration 
order of medetomidine enantiomers in the presence of CDs was investigated. This involved the opposite 
migration order in the presence of β-CD and γ-CD as well as S-β-CD and HS-β-CD, which was observed 
during the screening of various CDs as possible chiral selectors. The apparent complexation constants 
and complex mobilities of the diastereomeric CD–analyte complexes were determined by CE. 
Additionally, the complexation was studied in detail by NMR spectroscopy and molecular modeling. 
S-β-CD was not included in NMR and molecular modeling because it is a mixture of positional and 
substitution isomers so that meaningful data could not be obtained by these techniques.  
The enantioseparation in the case of β-CD as well as γ-CD was governed by the complexation constants. 
The opposite EMO In the case of β-CD and γ-CD could be explained by opposite affinities of the analyte 
enantiomers toward the respective CDs. D-MDT bound stronger to β-CD compared to L-MDT, while the 
opposite was found for γ-CD, and thus the stronger bound enantiomer migrates second.  
Opposite recognition of the medetomidine enantiomers was also found for S-β-CD and HS-β-CD.  
D-MDT is complexed stronger than its enantiomer by S-β-CD, while L-MDT is complexed stronger than 
D-MDT by HS-β-CD. Contrary to β-CD and γ-CD, the separation of the MDT enantiomers with the 
negatively charged S-β-CD and HS-β-CD is governed by both, the complexation constants and the 




complex mobilities. For S-β-CD, both enantioselective principles in CE cooperate leading to a large 
enantioresolution while they counteract each other in the case of HS-β-CD resulting in a loss of 
enantioseparation at higher CD concentrations.  
NMR data supported the results of mechanistic CE studies. Thus, D-MDT was bound stronger by β-CD 
than L-MDT, which was also reflected in an enantioselective NOE of the resonance of the imidazole H-
5 and H-6 of the phenyl moiety of the drug in ROESY experiments. In contrast, levomedetomidine was 
complexed stronger by γ-CD and HS-β-CD and a stronger NOE was observed for the phenyl H-6 in the 
presence of both CDs as well as the imidazole protons when complexed with HS-β-CD. 
Molecular modeling also agreed with the structures derived from NMR experiments. In the case of β-
CD and γ-CD, the phenyl ring of medetomidine entered the cavity through the wider secondary rim of 
the CDs, whereas the protonated imidazole ring was positioned inside the CD cavity interacting with the 
sulfate groups of HS-β-CD. Compared to CE and NMR data, enantioselective recognition of the 
medetomidine enantiomers by the CDs was also suggested by MD simulations and reflected the 
observed reversal of the enantiomer migration order in the case of β-CD and γ-CD.   
Lastly, during a screening of CDs as chiral selectors for the separation of DCV and its enantiomer by 
CE, an unprecedented phenomenon for CDs was observed, that is two peaks with a plateau in between 
using γ-CD as chiral selector. The same result was encountered when enantiopure DCV was injected 
or when analyzing a sample containing enantiopure DCV and γ-CD in a CD-free background electrolyte. 
Coalescence of peaks was observed at 45 °C and at a pH above 3.5. Two peaks with a plateau were 
also observed for DCV stereoisomers as well as a structural analog. However, only a single peak was 
detected if one or both amino acid moieties of DCV were lacking. NMR experiments including NOE-
based methods showed that in solution DCV adopted a folded conformation in which the isopropyl side 
chain of the valine residues pointed toward the aromatic rings of DCV. Moreover, NMR unequivocally 
demonstrated the simultaneous formation of DCV-γ-CD inclusion complexes with 1:1 and 2:1 
stoichiometry, which was corroborated by mass spectrometry. In both complexes, DCV also adopted a 
folded structure. The RSSR-diastereomer of DCV as well as an analog lacking one of the amino acid 
moieties also formed 1:1 and 2:1 complexes with γ-CD although a plateau was only observed in the 
case of the RSSR-diastereomer. As shown by CE-MS, both DCV-γ-CD complexes surprisingly 
comigrated as the first peak, while the second migrating peak represents non-complexed DCV. 






Die Stereochemie der Arzneimittel spielt für ihre pharmakologischen Wirkungen eine wichtige Rolle, da 
die Enantiomere chiraler Arzneimittel stereoselektiv mit den molekularen Targets interagieren, was zu 
unterschiedlichen Aktivitäten oder sogar unerwünschten Wirkungen führen kann. Die Bedeutung der 
Stereochemie von Arzneistoffen führte zur Entwicklung von Trennmethoden zur Bestimmung der 
chiralen Reinheit. 
CE ist eine mikroanalytische Technik, die aufgrund ihrer Vorteile wie kleinem Probenvolumen, hoher 
Auflösung, geringen Kosten und reduziertem Einsatz organischer Lösungsmittel zunehmend in der 
pharmazeutischen Analyse eingesetzt wird. Darüber hinaus ist die chirale CE eine etablierte Methode 
zur analytischen Enantiomerentrennung von Arzneimitteln, was durch zahlreiche Literaturbeispiele 
belegt ist. Die Entwicklung chiraler CE-Methoden ist besonders flexibel aufgrund der großen Anzahl 
verfügbarer chiraler Selektoren, insbesondere Cyclodextrinen, die neben nativen α-CD, β-CD und γ-CD 
viele neutrale und geladene Derivate beinhalten. 
Die QbD-Methodik ist die aktuelle Strategie für die Methodenentwicklung bei analytischen Trennungen 
einschließlich der CE. Dies beruht auf dem systematischen Ansatz, der es ermöglicht, die relativen 
Auswirkungen der experimentellen Faktoren und ihre Wechselwirkung untereinander mit einer 
geringeren Anzahl von Experimenten zu verstehen, anstatt nur jeweils einen Faktor zu variieren. QbD 
verwendet statistische Versuchsplanung und Risikobewertungsinstrumente zur Identifizierung von 
CPPs, welche die experimentellen Faktoren sind, die die CQAs der Methode beeinflussen. 
Anschließend wird der sogenannte Knowlege Space durch ein Screening-Design identifiziert, das ein 
erstes Verständnis der quantitativen Auswirkungen der CQAs auf den Analyseprozess liefert. Dies führt 
dazu, dass einige experimentelle Faktoren festgelegt und andere Faktoren als CPPs ausgewählt 
werden, die mithilfe von Response Surface-Methodik weiter optimiert werden sollen. Dies ermöglicht 
die Definition des Design Space und die Auswahl eines Arbeitspunkts. Die Robustheit des Arbeitspunkts 
wird getestet, indem die Auswirkungen absichtlicher kleiner Variationen der experimentellen Parameter 
auf die Methode bewertet werden. Dies erfolgt im Rahmen der QbD-Methodik unter Verwendung eines 
fraktionalen faktoriellen Designs (z. B. Plackett-Burman-Design). In Anbetracht aller bisherigen Aspekte 
wurde das risikobasierte QbD-Methodik bei der Entwicklung, Optimierung und Validierung von 
Analysemethoden befolgt. 
Folglich wurden drei Methoden zur Bestimmung der Enantiomerenreinheit von drei Wirkstoffen 
Ambrisentan (Amb), Dextromethorphan (DMX) und Dexmedetomidin (D-DMT) mittels  
Kapillarelektrophorese unter Verwendung von CDs als chiralen Selektoren entwickelt. Alle Methoden 
wurden gemäß den Anforderungen der ICH Q2 (R1) -Richtlinie validiert und erwiesen sich als robust 
mit akzeptabler Präzision und Genauigkeit für die Bestimmung der chiralen Verunreinigungen. Die 
Methoden waren unkompliziert, kostengünstig und hatten kurze Laufzeiten, so dass sie für 
Routineanalysen verwendet werden können. 




Die Arbeitspunktbedingungen der chiralen Reinheitsbestimmung von Amb umfassten eine BGE von 50 
mM Natriumacetatpuffer, pH 4,0, mit 30 mM γ-CD, in einer 40/50,2 cm, 75 µm ID Quarzglaskapillare bei 
einer angelegten Spannung von 25 kV und einer Kapillartemperatur von 25° C. Die Methode ermöglichte 
die Bestimmung einer relativen Konzentration des (R)-Enantiomers von 0,1% innerhalb von weniger als 
10 Minuten Laufzeit und wurde anschließend auf die Analyse einer Ambrisentan Probe angewendet. 
Bei der chiralen Reinheitsmethode von DXM wurde eine Quarzglaskapillare mit 30/40,2 cm und 50 μm 
ID und einer BGE verwendet, der aus 30 mM Natriumphosphatpuffer, pH 6,5, 16 mg/ml S-β-CD und 14 
mg/ml M-α-CD bestand. Die Kapillartemperatur beträgt 20° C bei einer angelegten Spannung von 20 
kV. Die Methode ermöglichte die Bestimmung von LVM mit akzeptabler Präzision und Genauigkeit bei 
0,1% innerhalb von ca. 5 Minuten Laufzeit und wurde zur Analyse einer Dextromethorphankapsel 
angewendet. 
Darüber hinaus wurden die scheinbaren Komplexierungskonstanten und Mobilitäten der 
diastereomeren CD-Enantiomerkomplexe bestimmt, um die chiralen Trennungsmechanismen für DXM 
zu erklären, die zur Verbesserung der Peakform durch Zugabe von M-α-CD zum S‐β-CD-haltiges BGE 
führten. Das stärkere Tailing des LVM-Peaks im Vergleich zum DXM-Peak, insbesondere bei höheren 
S-β-CD-Konzentrationen, könnte durch die hohe Mobilität des CD-LVM-Komplexes erklärt werden. 
Beide Enantiomere zeigten im Fall von M-α-CD ähnliche komplexe Mobilitäten, die ebenfalls erheblich 
niedriger waren als die Mobilitäten der entsprechenden S-β-CD-Komplexe. Dies verringerte die 
Gesamtmobilität von LVM und DXM, wodurch die Peakform verbessert wurde. 
S-β-CD wurde als chiraler Selektor zur Bestimmung der stereochemischen Reinheit von D-MDT 
ausgewählt. Die Trennung nach dem EOF in einem BGE pH 6,5 führte zu der gewünschten 
Migrationsreihenfolge, so dass die Verunreinigung L-MDT vor dem großen Peak von D-MDT wanderte. 
Für die Trennung wurde eine Quarzglaskapillare mit 21,3/31,5 cm und 50 μm ID verwandt, mit einem 
BGE aus 50 mM Natriumphosphatpuffer, pH 6,5, enthaltend 40 mg/ml sulfatiertes β-Cyclodextrin und 
eine Kapillartemperatur von 17° C und eine angelegte Spannung von 10 kV. Die Analysezeit betrug 
weniger als 10 Minuten, und dies war die erste CE-Methode zur Bestimmung der Enantiomerenreinheit 
von D-MDT mit akzeptabler Präzision und Richtigkeit bei 0,1%. 
Darüber hinaus wurde die Rolle der Größe der Kavität und des Substitutionsmusters der CDs in der 
Migrationsreihenfolge der Medetomidin-Enantiomere untersucht. Dies beinhaltete die entgegengesetzte 
Migrationsreihenfolge in Gegenwart von β-CD und γ-CD sowie S-β-CD und HS-β-CD, die während des 
Screenings verschiedener CDs als mögliche chirale Selektoren beobachtet wurde. Die scheinbaren 
Komplexierungskonstanten und Komplexmobilitäten der diastereomeren CD-Analyt-Komplexe wurden 
durch CE bestimmt. Zusätzlich wurde die Struktur der Komplexe durch Kernspinresonanzspektroskopie 
und molekulare Modellierung detailliert untersucht. S-β-CD wurde nicht in die 
Kernspinresonanzspektroskopie und Molekülmodellierung einbezogen, da es eine Mischung aus 
Positions- und Substitutionsisomeren ist, so dass mit diesen Techniken keine aussagekräftigen Daten 
erhalten werden konnten. 




Die Enantiomerentrennung sowohl mit β-CD als auch mit γ-CD wurde durch die 
Komplexierungskonstanten beeinflusst. Die entgegengesetzte Migrationsreihenfolge im Fall von β-CD 
und γ-CD könnte durch entgegengesetzte Affinitäten der Enantiomere zu den jeweiligen CDs erklärt 
werden. D-MDT wurde im Vergleich zu L-MDT stärker an β-CD gebunden, während für γ-CD das 
Gegenteil gefunden wurde und somit das stärker gebundene Enantiomer an zweiter Stelle wandert. 
Eine entgegengesetzte Erkennung der MDT-Enantiomere wurde auch für S-β-CD und HS-β-CD 
gefunden. Dexmedetomidin wird mit S-β-CD stärker als sein Enantiomer komplexiert, während 
Levomedetomidin mit HS-β-CD stärker als Dexmedetomidin komplexiert wird. Im Gegensatz zu β-CD 
und γ-CD wird die Trennung der MDT-Enantiomere mit dem negativ geladenen S-β-CD und HS-β-CD 
sowohl von den Komplexierungskonstanten als auch von den komplexen Mobilitäten beeinflusst. Bei  
S-β-CD wirken beide enantioselektiven Mechanismen in CE zusammen, was zu einer großen 
Enantioresolution führt, während sie sich im Fall von HS-β-CD gegenseitig entgegenwirken, was bei 
höheren CD-Konzentrationen zu einem Verlust der Enantioseparation führt. 
NMR-Daten bestätigten die Ergebnisse mechanistischer CE-Studien. D-MDT wurde durch β-CD stärker 
gebunden als L-MDT, was sich auch in einem enantioselektiven Kern-Overhauser-Effekt der Resonanz 
des Imidazols H-5 und H-6 der Phenyleinheit des Arzneimittels in ROESY-Experimenten zeigte. Im 
Gegensatz dazu wurde L-MDT mit γ-CD und HS-β-CD stärker komplexiert, und ein stärkeres Kern-
Overhauser-Effekt wurde für das Phenyl H-6 in Gegenwart beider CDs sowie der Imidazolprotonen 
beobachtet, wenn es mit HS-β-CD komplexiert wurde. 
Die molekulare Modellierung stimmte auch mit den aus NMR-Experimenten abgeleiteten Strukturen 
überein. Im Fall von β-CD und γ-CD trat der Phenylring von Medetomidin durch den breiteren 
Sekundärrand der CDs in den Hohlraum ein, während der protonierte Imidazolring innerhalb des CD-
Hohlraums positioniert war und mit den Sulfatgruppen von HS-β-CD interagierte. Wie aus CE- und 
NMR-Daten hervorgeht, wurde die enantioselektive Erkennung der MDT-Enantiomere durch die CDs 
auch durch Molekulardynamik-Simulationen vorgeschlagen und spiegelte die beobachtete Umkehrung 
der Enantiomeren-Migrationsreihenfolge im Fall von β-CD und γ-CD wider. 
Schließlich, Während eines Screenings von CDs als chirale Selektoren für die Trennung von DCV und 
seinem Enantiomer durch Kapillarelektrophorese wurde ein bislang beispielloses Phänomen für CDs 
beobachtet. In Gegenwart von γ-CD wurden zwei Peaks mit einem Plateau beobachtet. Das gleiche 
Ergebnis wurde erzielt, wenn enantiomerenreines DCV injiziert wurde oder wenn eine Probe, die 
enantiomerenreines DCV und γ-CD enthielt, in einem CD-freien BGE analysiert wurde. Koaleszenz der 
Peaks wurde bei 45 ° C und einem pH-Wert über 3,5 beobachtet. Zwei Peaks mit einem Plateau wurden 
auch für DCV-Stereoisomere sowie ein Strukturanalogon beobachtet. Es wurde jedoch nur ein einziger 
Peak nachgewiesen, wenn eine oder beide Aminosäureeinheiten von DCV fehlten. NMR-Experimente, 
einschließlich auf dem Kern-Overhauser-Effekt basierender Methoden, zeigten, dass DCV in Lösung 
eine gefaltete Konformation annahm, bei der die Isopropylseitenkette der Valinreste auf die 
aromatischen Ringe von DCV zeigte. Darüber hinaus zeigte NMR eindeutig die gleichzeitige Bildung 




von DCV-γ-CD-Einschlusskomplexen mit 1:1- und 2:1-Stöchiometrie, was durch Massenspektrometrie 
bestätigt wurde. In beiden Komplexen nahm DCV auch eine gefaltete Struktur an. Das RSSR-
Diastereomer von DCV sowie ein Analogon ohne eine der Aminosäureeinheiten bildeten ebenfalls 1:1- 
und 2:1-Komplexe mit γ-CD, obwohl nur im Fall des RSSR-Diastereomers ein Plateau beobachtet 
wurde. Wie durch CE-MS gezeigt, wanderten beide DCV-γ-CD-Komplexe überraschenderweise als 
erster Peak zusammen, während der zweite wandernde Peak nicht komplexiertes DCV darstellt. 
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Table S1. Matrix of the fractional factorial Res V+ design used for critical process parameter 
screening and experimental responses peak resolution (RS) and (S)-ambrisentan migration 
time (MT).  










1 25 15 200 5.5 10 1.81 12.31 
2 20 20 125 4.65 30 2.92 8.48 
3 25 25 50 5.5 10 0 4.51 
4 25 25 50 3.8 50 2.29 5.36 
5 25 15 50 5.5 50 0 8.74 
6 15 25 50 5.5 50 0 6.88 
7 25 15 50 3.8 10 3.02 10.32 
8 25 25 200 3.8 10 2.53 6.09 
9 15 15 200 5.5 50 2.55 19.51 
10 20 20 125 4.65 30 2.81 8.38 
11 25 25 200 5.5 50 1.86 8.06 
12 15 15 50 5.5 10 0.99 11.60 
13 25 15 200 3.8 50 3.35 13.40 
14 15 25 200 5.5 10 1.85 9.07 
15 15 15 200 3.8 10 4.09 16.68 
16 15 25 200 3.8 50 4.24 11.55 
17 15 15 50 3.8 50 3.24 12.92 
18 15 25 50 3.8 10 3.27 8.45 
19 20 20 125 4.65 30 2.81 8.40 
V: applied voltage; Temp: capillary temperature; Buf: acetate buffer concentration; CD: γ-CD 
concentration; pH: pH of the BGE. 
 
  




Table S2. Response surface design matrix of the three level central composite face-centered design 
used for method optimization and experimental responses peak resolution (RS) and (S)-
ambrisentan migration time (MT).  








1 20 20 125 4.35 11.06 
2 25 25 200 4.01 9.08 
3 15 25 50 3.44 8.31 
4 15 15 50 3.61 14.49 
5 25 15 50 2.96 11.58 
6 15 20 125 4.23 13.92 
7 20 20 50 3.18 9.51 
8 15 15 200 4.19 20.68 
9 20 25 125 3.82 9.49 
10 25 20 125 3.75 11.35 
11 15 25 200 4.76  13.80 
12 20 20 200 4.59 16.02 
13 20 15 125 3.88 17.90 
14 20 20 125 3.77 13.06 
15 25 25 50 2.66 6.53 
16 20 20 125 3.68 13.11 
17 25 15 200 4.11 18.95 
V: applied voltage; Temp: capillary temperature; Buf: acetate buffer concentration. 
  




Table S3. Matrix of the Plackett-Burman design for robustness testing experimental responses peak 
resolution (RS) and (S)-ambrisentan migration time (MT). 










1 26 24 48 4.1 27.5 1.72 8.38 
2 26 26 48 3.9 32.5 1.77 7.65 
3 26 26 52 3.9 27.5 1.79 7.16 
4 24 26 52 4.1 27.5 1.77 9.41 
5 26 24 52 4.1 32.5 1.71 9.02 
6 24 26 48 4.1 32.5 1.73 8.05 
7 24 24 52 3.9 32.5 1.73 8.55 
8 24 24 48 3.9 27.5 1.73 7.91 
9 25 25 50 4.0 30 1.78 8.90 
10 25 25 50 4.0 30 1.79 8.22 
11 25 25 50 4.0 30 1.80 7.90 
V: applied voltage; Temp: capillary temperature; Buf: acetate buffer concentration; CD: γ-CD 
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Table S1. Matrix of the fractional factorial resolution IV design used for evaluation of CCPs in the 
investigation of the knowledge space. Resolution (RS) and migration time of the LVM peak 
(MTLVM) were used as responses.  
 Parameters Responses 











1 15 10 30 6.6 10 6 9.12 7.66 
2 25 10 30 6.5 24 6 13.86 10.28 
3 15 20 30 6.5 24 20 12.06 4.34 
4 25 20 30 6.5 10 20 4.99 4.45 
5 15 10 100 6.4 24 20 3.96 8.4 
6 25 10 100 6.4 10 20 5.28 5.64 
7 15 20 100 6.5 10 6 8.43 3.97 
8 25 20 100 6.4 24 6 14.02 10.16 
9 15 10 30 8.2 10 20 3.68 6.07 
10 25 10 30 8.0 24 20 8.8 6.35 
11 15 20 30 8.0 24 6 15.86 5.43 
12 25 20 30 8.0 10 6 6.86 2.7 
13 15 10 100 8.0 24 6 11.41 11.51 
14 25 10 100 8.0 10 6 8.03 6.28 
15 15 20 100 8.2 10 20 0 2.78 
16 25 20 100 8.0 24 20 3.79 3.16 
17 20 15 65 7.2 17 13 5.97 4.4 
18 20 15 65 7.2 17 13 6.19 4.53 








Table S2. Design matrix for the central composite face centered design for method optimization. 
Responses were migration time (TMLVM), number of theoretical plates (NLVM) and height 
(HLVM) of the LVM peak and the tailing factor of the DXM peak (TFDXM). Peak resolution, RS, 








(mg/mL) RS TMLVM NLVM HLVM TFDXM 
N01 10 10 5 11.8 10.12 30835 2370 8.3 
N02 20 10 5 11.8 5.23 29408 2052 4.89 
N03 10 30 5 21.3 22.98 26698 2505 8.09 
N04 20 30 5 19.3 10.5 25162 2077 5.48 
N05 10 10 15 13.3 7.82 73057 3535 0.69 
N06 20 10 15 10.1 3.45 53058 3099 0.9 
N07 10 30 15 22.1 12 79843 3559 0.63 
N08 20 30 15 22.3 5.63 65006 3120 0.85 
N09 10 20 10 11.5 18.6 51786 3355 3.99 
N10 20 20 10 15.8 5.25 42992 3100 2.79 
N11 15 10 10 13.0 5.33 47218 2946 2.48 
N12 15 30 10 24.9 9.67 52091 2758 2.66 
N13 15 20 5 19.5 14.86 23991 1997 7.97 
N14 15 20 15 20.4 6.27 78643 3294 0.95 
N15 15 20 10 17.4 7.26 51371 3150 3.23 
N16 15 20 10 19.0 8.22 49950 2908 3.17 
N17 15 20 10 17.8 7.23 54385 3098 3.13 
  




Table S3. Design matrix of the Plackett-Burman design used for robustness testing. Responses were 
migration time (TMLVM), number of theoretical plates (NLVM) and height (HLVM) of the LVM 
peak and the tailing factor of the DXM peak (TFDXM). 
 
 Parameters Responses 












Batch MTLVM NLVM HLVM TFDXM 
N01 21 19 31 6.4 15 13 S2 M2 5.14 21170 4941 4.6 
N02 21 21 29 6.6 15 13 S1 M2 4.40 22859 5119 4.2 
N03 19 21 31 6.4 17 13 S1 M1 4.42 30803 5540 1.9 
N04 21 19 31 6.6 15 15 S1 M1 4.18 45965 6760 1.3 
N05 21 21 29 6.6 17 13 S2 M1 4.11 33379 5904 2.3 
N06 21 21 31 6.4 17 15 S1 M2 4.52 26188 5099 3.8 
N07 19 21 31 6.6 15 15 S2 M1 3.89 39647 5986 1.1 
N08 19 19 31 6.6 17 13 S2 M2 5.54 25193 5344 4.4 
N09 19 19 29 6.6 17 15 S1 M2 5.33 29129 5396 4.6 
N10 21 19 29 6.4 17 15 S2 M1 4.55 33695 5974 1.7 
N11 19 21 29 6.4 15 15 S2 M2 4.56 23432 4604 4.3 
N12 19 19 29 6.5 15 13 S1 M1 4.69 32758 5659 1.9 
N13 20 20 30 6.5 16 14 S1 M1 4.29 38234 6050 1.5 
N14 20 20 30 6.5 16 14 S1 M1 4.25 38152 6113 1.5 
N15 20 20 30 6.5 16 14 S1 M1 4.27 37972 6092 1.5 
 
  






Figure S1. Sweet spot plots with buffer concentration set at 30 mM and temperature at 20° C. 
Green: sweet spot (all criteria met), blue: 1 criterion met. Threshold of the responses: 
Resolution (RS ≥ 5) and migration time LVM (t ≤ 8 min).  
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Figure S2 Coefficient plot (scaled and centered) of the screening design showing the relative effect 
of the factors on the responses; x*x represents the quadratic terms for the respective 
parameters and x*y the interaction terms between two parameters. Temp, capillary 
temperature; V, Applied voltage; Buf, buffer concentration; pH, buffer pH; S-β-CD, S-β-
CD concentration;  M-α-CD, M-α-CD concentration; S1 and S2, S-β-CD batches; M1 and 
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Table S1. Matrix of the fractional factorial resolution V+ design used for evaluation of CPPs in the 
investigation of the knowledge space. The responses were α-value, migration time of the 
D-MDT peak (MT D-MDT) and the resulting current (Cur).  
 Parameters Responses 











1 15 6 50 6.4 50 1.181 22.5 46 
2 25 6 50 6.4 30 1.068 10.7 37.5 
3 15 6 100 6.4 30 1.000 11.1 42.7 
4 25 6 100 6.4 50 1.074 10.9 65.2 
5 15 10 50 6.4 30 1.101 8.8 55.6 
6 25 10 50 6.4 50 1.114 8.3 92.4 
7 15 10 100 6.4 50 1.093 8.0 96.5 
8 25 10 100 6.3 30 1.000 4.8 94 
9 15 6 50 8.1 30 1.000 7.3 39.8 
10 25 6 50 8.5 50 1.000 6.2 61.4 
11 15 6 100 8.3 50 1.000 9.5 66.6 
12 25 6 100 8.1 30 1.000 6.7 66.4 
13 15 10 50 8.0 50 1.000 5.3 90 
14 25 10 50 8.5 30 1.000 3.3 85.2 
15 15 10 100 8.1 30 1.000 4.6 101 
16 25 10 100 8.0 50 1.000 3.9 144 
17 20 8 75 7.2 40 1.039 6.2 76.4 
18 20 8 75 7.2 40 1.037 6.1 76 








Table S2. Design matrix for the central composite face centered design for method optimization. The 
responses were α-value, migration time of the D-MDT peak (MT D-MDT) and the resulting 
current (Cur). 
 Parameters Responses 









N01 15 6 30 1.110 17.7 32.4 
N02 25 6 30 1.054 10.6 39.9 
N03 15 10 30 1.098 9.6 56 
N04 25 10 30 1.053 5.9 68.8 
N05 15 6 50 1.162 22.5 48 
N06 25 6 50 1.114 15.0 54.7 
N07 15 10 50 1.188 13.4 79.7 
N08 25 10 50 1.084 7.8 99.5 
N09 15 8 40 1.086 8.7 50.5 
N10 25 8 40 1.049 6.2 61.6 
N11 20 6 40 1.059 10.0 41 
N12 20 10 40 1.058 5.8 72.3 
N13 20 8 30 1.076 10.1 48.4 
N14 20 8 50 1.117 11.9 68.8 
N15 20 8 40 1.060 7.4 56.2 
N16 20 8 40 1.080 7.7 56.3 










Table S3. Design matrix of the Plackett-Burman design used for robustness testing. The responses 
were α-value, migration time of the D-MDT peak (MT D-MDT) resulting current (Cur) and the 
corrected area ratio of D-MDT to that of the internal standard (AD/AISt). 
 
 Parameters Responses 














N1 18 47.5 9.5 6.6 38 S-2 1.090 7.5 73.5 0.839 
N2 18 52.5 9.5 6.4 42 S-1 1.110 8.1 69.5 0.743 
N3 18 52.5 10.5 6.4 38 S-2 1.090 7.1 73.5 0.804 
N4 16 52.5 10.5 6.6 38 S-1 1.086 6.7 65.5 0.763 
N5 18 47.5 10.5 6.6 42 S-1 1.089 6.9 78.0 0.861 
N6 16 52.5 9.5 6.6 42 S-2 1.090 8.0 68.0 0.862 
N7 16 47.5 10.5 6.5 42 S-2 1.117 8.2 75.0 0.863 
N8 16 47.5 9.5 6.4 38 S-1 1.104 8.1 59.3 0.792 
N9 17 50 10 6.5 40 S-1 1.096 7.4 74.5 0.824 
N10 17 50 10 6.5 40 S-1 1.091 7.7 74.0 0.870 
N11 17 50 10 6.5 40 S-1 1.102 7.5 74.6 0.821 
 
  





















































Figure S1. Coefficient plot (scaled and centered) of the screening design showing the relative effect 
of the factors on the responses (A) α-value, (B) migration time of D-MDT and (C) current. 
x*y represent the interaction terms between two parameters. V, Applied voltage; Temp, 
capillary temperature; pH, pH of BGE; Buf, BGE concentration; SB, S-β-CD concentration. 



















































































































































































































Figure S2. Coefficient plot (scaled and centered) of the Plackett-Burman design showing the relative 
effect of the factors on the migration time of D-MDT. Temp, capillary temperature; V, 
Applied voltage; pH, pH of BGE; Buf, BGE concentration; CD-C, S-β-CD concentration; 
CD-B, batches of S-β-CD. The error bars represent the 95 % confidence interval. 
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Reference spectrum medetomidine 












Fig. S1. Expanded 
1
H NMR (top) and 1D ROESY (bottom) spectra of the complex between β-CD and medetomidine spiked with 
dexmedetomidine upon irradiation of β-CD H-3 and H-6. The enantioselective ROESY response is indicated with a frame. 






Fig. S2. Expanded 
1
H NMR (top) and 1D ROESY (bottom) spectra of the complex between γ-CD and medetomidine spiked with dexmedetomidine 
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Fig. S3. Expanded 
1
H NMR (top) and 1D ROESY (bottom) spectra of the complex between HS-β-CD and medetomidine spiked with 
dexmedetomidine upon irradiation of HS-β-CD H-6. The enantioselective ROESY responses are indicated with frames. 
6.656.706.756.806.856.906.957.007.057.107.157.207.257.307.358.358.408.458.508.558.608.65
f1 (ppm)
reference spectrum medetomidine 
irr. at HS‐β‐CD H‐6 
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SYNTHESIS OF HALF-DCV 










































xylene, reflux, 8 h
MOC-L-Val, HOBt·H2O




(S)-tert-butyl 2-(2-oxo-2-phenylethylcarbamoyl)pyrrolidine-1-carboxylate (2) 
12 g (55.8 mmol) BOC-L-Pro and 17.6 mL N,N-diisopropylethylamine in 120 mL dry dichloromethane 
were stirred under nitrogen at 0 °C for 10 min. 11 g (55 mmol) of 2-bromoacetophenone (1) were 
added, the solution was warmed to room temperature and stirred overnight. Subsequently the solution 
was washed with 100 mL water and 100 mL brine and dried over sodium sulfate. Removal of the 
organic solvent under reduced pressure yielded an off-white solid (16 g, 85 %), which was used in the 
next step without further purification.  
 
(S)-tert-butyl 2-(5-phenyl-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (3) 
14 g (42 mmol) of 2 and 30 g ammonium acetate in 120 mL toluene were refluxed for 8 h. The solution 
was cooled to room temperature, diluted with 100 mL ethyl acetate and washed with 100 mL water 
and 100 mL brine and dried over sodium sulfate. Evaporation of the solvent under reduces pressure 
yielded an oil, which was further purified by column chromatography (hexane/ethyl acetate 2:1, 
followed by methanol) to yield an off-white solid. Yield 6 g (45 %); m.p. 63-64 °C (ref. 2, 63-65 °C); 
MS: m/z = 314 [M+H]+, 313 M+, 257, 240, 213, 212, 185, 171, 170, 158, 57; 1H-NMR (250 MHz, 
CDCl3) δ (ppm) = 1.51 (s, 9H), 1.98-2.18 (m, 4H), 2.90 (br s, 1H), 3.43-3.48 (m, 1H), 5.03 (br s, 1H), 
7.23-7.28 (m, 3H), 7.35-7.38 (m, 2H), 7.60 (s, 1H). 
 
(S)-5-phenyl-2-(pyrrolidin-2-yl)-1H-imidazole (4) 
1.5 g (4.8 mmol) of 3 were stirred in 15 mL dry dioxane and 15 mL 6 M HCl in dioxane at 0 °C for 1 h. 
Removal of the solvent under reduced pressure yielded a white solid. Yield 0.9 g (66 % as 
hydrochloride); m.p. 243-244 °C; MS: m/z = 214 [M+H]+, 213 M+, 185, 184, 171, 170, 158; 1H-NMR 
(250 MHz, D3COD) δ (ppm) = 2.24-2.78 (m, 4H), 3.61-3.78 (m, 2H), 5.26 (t, J = 8.2 Hz, 1H), 7.52-7.60 
(m, 3H), (d, J = 6.5 Hz, 2H), 8.07 (s, 1H). 
 
  





methyl ester (5, half-DCV) 
1.52 g (8.6 mmol) N-MOC-L-Val, 1.46 g (10.8 mmol) HOBt and 1.82 g (11.7 mmol) 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide were stirred under nitrogen in 50 mL dry acetonitrile for 1 h at room 
temperature. Upon cooling to 0 °C, 1.68 g (5.9 mmol) of 4 (as hydrochloride) were added followed by 
dropwise addition of 5 mL N,N-diisopropylethylamine. The mixture was warmed to room temperature 
and stirring was continued for 24 h. 120 mL brine were added, the mixture was stirred at 50 °C for 1 h 
and after cooling to room temperature extracted with 100 mL ethyl acetate. The organic phase was 
washed with 0.5 M NaOH (2 times 50 mL) and brine (50 mL). Evaporation of the solvent under 
reduced pressure yielded 2 g of a brown oil. Column chromatography (ethyl acetate:hexane, 40:60 
followed by ethyl acetate) yielded 450 mg of a yellowish oil, which were dissolved in the minimum 
amount of methanol. Upon addition of 5 drops toluene, the solvents were removed under reduced 
pressure yielding an off-white solid. Yield 400 mg (13 %); m.p. 133-134 °C; MS: m/z = 371 [M+H]+, 
370 M+, 282, 240, 212, 130, 98, 43. For 1H-NMR data see Fig. S11A and Table S8. Purity: 97.6 % by 
CE (40/50.2 cm, 50 µm ID fused-silica capillary, 50 mM sodium phosphate, pH 2.5, 20 °C, detection at 
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Figure S1 Structures of the RRRR-DCV, RSSS-DCV, Ile-DCV, BPIB and BOC-BPIB. 
  








Figure S2 Electropherograms of the analysis of DCV using sodium phosphate buffer, pH 2.5, as 
BGE. (A) Effect of γ-CD concentration in 50 mM sodium phosphate buffer, (B) effect of 
buffer concentration in the presence of 20 mM γ-CD. For other experimental conditions 
see experimental procedures section. 
 
  






Figure S4 Electropherograms showing the effect of (A) temperature and (B) pH of the BGE using a 
50 mM sodium phosphate buffer, pH 2.5, containing 20 mM γ-CD. For other experimental 

















15.0 288.15 0.0007 21.02 20.80 - 0.56 
20.0 293.15 0.0015 20.95   
25.0 298.15 0.0030 20.89   
30.0 303.15 0.0048 20.97   
35.0 308.15 0.0089 20.95   




Figure S4 Experimental (red) and simulated (blue) electropherograms of DCV using a 50 mM 
sodium phosphate buffer, pH 2.5, containing 20 mM γ-CD as BGE at variable 
temperature. Experimental plots have been baseline corrected for comparison with 
simulated plots. ∆G12ǂ values are within 0.01 kcal/mol, k12 constant of interconversion of 
peak 1 to peak 2. 
  







Figure S5 Electropherograms of the analysis of (A) RSSR-DCV, (B) RSSS-DCV, (C) Ile-DCV, (D) 
mono-DCV, (E) BPIB, (F) BOC-BPIB and (G) half-DCV using 50 mM sodium phosphate 
buffer, pH 2.5, containing 20 mM γ-CD as BGE. For other experimental conditions see 
experimental procedures section. * synthetic impurity. 
 
  







Figure S6 Chromatograms of the analysis of (A) a non-racemic mixture of DCV and RRRR-DCV 
and (B) a sample containing DCV and γ-CD on a Lux i-Cellulose 5 column (150 x 4.6 mm, 
5 µm), mobile phase: 1.58 g/L NH4HCO3 in water/acetonitrile (30:70, v/v), 1.0 mL/min, 
40 °C, detection wavelength 305 nm. The sample was prepared by dissolving DCV.2HCl 
at a concentration of 200 µg/mL in 50 mM sodium phosphate buffer, pH 2.5, containing 
20 mM γ-CD and keeping it at room temperature for 30 min before injection. 
Measurements were performed on a Shimadzu HPLC system from (Shimadzu, Kyoto, 
Japan) consisting of two LC-10AS pumps, a SPD-10 A UV-vis detector, a SIL-10 A auto 
injector, a CTO-20AC column oven and a SCL-10AVP system control unit using the 













T (°C) T (K) k12 (s-1) ΔG12ǂ (kcal·mol-1) 
20.0 293.15 0.00057 21.51 
30.0 303.15 0.00295 21.26 





Figure S7 Experimental (red) and simulated (blue) electropherograms of a sample containing DCV 
(sample concentration 200 μg/mL as 2HCl salt) and 20 mM γ-CD analyzed in 50 mM CD-
free sodium phosphate buffer, pH 2.5, at variable temperature. Experimental plots have 
been baseline corrected for comparison with simulated plots. ∆G12ǂ values are within 
0.01 kcal/mol 
  






Figure S8 Expanded 2D ROESY spectrum of DCV in 50 mM deuterated sodium phosphate buffer in 
D2O, apparent pH 2.5, showing intramolecular NOEs. Experimental conditions: 3.6 mg 
DCV·2HCl in 0.7 mL 50 mM D3PO4 in D2O, pH 2.5, 25 °C. 
 
  







Figure S9 Expanded 2D ROESY spectrum of DCV in the presence of γ-CD in 50 mM deuterated 
sodium phosphate buffer in D2O, apparent pH 2.5, showing intermolecular NOEs 
between aromatic DCV protons and γ-CD protons. Experimental conditions: 3.0 mg 
DCV·2HCl and 13.0 mg γ-CD in 0.7 mL 50 mM D3PO4 in D2O, pH 2.5, 25 °C. 
 
  







Figure S10 Expanded 1H-NMR spectrum (aromatic region) of (A) DCV plus γ-CD in 0.05 M 
deuterated phosphate buffer in D2O, apparent pH 2.5, and (B) 1D ROESY spectrum 
irradiating at Ph H-2,6 of DCV-(III) (7.25 ppm), showing the intermolecular interaction with 
Ph H-2,6 of DCV-(II) (7.18 ppm) within the 2:1 complex. Experimental conditions: 3.0 mg 
DCV·2HCl and 13.0 mg γ-CD in 0.7 mL 50 mM D3PO4 in D2O, pH 2.5, 25 °C. 
 
  








Figure S11 1H-NMR spectrum (A) DCV and (B) of a mixture of DCV and γ-CD in 50 mM deuterated 
sodium phosphate buffer in D2O, apparent pH 4.0. The insert shows the expanded region 
of the aromatic protons. Experimental conditions: 3.4 mg DCV·2HCl and 14.1 mg γ-CD in 
0.8 mL 50 mM D3PO4 in D2O (5.2 mM, 13.6 mM), pH 4.0, 25 °C. 
 
  








Figure S12 ESI-mass spectra of a sample of DCV and γ-CD. The sample contained 0.1 mg/mL DCV 
and 2.5 mM γ-CD dissolved in 50 mM ammonium formate buffer pH 2.6. Experimental 
conditions: Agilent 6520 QTOF with a Dual-ESI Source (G6510A, G3251B; Agilent, Santa 
Clara, CA, U.S.A.). The sample was delivered by a syringe pump Model 100 Series (KD 
Scientific, Holliston MA, U.S.A.) with a 500 µL syringe (Trajan Scientific, Victoria, 
Australia). The MS instrument settings were as follows: sample delivery rate of 4 µL/min, 
spray voltage (VCap) of 4,5 kV, nebulizer and dry gas flow of 15 psig and 4 L/min, gas 
temperature of 275 °C, fragmentor, skimmer and OCT 1RF voltage of 200 V/65 V/600 V. 
Measurements were performed in a range of m/z 150-3000 and with an acquisition rate of 








Table S1 Results of screening of CDs as selectors for the separation of DCV and RRRR-DCV. 
 
Cyclodextrin1) Concentration Separation factor α Migration order Comments 
α-CD 5 mM 1.000 − − 
20 mM 1.000 − − 
M-α-CD 5 mM 1.000 − − 
20 mM 1.000 − − 
HP-α-CD 5 mM 1.000 − − 
20 mM 1.000 − − 
CM-α-CD 5 mM 1.013 RRRR2) > DCV Partial separation 
20 mM 1.049 RRRR > DCV Partial separation 
S-α-CD 5 mM 1.000 − − 
20 mM 1.000 − − 
β-CD 5 mM 1.000 − − 
20 mM 1.000 − − 
M-β-CD 5 mM 1.070 DCV > RRRR Baseline separation 
20 mM 1.053 DCV > RRRR Baseline separation 
HP-β-CD 5 mM 1.000 − − 
20 mM 1.036 DCV > RRRR Partial separation 
CM-β-CD 5 mM 1.000 − − 
20 mM 1.000 − − 
S-β-CD 5 mM − − Plateau between peaks 
20 mM − − Plateau between peaks 
γ-CD 5 mM − − Plateau between peaks 
20 mM − − Plateau between peaks 
M-γ-CD 5 mM 1.000 − Shoulder 
20 mM 1.000 − − 
HP-γ-CD 5 mM 1.000 − − 
20 mM 1.000 − − 
CM-γ-CD 5 mM 1.080 DCV > RRRR Baseline separation 
20 mM 1.066 DCV > RRRR Baseline separation 
S-γ-CD 5 mM 1.038 DCV > RRRR Baseline separation 
20 mM 1.060 DCV > RRRR Baseline separation 
1) M-α-CD, methyl-α-CD; HP-α-CD, 2-hydroxypropyl-α-CD; CM-α-CD, carboxymethyl-α-CD; S-α-CD sulfated α-
CD; M-β-CD, methyl-β-CD; HP-β-CD, 2-hydroxypropyl-β-CD; CM-β-CD, carboxymethyl-β-CD; S-β-CD sulfated 
β-CD; M-γ-CD, methyl-γ-CD; HP-γ-CD, 2-hydroxypropyl-γ-CD; CM-γ-CD, carboxymethyl-γ-CD; S-γ-CD sulfated γ-
CD.  
2) RRRR-DCV (enantiomer) 
Experimental conditions: 40/50.2 cm, 50 µm ID fused-silica capillary, 50 mM sodium phosphate buffer, pH 2.5, 20 
°C and 20 kV. Detection was carried out at 200 nm at the cathodic end of the capillary. In the case of sulfated CDs 
the applied voltage was –20 kV and detection was performed at the anodic end. The sample consisted of 100 µg/mL 
DCV and 50 µg/mL DCV enantiomer dissolved in 0.01 mM HCl. 















H‐2 4.15 4.15 
H‐3 1.95 1.95 
H‐4 (Me) 0.73, 0.80 0.73, 0.80 
OMe 3.53 3.22 
Pyr‐2 5.14 (t, J = 7.6 Hz) 5.61 (dd, J = 7.6, 1.5 Hz) 
Pyr‐3 2.01, 2.43 2.18, 2.46 
Pyr‐4 2.02, 2.12 1.74, 1.99 
Pyr‐5 3.79, 3.92 3.48, 3.74 
Im‐4 7.52 7.52 
Ph‐2,6 7.66 7.66 
Ph‐3,5 7.59 7.58 
 































































Table S3 1H-NMR resonances of DCV–γ-CD complexes in buffered D2O at pH 2.5 in ppm. For assignments see structures. 
 
 
1:1 Complex  2:1 Complex 
Proton(s) DCV (I) Proton(s) γ-CD (I)  Proton(s) DCV (II) DCV (III) Proton(s) γ-CD (II) 
H-2 4.18 H-1 4.98  H-2 4.17 4.21 H-1 4.87 
H-3 1.98 H-2 3.52  H-3 1.94 2.04 H-2 3.46 
H-4 (Me) 0.74, 0.80 H-3 3.80  H-4 (Me) 0.73, 0.80 0.80, 0.87 H-3 3.47 
OMe 3.55 H-4 3.46  OMe 3.55 3.55 H-4 3.38 
Pyr-2 5.18 H-5 3.74  Pyr-2 5.07 5.10 H-5 3.33 
Pyr-3 2.06, 2.47 H-6 3.73  Pyr-3 1.98, 2.36 1.98, 2.36 H-6 3.48, 3.53 
Pyr-4 2.06, 2.16    Pyr-4 2.01, 2.16 2.01, 2.16   
Pyr-5 3.82, 3.94    Pyr-5 3.80, 3.97 3.80, 3.97   
Im-4 7.59    Im-4 7.48 7.42   
Ph-2,6 7.72    Ph-2,6 7.18 7.25   
Ph-3,5 7.70    Ph-3,5 7.37 7.45   
 







































































Table S4 Observed and calculated masses in ESI-TOF-MS 
 
 Molecular formula Ion m/z observed m/z calculated delta (ppm) 
DCV C40H50N8O6 
[M+H]+ 739.3926 739.3926 0.0 
[M+2H]2+ 370.2028 370.1999 –7.8 
DCV:γCD (1:1) C88H130N8O46 [M+2H]2+ 1018.4127 1018.4112 –1.4 
DCV:γCD (2:1) C128H180N16O52 
[M+2H]2+ 1387.6058 1387.6039 –1.4 








ELUCIDATION OF THE SOLUTION STRUCTURE AS WELL AS THE STRUCTURES OF THE 
COMPLEXES WITH γ-CD BY 1H-NMR SPECTROSCOPY 
 
RSSR-DCV 
The spectrum RSSR-DCV is shown in Figure SA 1A, for signal assignments see Table SA 1. A minor 
signal for the pyrrolidine H-2 at 5.78 ppm (dd, J = 8.3, 1.5 Hz) and a major signal at 5.26 ppm (dd, J = 
8.3 Hz, 3.5 Hz) were observed indicating the presence of two conformers with a ratio of about 0.05:1.0, 
which is lower than that found for DCV. The coupling constants point to equatorial configurations of the 
proton at pyrrolidine C-2 in both conformers in contrast to DCV. Another difference is the large upfield 
shift of the methyl protons of the valine side chain to 0.45 and 0.68 ppm. This might be explained by the 
anisotropic ring current of the aromatic moieties in case of a folded structure with the methyl groups in 
the proximity to the phenyl rings. However, this tentative structure could not be corroborated from 
ROESY experiments because no significant NOEs were observed (data not shown). The major RSSR-
DCV conformer displayed NOEs between the phenyl hydrogens at 7.58 and 7.64 ppm and the methoxy 
function at 3.47 ppm. Thus, RSSR-DCV also adopts a folded structure but unlike DCV, the methoxy 
groups of the MOC residues were folded back toward the aromatic structures, while the valine side 
chains pointed away from the molecule. 
The 1H-NMR spectrum of the mixture of RSSR-DCV and γ-CD in deuterated phosphate buffer in 
comparison to RSSR-DCV is displayed in Figure SA 1B, for signal assignment see Table SA 2. As in 
the case of DCV, three sets of signals were observed for RSSR-DCV, while two other sets of signals 
were consistent with γ-CD. The minor γ-CD component is best evidenced by the upfield shift of the 
anomeric H-1 proton at 4.87 ppm and of the internal H-3 and H-5 protons at 3.51 and 3.35 ppm, 
respectively. The presence of three sets of signals for RSSR-DCV in the aromatic region (Figure SA 1B, 
insert). The ratio of the integrals was about the same, so that no "minor" and "major" RSSR-DCV species 
could be assigned. The simultaneous presence of 1:1 and 2:1 inclusion complexes was concluded 
based on intermolecular NOE responses between the aromatic protons of all RSSR-DCV species and 
the inner H-3 and H-5 hydrogens of γ-CD in a 2D ROESY experiment (Figure SA 2). In addition, an 
intermolecular NOE cross peak was observed between the aromatic signals of the phenyl H-3,5 protons 
at 7.13 and 7.22 ppm of two of the RSSR-DCV species. This substantiates a 2:1 complex in addition to 
the 1:1 complex. Based on the integrals of the signals of aromatic protons and the anomeric proton of 
the minor “minor” γ-CD at 4.87 ppm a molar ratio of 1:1:1 was derived further supporting a 2:1 complex, 
while the NOE interactions found for the aromatic RSSR-DCV protons at lower field with the "major" γ-
CD protons were consistent with a 1:1 complex. An approximate ratio of 1:1 for the complexes at 25 °C 
was estimated from the integrals of the aromatic protons. Thus, the ratio is different from DCV 
No NOEs were detected between protons of the Val side chain and aromatic protons, while NOEs 
indicated spatial vicinity between Val-Hα and pyrrolidine H-5 of all three RSSR-DCV species. In the 
case of the 1:1 complex a NOE of pyrrolidine H-5 (3.75 ppm) with valine H-α (4.15 ppm) was also 
observed. These results indicated that RSSR-DCV adopted an extended conformation in both types of 
complexes, which is in contrast to the folded structure of DCV in the complexes. Thus, the 
stereochemistry of the MOC-valine side chain does not affect the formation of a 2:1 complex with γ-CD 








Figure SA 1 1H-NMR spectra of (A) RSSR-DCV and (B) RSSR-DCV plus γ-CD in 0.05 M deuterated 
phosphate buffer in D2O, apparent pH 2.5. For signal assignments see Tables S4 and 
S5 (supplementary electronic material). Experimental conditions: (A) 2.3 mg RSSR-
DCV in 0.6 mL 50 mM D3PO4 in D2O (5.2 mM), pH 2.5, 25 °C; (B) 2.0 mg RSSR-DCV 
and 12.4 mg γ-CD in 0.7 mL 50 mM D3PO4 in D2O (3.9 mM, 13.7 mM), pH 2.5, 25 °C. 






Figure SA 2 Expanded 2D ROESY spectrum of a mixture of RSSR-DCV and γ-CD in 50 mM 
deuterated sodium phosphate buffer in D2O, apparent pH 2.5, showing intermolecular 
NOEs. Experimental conditions: 2.0 mg RSSR-DCV and 12.4 mg γ-CD in 0.7 mL 50 



















H-2 4.19 3.63 
H-3 1.95 1.68 
H-4 (Me) 0.84, 0.87 0.45, 0.68 
OMe 3.47 3.51 
Pyr-2 5.26 (dd, J = 8.3, 3.5 Hz) 5.78 (dd, J = 8.3, 1.5 Hz) 
Pyr-3 2.04, 2.39 2.11, 2.40 
Pyr-4 2.04 1.86, 1.99 
Pyr-5 3.73, 3.97 3.49, 3.72 
Im-4 7.50 7.53 
Ph-2,6 7.64 n.d. 
Ph-3,5 7.58 n.d. 
 
 






























































Table SA 2 1H-NMR resonances of RSSR-DCV–γ-CD complexes in buffered D2O at pH 2.5 in ppm. For assignments see structures. 
 
 
1:1 Complex  2:1 Complex 
Proton(s) RSSR-DCV (I) Proton(s) γ-CD (I)  Proton(s) RSSR-DCV (II) RSSR-DCV (III) Proton(s) γ-CD (II) 
H-2 4.15 H-1 4.97  H-2 4.28 or 4.29 4.28 or 4.29 H-1 4.87 
H-3 1.91 H-2 3.52  H-3 2.03 2.03 H-2 3.49 
H-4 (Me) 0.86 H-3 3.79  H-4 (Me) 0.82 or 0.84, 0.90 0.82 or 0.84, 0.90 H-3 3.51 
OMe approx. 3.50 H-4 3.45  OMe approx. 3.50 approx. 3.50 H-4 3.36 
Pyr-2 5.33 (dd, J = 8, 4 Hz) H-5 3.71  Pyr-2 5.22 (dd, J = 8, 4 Hz) 5.25 (dd, J = 8, 4 Hz) H-5 3.35 
Pyr-3 2.11, 2.43 H-6 3.72 (x 2)  Pyr-3 1.90, 2.37 1.93, 2.39 H-6 3.50 (x 2) 
Pyr-4 2.07 (x 2)    Pyr-4 2.04 (x 2) 2.03 (x 2)   
Pyr-5 3.75, 4.07    Pyr-5 3.74, 3.94 3.73, 3.97   
Im-4 7.60    Im-4 7.36 7.32   
Ph-2,6 7.55    Ph-2,6 7.44 7.31   
Ph-3,5 7.70    Ph-3,5 7.22 7.13   
 








































































The 1H-NMR spectrum of mono-DCV in phosphate buffer also revealed the presence of a major and a 
minor isomer (Figure SA 3A, Table SA 3). In the pyrrolidine ring substituted with MOC-valine, H-2 is 
equatorial in the minor isomer (5.61 ppm, dd, J = 8, 1.5 Hz) and axial in the major species (5.15 ppm, t, 
J = 8 Hz), i.e. very similar to DCV. In the unsubstituted pyrrolidine ring, only the axial configuration was 
derived for H-2 (5.01 ppm, dd, J = 10, 8 Hz). The molar ratio of major-to-minor isomer at 25 °C was 
about 1.0:0.13, i.e. in the same range as seen for DCV. The MOC-valine moiety is also "folded back" 
toward the aromatic rings as concluded from NOEs between the methyl protons of the side chain and 
the aromatic protons. As in the case of DCV, a NOE was also seen between the valine methyl groups 
and H-2 of the minor isomer. Thus, the conformation of the substituted pyrrolidine moiety of mono-DCV 
has the same folded structure as DCV. 
The 1H-NMR spectrum of mono-DCV in the presence of γ-CD (Figure SA 3B, Table SA 4) was less 
resolved compared to the spectrum of DCV and γ-CD as considerable signal overlap was encountered. 
Like DCV and the RSSR-diastereomer, five sets of signals were identified, two referring to γ-CD and 
three to mono-DCV. The γ-CD signals were divided into a minor and a major abundant species with 
signals of the minor species displaying an upfield shift of almost all resonances. The three sets of 
resonances due to mono-DCV could not be clearly assigned to higher and lower abundant species due 
to signal overlap (Figure SA 3B insert). However, six partially overlapping doublets between 0.7 and 0.8 
ppm were observed for the methyl groups of the valine side chain indicating three different species of 
mono-DCV. A 2D ROESY experiment (Figure SA 4) showed intermolecular NOE interactions between 
all mono-DCV aromatic hydrogens with the H-3, H-5 and H-6 protons of both, the "major" and the "minor" 
γ-CD, indicating the presence of two different complexes, presumably with 1:1 and 2:1 stoichiometry. 
Due to the signal overlap in the aromatic region of the spectrum, no clear intermolecular NOEs between 
the aromatic protons of different mono-DCV species were detected so that no unequivocal proof of a 
2:1 complex could be derived. Nonetheless, based on the integrals of the (overlapping) aromatic protons 
the molar ratio between the minor and the major complexes was about 0.4:1.0. Therefore, it can be 
assumed, that both complexes with 1:1 and 2:1 stoichiometries are also formed between mono-DCV 
and γ-CD. The exact orientation of the mono-DCV molecules inside the CD cavity, i.e. the orientation of 
the MOC-valine group versus the wider or narrower rim of γ-CD, could not be derived either because no 
sufficient NOE evidence was obtained. 
 






Figure SA 3 1H-NMR spectra of (A) mono-DCV and (B) mono-DCV plus γ-CD in 0.05 M deuterated 
phosphate buffer in D2O, apparent pH 2.5. For signal assignments see Tables S6 and 
S7 (supplementary electronic material). Experimental conditions: (A) 2.7 mg mono-DCV 
in 0.7 mL 50 mM D3PO4 in D2O (6.6. mM), pH 2.5, 25 °C; (B) 2.7 mg mono-DCV and 














Figure SA 4 Expanded 2D ROESY spectrum of a mixture of mono-DCV and γ-CD in 50 mM 
deuterated sodium phosphate buffer in D2O, apparent pH 2.5, showing intermolecular 
NOEs. Experimental conditions: 2.7 mg mono-DCV and 13.0 mg γ-CD in 0.7 mL 50 mM 


















(A)   
H-2 4.14 n.d. 
H-3 1.94 n.d. 
H-4 (Me) 0.72, 0.79 0.80* 
OMe 3.53 n.d. 
Pyr-2 5.15 (t, J = 8 Hz) 5.61 (dd, J = 8, 1.5 Hz) 
Pyr-3 2.01, 2.43 2.19, 2.45* 
Pyr-4 2.01, 2.12 1.78, 1.99* 
Pyr-5 3.79, 3.92 3.50, 3.76* 
Im-4 7.54 n.d. 
Ph-2,6 7.71 n.d. 
Ph-3,5 7.62 n.d. 
(B)   
Pyr-2 5.01 (dd, J = 10.1, 8 Hz) n.d. 
Pyr-3 2.36, 2.54 n.d. 
Pyr-4 2.08, 2.25 n.d. 
Pyr-5 3.43 n.d. 
Im-4 7.67 n.d. 
Ph-2,6 7.69-7.74 n.d. 
Ph-3,5 7.69-7.74 n.d. 
* doubtful 
 






















































Table SA 4 1H-NMR resonances of mono-DCV–γ-CD complexes in buffered D2O at pH 2.5 in ppm. 





2:1 and 1:1 complexes  1:1 complexes 2:1 complexes 
Proton(s) Mono-DCV Proton(s) γ-CD (II) γ-CD (I) 
(A)     
H-2 4.16 H-1 4.97 4.87 
H-3 1.97 H-2 3.51 3.49 
H-4 (Me) 0.70 - 0.88** H-3 3.79 3.49 
OMe 3.55 H-4 3.45 3.38 
Pyrr-2 5.08 H-5 3.71 3.38 
Pyrr-3 2.15, 2.33 H-6 3.73 (x 2) 3.50, 3.54 
Pyrr-4 approx. 2.00 (x 2)    
Pyrr-5 3.79, 3.95    
Im-4 
7.09-7.78** 
   
Ph-2,6    
Ph-3,5    
(B)     
Pyr-2 4.81    
Pyr-3 2.15*, 2.33*    
Pyr-4 2.06, 2.17    
Pyr-5 3.41 (x 2)    
Im-4 
7.09 - 7.78** 
   
Ph-2,6    
Ph-3,5    
* doubtful 
** poorly resolved due to overlapping 
 
Experimental conditions: 2.7 mg mono-DCV and 13.0 mg γ-CD in 0.7 mL 50 mM D3PO4 in D2O, pH 































































The 1H-NMR spectra of half-DCV in the absence and presence of γ-CD are shown in Figure SA 5, for 
peak assignment see Tables SA 5 and SA 6). As seen for DCV and analogs, two conformers with regard 
to the conformation of the pyrrolidine ring could be detected at a ratio of about 1.0:0.12, which is similar 
to the one found for DCV. The triplet of the major conformer at 5.15 ppm refers to the axially oriented 
H-2, while the double doublet at 5.62 ppm indicated that the pyrrolidine H-2 is in the equatorial position 
in the minor conformer. From 2D ROESY spectra a folded structure of half-DCV was concluded in 
analogy to DCV. NOEs were observed between the aromatic protons and the methyl protons of the 
isopropyl side chain of the major conformer. In case of the minor conformer, a NOE response was seen 
between the methoxy protons and pyrrolidine H-2. Moreover, the resonances of H-2 as well as the 
methoxy group appear at a higher filed compared to the major conformer (3.84 and 3.23 ppm versus 
4.16 and 3.54 ppm). This can be explained by a ring current anisotropy when the Val side chain is close 
to the aromatic rings in agreement with a folded structure of the minor conformer.  
In the presence of γ-CD, the resonances of half-DCV did not shift significantly compared to the spectrum 
in the absence of the CD (Figure SA 5B). All resonances were approximately identical. A 2D ROESY 
experiment also indicated a folded conformation of the compound. Moreover, for the major conformer 
intermolecular NOEs between H-5 and to a minor extent H-3 of γ-CD with the aromatic hydrogens of the 
phenyl and imidazole rings indicated that half-CDV enters the cavity via the narrower primary rim of the 
CD as schematically shown in Figure SA 6. In case of the minor conformer, no significant NOEs could 
be detected probably due to low signal intensity. No indication of a 2:1 complex could be derived. Thus, 
a dimeric biphenyl structure appears to be required for the formation of a 2:1 complex. 
 







Figure SA 5 1H-NMR spectra of (A) half-DCV and (B) half-DCV plus γ-CD in 0.05 M deuterated 
phosphate buffer in D2O, apparent pH 2.5. For signal assignments see Tables S8 and 
S9. Experimental conditions: (A) 3.0 mg half-DCV in 0.7 mL 50 mM D3PO4 in D2O (11.6 
mM), pH 2.5, 25 °C; (B) 3.0 mg half-DCV and 16.0 mg γ-CD in 0.7 mL 50 mM D3PO4 in 










Figure SA 6 Schematic representation of the complex formed between half-DCV and γ-CD. The 
intermolecular NOEs derived from ROESY experiments are indicated by blue arrows. 
Table SA 5 1H-NMR resonances of half-DCV in buffered D2O at pH 2.5 in ppm. For assignments 







































H-2 4.16 3.84 
H-3 1.95 1.90 
H-4 (Me) 0.72, 0.79 0.77, 0.81 
OMe 3.54 3.23 
Pyr-2 5.15 5.62 
Pyr-3 2.03, 2.45 2.21, 2.47 
Pyr-4 2.02, 2.14 1.77, 1.99 
Pyr-5 3.81, 3.93 3.49, 3.76 
Im-4 7.50 7.50 
Ph-2,6 7.53 7.57 
Ph-3,5 7.42 7.42 
Ph-4 7.39 7.39 
 
 









Table SA 6 1H-NMR resonances of half-DCV–γ-CD complexes in buffered D2O at pH 2.5 in ppm. 












































 Half-DCV   
Proton(s) (major isomer) (minor isomer) Proton(s) γ-CD 
H-2 4.17 3.83 H-1 4.98 
H-3 1.96 1.95* H-2 3.53 
H-4 (Me) 0.72, 0.80 0.78, 0.81 H-3 3.80 
OMe 3.55 3.23 H-4 3.46 
Pyr-2 5.15 5.62 H-5 3.72 
Pyr-3 2.04, 2.45 2.22, 2.47 H-6 3.74 (x2) 
Pyr-4 2.04, 2.15 1.78, 1.99   
Pyr-5 3.81, 3.92 3.48, 3.75   
Im-4 7.50 7.50   
Ph-2,6 7.53 7.57   
Ph-3,5 7.41 7.42   
Ph-4 7.39 7.39   
 * doubtful 
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